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Abstract
Myelin damage in central nervous system white matter disorders such
as multiple sclerosis (MS) leads to axonal dysfunction/degeneration and
clinical disability. Regeneration of myelin (termed remyelination) can oc-
cur and requires oligodendrocyte progenitor cells (OPCs) to differentiate
into mature oligodendrocytes, which are then able to make contact with
axons and ensheath them. However, this process fails in progressive MS.
The lack of approved therapies aimed at promoting remyelination high-
light the need to identify mechanisms driving this regenerative process
to develop novel therapeutic strategies.
Previous work in the lab identified the TGF-β superfamily member
activin-A as being increased during remyelination in vivo and sufficient
in stimulating activin receptor-driven OPC differentiation into mature
oligodendrocytes in vitro. Here, these studies were followed up by under-
taking a comprehensive assessment of the role of activin receptors and
their ligands during remyelination. Using an ex vivo brain explant model
of demyelination, the stimulation of activin receptors using activin-A
was sufficient to enhance remyelination. Blocking activin receptors us-
ing an endogenous inhibitor (Inhibin) hindered remyelination, demon-
strating the requirement of activin receptor signalling for this process.
Surprisingly, blocking the binding of endogenous activin-A to activin re-
ceptors using follistatin did not impact remyelination, suggesting that
other activin receptor ligands are involved in driving remyelination. As
activin receptors may bind other ligands in the TGF-β superfamily, the
expression and function of alternative ligands was investigated, and each
was found to be important for remyelination (albeit with distinct tim-
ing/effects). Both activin receptors and their ligands were expressed on
microglia/macrophages in mouse and human disease tissue. Finally, anal-
ysis of activin receptor expression on oligodendrocytes in human tissue
revealed potential functional differences between receptor subtypes.
Together, these results demonstrate previously undefined roles of a
subset of TGF-β superfamily members in regulating remyelination, and




Multiple sclerosis (MS) is an autoimmune disease whereby the myelin
sheath, or the coating around nerve fibres, is destroyed. The brain is
capable of regenerating myelin (termed remyelination); however, with
disease progression, this process fails, leading to increasing clinical dis-
ability. There are no approved drug therapies to promote remyelination.
To address this challenge, we sought to discover new ways through which
remyelination could be promoted in MS to identify a novel therapeutic
target.
Previous work from our lab points towards an important role for a
naturally produced molecule called activin-A. This thesis explored the
role of its binding partners, activin receptors, in regulating the cellular
responses required for remyelination. In an animal model, when the ac-
tivin receptors were ‘turned on’ using activin-A, there was an increase in
remyelination. Conversely, when receptors were switched off, the regener-
ation of myelin was impaired. Interestingly, results showed that the main
molecule which turns receptors on (activin-A) was not needed for remyeli-
nation to take place. Next, it was important to identify other molecules
that affect the activity of activin receptors in the context of myelin repair.
In this thesis, three other molecules related to activin-A were identified
that are important for remyelination. In the absence of these naturally
occurring molecules, remyelination is impaired, suggesting that there are
many compounds that may affect this repair process. Finally, results
showed that there are two main cell types in the brain where activin re-
ceptors are active: myelin-making cells (oligodendrocytes), and immune
cells (microglia/macrophages).
Taken together, the work in this thesis characterizes the location and
function of activin receptors and their many ligands as a novel therapeutic
target for myelin regeneration.
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1 Chapter 1: Introduction
Multiple sclerosis (MS) is an autoimmune disease where the protective coating
around axons (myelin) is degenerated leading to axonal damage and loss. The cen-
tral nervous system (CNS) is capable of regenerating myelin via a process termed
remyelination. For successful remyelination to occur, oligodendrocyte progenitor
cells (OPCs) must become activated, proliferate, survive, and differentiate into ma-
ture myelinating oligodendrocytes. While there is evidence suggesting remyelination
occurs in early stages of MS, this process fails with disease progression and cognitive
and motor functions worsen. No currently approved therapies promote remyelina-
tion; therefore, there is a pressing need to identify strategies to achieve this.
This chapter will describe myelin generation, injury, and repair, as well as the
required oligodendrocyte lineage cell responses for this process. Further, I will review
the clinical features and disease pathology of MS. Finally, I will outline current
available therapies for MS, discuss remyelination drugs that are in the pipeline, as
well as explore activin receptors as a novel therapeutic target for remyelination.
1.1 Myelination
1.1.1 Composition of myelin
Myelin is an important component of both central and peripheral nervous sys-
tems. Myelin insulates neurons, provides trophic and metabolic support, and allows
for rapid transduction of electrical signals [1, 2]. In the CNS, oligodendrocytes pro-
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duce plasma membranes that make contact with and wrap around axons in a spiral
shape, resulting in a multi-layered myelin sheath [2]. The dry mass of myelin is mostly
composed of lipids (70-85%) and proteins (15-30%). This high lipid to protein ratio is
characteristic of myelin. Of the many lipids within myelin (i.e. cholesterol, lecithin,
and sphingomyelin), cerebroside (also known as galactosylceramide) is the most typ-
ical, with total concentrations being directly proportional to the amount of myelin
in the brain [3]. Surprisingly, in a study where the final step in cerebroside biosyn-
thesis was knocked out, resulting in an elimination of this lipid, myelin formation
was normal, likely due to a compensatory effect from glucocerebroside, a previously
unidentified lipid in myelin. However, aged knockout animals eventually developed
hindlimb paralysis and myelin abnormalities in the spinal cord, suggesting that while
these lipids may not be required for myelin formation, they play an important role in
myelin maintenance [4]. The remaining components of myelin are proteins, includ-
ing myelin basic protein (MBP), proteolipid protein (PLP), Myelin/oligodendrocyte
glycoprotein (MOG), Myelin-associated glycoprotein (MAG), 2′, 3′−cyclic nucleotide
3′−phosphodiesterase (CNPase), and oligodendrocyte/myelin glycoprotein (OMgp).
1.1.2 Process of myelination
While rodent myelination begins only post-natally, human myelination starts
in midgestation (17-22 weeks) and continues well into adulthood, with new myelin
being continuously generated in a healthy adult brain [5–8]. Indeed, adult myelin
is also constantly remodelled, with recent evidence showing white matter volume
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changes after practising a new skill [9, 10] or learning a language [11]. This change
in adult myelin could arise from production of new membrane by existing mature
oligodendrocytes, or from oligodendrocyte progenitors undergoing a process similar
to developmental myelination.
Developmental myelination is a tightly regulated process that begins with highly
proliferative OPCs migrating from the subventricular zone into what will become
the white matter of the brain [1]. OPCs then begin to differentiate and mature
into myelin-making cells, express myelin-associated proteins, and make contact with
axons [12]. Important strides made in imaging techniques in recent years have al-
lowed researchers to explore how actively myelinating cells actually form wraps; a
question whose answer had been long debated but not fully elucidated. A study
from 2011 used live imaging of enhanced green fluorescent protein (EGFP) express-
ing mice to show that oligodendrocytes extend triangular processes which then coil
around the axon as membrane spreads longitudinally [13]. Another study from 2014
used high resolution in vivo imaging combined with 3D reconstructions of the op-
tic nerve to show that myelination involves an incorporation of the oligodendrocyte
plasma membrane alongside the axon, and this new membrane expands laterally to
form paranodal loops [14]. During developmental myelination, cytoplasmic chan-
nels enable communication between the outside environment and the inside of the
nascent myelin sheath; once myelination is complete, these channels resolve. When
PTEN (an Akt/mTOR signalling inhibitor) was deleted in adult mice, these cyto-
plasmic channels were re-introduced and the thickness of existing myelin sheaths
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was increased. While a single factor or mechanism regulating myelination remains
unidentified, the authors provide evidence that Akt/mTOR signalling can control
these channels, and therefore, could be one of the regulators of myelination.
During development, oligodendrocytes will produce an amount of myelin that
is proportional to the diameter of an axon; smaller axons have thinner sheaths,
and larger axons have thicker sheaths [1]. Another outstanding question in the
field is how an oligodendrocyte determines how much myelin to make for a specific
axon. An interesting study in zebrafish revealed that oligodendrocytes can adapt to
localized cues from axons—a single oligodendrocyte can produce the correct amount
of myelin for both small and large calibre axons at the end of different processes,
suggesting that the amount of myelin is locally determined [15]. A likely hypothesis is
that there is synergistic cross-talk between axons and oligodendrocytes that regulate
the selection of axons to be myelinated and the thickness of the sheath produced;
however, the exact signalling pathways involved remain elusive.
1.1.3 Myelin is important for normal neuronal function
Myelin does not simply serve as a static insulating material; rather, axons and
oligodendrocytes engage in dynamic bidirectional communication. This interaction is
essential for the many functions of myelin, including rapid transduction of electrical
impulses along the axon, and trophic and metabolic support [1].
Myelin ensheaths long segments of axons (termed internodes); between these seg-
ments are Nodes of Ranvier, or short sections of axons that remain unmyelinated.
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The Node of Ranvier formation allows clustering of sodium channels at the node and
facilitates saltatory conduction of electrical impulses, increasing conduction speeds
20-100 fold depending on the diameter of the axon [2, 16, 17]. The rapid neuronal
signalling facilitated by myelinated axons in the CNS is important for normal motor,
sensory, and cognitive functions [2]. Axo-glial interactions involving myelin are also
important for axonal survival. Mice lacking PLP, a myelin protein, may only be
expected to exhibit a myelin phenotype, but they also show long-term axonal degen-
eration as well as disrupted axo-plasmic transport [18, 19]. Furthermore, myelinating
oligodendrocytes have been implicated in providing trophic and metabolic support
to neurons [20–22]. Specifically, there is experimental evidence of trophic exchange of
energy metabolites between oligodendrocytes and axons via monocarboxylate trans-
porter 1 (MTC1) [20]. Axons lacking these energy metabolites are more prone to
neurodegeneration. Therefore, oligodendrocytes and myelin are essential components
of the CNS required for fast neuronal signaling and axonal health.
1.1.4 Diseases associated with myelin abnormalities
The importance of myelin in both the central and peripheral nervous systems is
perhaps best exemplified by the many diseases associated with myelin abnormalities.
Table 1 includes a list of such diseases [23].
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Table 1. Diseases associated with myelin abnormalities.
Category Disease








Peripheral Nervous System Guillain-Barré syndrome
Chronic inflammatory demyelinating polyradiculoneuropathy
Paraproteinemic demyelinating neuropathy
Charcot-Marie-Tooth disease
1.2 Myelin regeneration requires oligodendrocyte lineage cell
responses
In the event myelin is damaged and lost (for example, in demyelinating diseases
such as MS), it can be regenerated in a process called remyelination. For adult
remyelination to successfully occur, adult oligodendrocyte progenitor cells (aOPCs)
must become activated, proliferate, migrate into the lesion, differentiate, and survive
such that mature oligodendrocytes are able to contact axons and regenerate the
myelin sheath (Figure 1) [24, 25]. The timely execution and coordination of these
processes is essential for efficient remyelination, and as such, investigations have been
carried out to elucidate the intricacies of oligodendrocyte maturation [26]. Current
knowledge regarding factors and mechanisms involved in the phases of this important
process is discussed in this section.
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Figure 1. Oligodendrocyte progenitor cell responses required for remyelination and asso-
ciated factors.
1.2.1 Activation of adult oligodendrocyte progenitor cells
Adult oligodendrocyte progenitor cells, or aOPCs, make up about 6% of cells in
the brain, and they work to generate new oligodendrocytes throughout adulthood
[27]. Given that these cells derive from developmental OPCs which are still present
in adulthood [28], a likely hypothesis is that aOPCs generate new oligodendrocytes
that contribute to remyelination after injury. Genetic fate mapping studies have been
able to confirm this hypothesis: marker genes expressed by aOPCs (PDGFR-α/NG2)
allowed researchers to follow their differentiation fates, providing evidence that new
oligodendrocytes are indeed a product of aOPCs [29–31]. Interestingly, a study
seeking to identify the developmental origins of aOPCs using dual-coloured reporter
mice saw differences between regenerative capacity of aOPCs derived from dorsal
and ventral origins, where the former had increased recruitment and differentiation
[32]. This suggests that lesions may have different repair success rates depending
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on where the recruited aOPCs derive from. Neural stem cell populations in the
subventricular zone have also been shown to contribute to new oligodendrocytes in
nearby areas of injury [33–35]; however, aOPCs are the major contributors to new
oligodendrocytes after injury.
The first step in this process is the activation of aOPCs, where a number of
injury-induced morphological and gene expression changes occur. An elegant study
established the genetic profiles of resting aOPCs in non-injured white matter and
activated aOPCs post-demyelination, and compared these to developmental OPCs
and mature oligodendrocytes [36]. While resting aOPCs had transcriptomes similar
to mature oligodendrocytes, once activated, they resembled developmental OPCs,
showing that genes regulating production of new oligodendrocytes are similar in de-
velopment and adulthood. While the exact mechanisms driving aOPC activation
are not yet understood, a working hypothesis postulates that after tissue injury,
signalling molecules are released from microglia, astrocytes, and damaged cells, re-
sulting in a distinct set of signals (such as factors discussed in Table 2) that cause
aOPCs to activate [26].
1.2.2 Coordination of oligodendrocyte recruitment, differentiation, and
myelin formation
Once activated, aOPCs are recruited to injured areas to produce sufficient oligo-
dendrocytes to carry out remyelination. In general, proliferation of progenitors pro-
duces a surplus of cells that are later pruned to the amount required; however, there
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are some clinical cases where a failure in remyelination has been associated with lack
of progenitors [37, 38]. The factors controlling OPC proliferation and migration to
lesion sites are many, and the redundancy of these signals speaks to the complexity
and importance of these cellular responses. Sources of such factors include microglia
and macrophages, activated astrocytes, cells of the vasculature, and cell-intrinsic
OPC signals [36, 39, 40]. A selection of important factors and their roles are illus-
trated in Figure 1 and listed in Table 2, with the notable exception of transforming
growth factor (TGF-β) superfamily to be discussed in detail in section 1.5. Follow-
ing recruitment of aOPCs to lesions, progenitors must exit the cell cycle in a timely
manner [41] in order to extend membrane processes around axons and produce a
new myelin sheath. While not much detail is known about this transition process,
one proposed mechanism involves a high progenitor density triggering differentiation,
and conversely, a low cell density inducing progenitor recruitment [42–44].
The final stage required for effective remyelination is compact myelin sheath for-
mation. Regenerated myelin sheaths are shorter and thinner than developmental
myelin [26], suggesting that some of the axo-glial signalling regulating these prop-
erties are absent or not required for remyelination. This difference in length and
thickness of myelin can be quantified using the g ratio, or the ratio of axonal circum-
ference to the circumference of the axon plus myelin. As such, the gold standard for
identifying areas of remyelination is to calculate the g ratio by electron microscopy.
An alternative method is to use fluorescent microscopy, which can show colocalization
of axonal and myelin immunolabeling, or be used to visualize internodes using para-
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nodal protein and sodium channel immunolabeling [45]. Since the length of myelin
is shorter in remyelination, it is expected that there will be a greater number of in-
ternodes in areas where remyelination has occurred [46]. We can use this method to
compare between areas of demyelination, where sodium channels will appear more
spread along the axon due to a lack of myelin, and areas of remyelination, where
sodium channels are distributed normally but more frequently along the axon. It is
unclear why this physical difference between myelinated and remyelinated sheaths
exists; however, one proposed hypothesis is that the interactions between myelinat-
ing cells and growing axons during myelination differ from those between myelinating
cells and mature axons during remyelination, due to changes in dynamic stress ex-
perienced by these cell types, as well as differences in signalling pathways [47]. The
thinner myelin sheath produced by remyelination is an important consideration in
determining whether a full functionality is restored to axons. Conduction velocity
is greater in axons with thicker myelin sheaths; computational studies predict that
while some conduction is restored in remyelinated axons, it would not fully return
to normal [48]. Further studies are required to determine the full and long-term
effects of remyelination on the function of neuronal circuits. However, it is clear that
the intricately choreographed mechanism of remyelination—from activation of adult
oligodendrocyte progenitors to mature myelin-producing cells—is an important post-
injury repair process resulting in the regeneration of a functionally relevant compact
myelin sheath.
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Regulates process outgrowth and branching
Reduced expression in MS post-mortem brains
[49–54]
CXCLs CXCL1,8,10 promote recruitment/migration via CXCR1-3
CXCL1,8,10 expressed on reactive astrocytes in MS lesions
CXCL1 overexpression results in milder EAE
CXCL12 promotes differentiation via CXCR4
Inhibition of CXCL12 reduces remyelination
[55–59]
Endothelin-2 Enhances differentiation
Promotes myelination and remyelination
Receptor expressed by oligodendrocytes and in MS lesions
[59–61]
IGF-1 Required for differentiation and myelin production
Induces development and proliferation via MAPK and Akt
Deletion reduces number of myelinating cells
Promotes survival in demyelinating conditions
[54, 62–69]
Laminin-2 Promotes myelin production via integrin receptors
Regulates survival and proliferation
Increased expression during remyelination
[54, 70–77]
PDGF-A Promotes proliferation and survival
Enhances recruitment and migration
PDGFα receptor expressed on OPCs
[54, 59, 78–80]
Retinoic Acid Boosts differentiation/remyelination via RXRγ receptor
Differentiation block in RXRγ KO mice rescued by agonist
[59, 81]
Sema3F Chemoattractant during development and post-injury




Accumulates in inflammatory lesions after spinal cord injury
Increased production by astrocytes in demyelinating lesions
[54, 59, 85–87]
LINGO-1 Negatively regulates differentiation and remyelination
KO mice increased remyelination in EAE
Blocking antibody treatment promoted differentiation
Clinical trial results discussed in 1.4.2
[59, 88–90]
Notch-1 Notch-1/Jagged signalling inhibits differentiation
KO results in accelerated differentiation/myelination
[59, 91–93]
Sema3A Chemorepellent during development and post-injury
Reduces OPC recruitment and remyelination
Expressed in MS lesions lacking OPCs/remyelination
[37, 59, 83]





Fibronectin Upregulated during demyelination
Promotes migration and proliferation at low concentration




Effect dependent on ligand-receptor complex/cell type
[54, 98–102]
GPR17 Early activation promotes differentiation
Late activation inhibits maturation and myelination
Upregulated in demyelinating lesions
Expressed mainly by newly formed oligodendrocytes
[54, 103–108]
Netrin-1 Early chemoattractant for OPC migration in optic nerve
Chemorepellent regulating OPC dispersal in spinal cord
Early expression impairs remyelination
Late expression enhances branching of processes
Expression in MS associated with low migration
[82, 109–115]
PSA-NCAM Low expresson coincides with differentiation/myelination
Downregulation crucial for myelin maintenance




Low concentrations promote differentiation
High concentrations inhibit differentiation
Associated with cytoprotective effects





High signalling inhibits differentiation and remyelination
Low signalling promotes differentiation and remyelination
Effects may depend on developmental stage
[54, 59, 130–
134]
1.2.3 Animal models of myelin injury and repair
There are no experimental animal models that fully recapitulate the complex
pathology of demyelinating diseases such as Multiple Sclerosis. Rather, different
models serve to mimic isolated aspects of the disease [26]. Focal lesioning mod-
els, where a demyelinating toxin is introduced to a brain region and repair occurs
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along a standardised time course, may be used to study the process of remyelination
independent of T-cell driven inflammatory response. Immune-mediated myelin dam-
age models, where acute demyelinating lesions can develop into chronic ones, offer
mechanistic insight into some potential aspects of MS immunopathogenesis. Neither
of these can truly mimic MS, however, as they do not reflect the characteristics of
disease progression, including a mix of acute and chronic inflammatory lesions, re-
myelination success and/or failure, and axonal degeneration. Models, such as the
ones described below, can still be valuable to study specific disease features within
the complex web of MS pathology (discussed further in the next section).
Focal lesioning models. Commonly, one of two toxins is used to induce demyeli-
nating lesions in white matter tracts of the CNS: ethidium bromide or lysolecithin.
These toxins differ mechanistically: ethidium bromide induces nucleated cell death
by intercalating DNA, thereby affecting oligodendrocytes and OPCs but sparing ax-
ons, and lysolecithin acts as a detergent and strips away myelin membranes [135].
Both are excellent tools to study the process of remyelination, with clear temporal
distinction between myelin injury and spontaneous repair [136–138]. Some impor-
tant factors to consider when using in vivo stereotaxic injection models are issues
with traumatic injury induced by toxin injection, blood-brain barrier breakdown,
and potential axonal damage [139–141]. Lysolecithin-induced demyelination can
also be employed to study remyelination in ex vivo organotypic brain slices, which
recapitulate in vivo cytoarchitecture and provide an excellent environment for phar-
macological manipulation [142, 143].
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Cuprizone model. Another method by which investigators can induce lesions is
by oral administration of cuprizone (bis-cyclo-hexanone oxaldihydrazone), a copper-
chelating toxin. Copper chelation has been implicated in dysregulating energy pro-
duction of oligodendrocytes via impairment of copper-dependent mitochondrial func-
tion [144]. Cuprizone administration results in oligdendrocyte cell death, vacuoliza-
tion of myelin membranes, and demyelination [145]. Demyelination and remyelina-
tion are not temporally distinct in this model: OPC proliferation and recruitment
begins during demyelination, and robust spontaneous myelin repair is seen as early
as 4 days post cuprizone withdrawal [145, 146].
Immune-mediated myelin damage models. The most widely used model for study-
ing the T-cell driven inflammatory mechanisms of MS is Experimental Autoimmune
Encephalomyelitis, or EAE. This model comes in many forms, where experimental
animals (commonly mice, but other animals such as marmosets have been used [147])
are immunized against a myelin antigen (usually MOG, but also PLP and MBP)
leading to inflammation-induced demyelination. While remyelination occurs in this
model, it is difficult to study due to the stochastic nature of the timing and loca-
tion of lesions [148]. Another interesting model is Theiler’s murine encephalomyelitis
virus (TMEV), where a picornavirus infection in the CNS results in oligodendrocyte
death, axonal damage, and demyelination [148, 149]. Limited remyelination occurs
in this model, possibly as a result of dysregulated oligodendrocyte maturation [150].
Like EAE, lesions in TMEV models are randomly distributed temporally and spa-
tially. Nevertheless, these are valuable models for answering mechanistic questions
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relating to the immune-mediated damage seen in MS.
1.3 Myelin injury and repair in Multiple Sclerosis
1.3.1 Clinical presentation of Multiple Sclerosis
Multiple Sclerosis exemplifies the critical role of myelin and oligodendrocytes. MS
is characterized by multi-centric demyelinating plaques: inflammatory lesions with
loss of oligodendrocytes and myelin, glial scarring, and initial preservation of axons
followed by irreversible axonal injury with disease progression [151, 152]. Patients
with MS typically first experience relapse-remitting MS (RRMS, 80-90%), where
their neurological symptoms resolve and relapse repeatedly, followed by secondary
progressive MS (SPMS), where the disease progresses steadily, symptoms no longer
resolve, and disability accumulates [46, 153]. Some patients (10%) experience pri-
mary progressive MS (PPMS), where they have progressively worsening disability
with no remissions from the onset of disease [46, 151].
MS is a heterogeneous disease, with unknown causes and a disease course that
is largely unpredictable. Natural history studies have postulated that about 10% of
patients with an initial presentation of symptoms have a mild form of the disease,
and about 70% of those with RRMS develop secondary progression. Predictors of
a more severe disease course include frequent relapses in the first two years, male
sex, and early motor and cerebellar abnormalities. Female sex and patients with
mainly sensory symptoms often have a better prognosis [154–156]. MS disease onset
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occurs typically at 20-40 years of age and affects females at approximately a 2:1
ratio compared to males. MS is geographically varied, with the highest prevalence
being in northern Europe, southern Australia, and North America [151]. While the
cause of MS remains elusive, there is evidence for both environmental and genetic
factors playing a role in disease onset [157, 158]. Several studies have shown various
lines of evidence for environmental risk factors, including geographical and temporal
clustering of cases [159, 160], changes in the frequency of MS in individuals who
migrate to and from high prevalence areas [161, 162], and vitamin D deficiency
[163]. Genetic risk factors have also been identified, the strongest and most studied
of which is the major histocompatability complex (MHC) class II region. However,
MHC-associated alleles are not sufficient to cause disease or predict its development,
suggesting a complex relationship between genetics and phenotype [151, 158]. Large
international genome-wide association studies (GWAS) have recently revealed over 50
non-MHC genetic risk factors (single nucleotide polymorphisms, or SNPs) associated
with MS [158]; however, given the heterogeneity of disease course and epidemiology,
it is evident that an intricate interaction between genes and environment underlies
individual susceptibility to MS.
1.3.2 Demyelination and neurodegeneration in Multiple Sclerosis
In MS, heterogeneity exists not only in clinical course, but also between lesions—
even within the same patient. This may point to different pathological processes
including autoimmune responses, primary oligodendrocyte dysfunction, and viral
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infection [164]. Alternatively, differences between lesions may also reflect different
stages of repair. As mentioned previously, the cause of MS is unknown; however,
there are two major competing theories. The first is the ‘outside-in’ auto-antigen
hypothesis, which postulates that there is a primary auto-reactive T cell driven
process whereby these cells cross the blood-brain barrier, and with the help of B
cells and macrophages, target and destroy myelin [151, 165, 166]. There are several
lines of evidence supporting this model. As mentioned above, there is an association
of the disease with MHC genes, which is part of the antigen-presenting machinery T
cells can use to target myelin [167]. T cells derived from MS patients show higher
reactivity to myelin antigens MBP, PLP, MAG, and MOG compared to healthy
participants [168, 169]. Additionally, the EAE mouse model of autoimmune myelin
damage can be induced by adoptive transfer of anti-MBP and anti-MOG35-55 reactive
T cells [170, 171]. Demyelination may also be triggered by monocyte infiltration into
the CNS. Evidence from EAE studies suggests that while tissue resident microglia
are not required for EAE induction/progression, infiltrating macrophages are [172–
175]. Indeed, depletion of monocytes results in inhibition of disease initiation and
progression in EAE mice [176], suggesting auto-reactive T cells are not the only
immune cells driving myelin destruction.
The second ‘inside-out’ theory of MS argues that there is a primary oligoden-
drocyte degeneration and this leads to a secondary autoimmune and inflammatory
response [165, 166]. There is evidence supporting this theory both in human and
rodent studies. Specifically, human studies have revealed evidence for oligodendro-
29
cyte death preceding significant T and B cell infiltration. Using tissue from patients
with rapidly deteriorating MS, the authors noted new brainstem lesions featuring
high oligodendrocyte death accompanied by activated microglia, but lacking infil-
trating lymphocytes or myelin phagocytes [177, 178]. Interestingly, when one study
combined in vivo induction of oligodendrocyte death with favourable conditions for
autoimmunity (removal of regulatory T cells, presence of myelin-reactive T cells)
in rodents, the authors found no subsequent CNS inflammation, suggesting oligo-
dendrocyte death may not induce anti-CNS immunity, even with immune activation
[179]. Conversely, another recent study used genetic ablation of oligodendrocytes in a
mouse model (Plp1-CreERT ;ROSA26-eGFP-DTA) and saw recovery from an initial
demyelinating event followed by late-onset demyelination and axon loss coinciding
with infiltration of myelin-specific T cells, suggesting oligodendrocyte death can, in
fact, trigger CNS autoimmunity [180]. While these studies seem contradictory, it is
important to note that the former study used a direct administration of diphtheria
toxin leading to a severe neurodegeneration and early death, precluding any possi-
ble findings of a late-onset disease in this model. The authors of the latter study
note that it may be important to give the autoimmune response time to develop,
rendering long-term animal survival post induction of oligodendrocyte ablation an
important caveat to studying triggers for CNS autoimmunity.
Neuronal degeneration could also play an important role in demyelination [166,
181]. There is indisputable evidence for neurodegeneration in MS: axonal transection
and loss can be seen in post-mortem MS brains [152], there is progressive atrophy
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in brains of MS patients [12], and reduced expression of neuronal marker N-acetyl
aspartic acid (NAA) [182]. Importantly, in active lesions undergoing inflammatory
demyelination, amyloid precursor protein (APP) can be detected, suggesting dis-
ruption of fast axonal transport and axonal transection [183]. The prevalence of
transected axons is correlated with inflammation [152, 183], suggesting the inflam-
matory microenvironment is implicated in neurodegeneration. Other factors may
be responsible for this effect, however. Glutamate-induced excitotoxicity can induce
neurodegeneration [184, 185], and evidence from MS tissue shows elevated glutamate
levels in acute lesions and normal-appearing white matter [186]. Another potential
contributor to neuronal degeneration in MS is intrinsic axonal dysfunction. Indeed,
gene expression studies in postmortem MS brains show evidence for mitochondrial
dysfunction in axons causing neurodegeneration [187, 188]. Together, these theories
purport the culprit behind the destruction of myelin to be the autoimmune response,
oligodendrocyte death, or neuronal injury. Given the heterogeneity of lesions within
patients, as well as differences between individuals with MS, it is possible that these
theories do not preclude one another: one or all of these proposed mechanisms could
be responsible for demyelination in MS.
Regardless of the responsible demyelinating mechanism, the prevailing idea is that
permanent disability in late stage SPMS and PPMS patients is due to irreversible
axonal damage as a result of loss of metabolic support offered by oligodendrocytes
(Figure 2) [22, 189]. While axonal damage and loss is also ample in early acute le-
sions, neuronal plasticity may account for the lack of disability accumulation in early
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stages of RRMS. A few studies used functional magnetic resonance imaging (fMRI)
to show activation of new cortical regions that could be part of this compensation
mechanism [190–193]. Once CNS plasticity is no longer able to counterbalance the
extensive neuronal loss, RRMS transitions to SPMS and brain atrophy worsens with-
out development of new inflammatory lesions, suggesting alternative mechanisms are
at play [166, 194]. The elusiveness of the underlying causes of MS render its pre-
vention a difficult task. While there are now several effective drugs to counteract
the inflammatory response and reduce relapses in patients, these drugs are not effec-
tive in progressive MS (with the exception of one promising new drug, ocrelizumab,
discussed further below). One idea is to hinder disease progression by developing
therapies targeted at reducing neurodegeneration. Since myelin is important to neu-
ronal health, harnessing the innate remyelination capabilities of the CNS may be a
way to achieve this goal.
1.3.3 Myelin regeneration in Multiple Sclerosis
Remyelination, distinct from developmental myelination, is a process that oc-
curs after injury. Both experimental and clinical evidence exist showing that re-
myelination can occur spontaneously post demyelination (see Figure 2). First, the
experimental evidence from toxin-induced demyelination in animal models (most
commonly using cuprizone or lysolecithin), both in vivo and ex vivo, suggests that
while this effect diminishes with age, axons generally do not remain demyelinated and
robust remyelination is achieved [26, 195, 196]. Further, there is evidence from post-
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Figure 2. Myelination, demyelination, and subsequent responses.
mortem human tissue for demyelination and remyelination co-existing in MS lesions
[197–200]. Importantly, one study examined MS lesions by electron microscopy and
found thinner and shorter internodes, which is indicative of reformed myelin [197].
Given the important role of myelin in the CNS, it is not surprising that restor-
ing myelin after a demyelinating injury is an important process. Remyelination is
neuroprotective; it restores axonal health both functionally and metabolically [26].
Evidence from human postmortem tissue indicates that neurodegeneration is more
prevalent in acute and chronic lesions compared to remyelinated lesions [201, 202].
Further, several convincing studies using different techniques in animals have shown
the neuroprotective effects of remyelination [203–205]. One study used a cuprizone
demyelination model combined with irradiation to prevent endogenous remyelination.
After transplanting progenitor cells leading to restoration of remyelination capacity
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and therefore remyelination, they saw a decrease in axonal injury [203]. A second
study genetically eliminated adult oligodendrocytes, leading to axonal injury which
was not resolved by blocking the axon-damaging effects of the adaptive immune sys-
tem [204]. Finally, in an EAE model, enhancing oligodendrocyte differentiation (and
thus remyelination) led to an increase in axonal preservation [205].
Evidence for the functionally restorative role of remyelination is well-established
in animal models [206, 207]. Remyelination was shown to restore rapid conduc-
tion in the spinal cord and brainstem of rodents as measured by electrophysiology
[206]. Further, a study done in cats with a demyelinating condition showed that
endogenous remyelination of intact axons reverses clinical deficits seen during de-
myelination [207]. Taken together, the evidence suggests that remyelination is an
important endogenous post-injury repair process.
1.3.4 Failure of remyelination in Multiple Sclerosis
As MS advances, remyelination often fails and neuronal loss occurs leading to
the progressive degeneration seen in PPMS and SPMS, an idea supported by both
experimental and clinical reports (see Figure 2) [46, 166, 195, 208]. In a marmoset
model of EAE, axonal spheroids and amyloid precursor protein (APP) were observed
in areas of inflammation and demyelination [147]. APP-positive axonal spheroids
are early markers of axonal injury and deficiencies in axonal transport, which can
eventually result in neuronal loss [196, 209–211]. Further, in post-mortem tissue
collected from MS patients, axonal spheroids containing APP are present in areas
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of demyelination and inflammation [183, 212, 213]. Remyelination is believed to be
critical for dampening disease progression and reducing severe long-term disability;
as such, it is important to understand why this process fails. A reduction or failure
of OPC recruitment, maturation, and ensheathment could be due to generic factors
such as ageing [214–217], or due to disease-specific factors, such as the post-injury
microenvironment and inflammation [26, 218]. While remyelination can fail due to
arrested development of oligodendrocytes at any stage, the current evidence points
towards a key failure in OPC differentiation and maturation in MS, as 70% of lesions
contain OPCs but lack mature oligodendrocytes, compared to 30% of lesions lacking
OPCs, indicating insufficient recruitment [37, 80, 208, 217, 219–222].
In general, ageing is associated with decreased efficiency of regenerative processes;
it therefore follows that regeneration of myelin also slows down with age [223–225].
Cohort studies support the hypothesis that the transition from RRMS to SPMS is
likely associated with an age-related decline in remyelination efficiency combined
with consequent progressive neurodegeneration. Specifically, MS patients of certain
age groups tend to have a similar level of disability, regardless of heterogeneity in
initial disease patterns and age of onset [214]. Further, both imaging and pathology
studies show evidence for age-related decline in remyelination efficiency [215, 216].
The relationship between ageing and remyelination failure could be due to ageing-
driven intrinsic changes in oligodendrocytes. For example, one study found that
young brains are efficient in epigenetic control of gene expression, enabling the re-
cruitment of histone deacetylases (HDAC) to promoter regions of genes important for
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oligodendrocyte differentiation. Old brains, however, lack this efficiency in HDAC
recruitment, leading to poor control of gene expression required for remyelination
[226].
Another reason for a failure in oligodendrocyte maturation could be the post-
injury microenvironment. Indeed, there is evidence from both human and animal
studies showing inhibitory factors are present in demyelinated lesions (hyaluronan
[85, 86], PSA-NCAM [117, 227]). Lesions may also lack signals that promote differ-
entiation (IGF-1, TGF-β [47]) — see Table 2 for a list of selected extracellular factors
that influence remyelination. These factors are part of an environment that is not
conducive to OPC maturation, and thus affect the efficiency of remyelination [195].
Additionally, evidence from post-mortem MS brains show that in some chronic le-
sions, pre-myelinating oligodendrocytes are present and associate with demyelinated
axons but do not myelinate, possibly due to a a dysregulation of growth factors,
inhibitory signals, or a changing molecular composition of axonal signals preventing
myelin wrapping [228].
Remyelination efficiency may also be affected by the immune response to demyeli-
nation [26]. One function of post-injury inflammation is to prepare the damaged
tissue for repair, and while the inflammatory response in MS has typically been seen
as detrimental [229, 230], it is clear that some immune cells in MS (microglia and
macrophages) have a complex role, with both beneficial and detrimental aspects.
Investigations in toxin-induced demyelination (models where the immune response
is a product of demyelination, not vice-versa) showed that depleting macrophages
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can impair remyelination [231], suggesting an important interaction between the
immune response and regeneration potential. An abundance of myelin debris is
produced post-injury, which has been shown to be detrimental to OPC differentia-
tion and subsequent remyelination [232–235]. Both resident microglia and recruited
macrophages are responsible for clearing this debris, and their efficiency in perform-
ing this task impacts the efficiency of repair processes [26]. However, these immune
cells may have different functions depending on their activation state or phenotype.
It has been shown that pro-inflammatory microglia are important during the early
recruitment stage of remyelination, while pro-repair microglia are required during
oligodendrocyte differentiation. A timely transition from pro-inflammatory to pro-
repair microglia is critical for effective remyelination; therefore, one possible factor
influencing a failure in remyelination is the persistence of pro-inflammatory immune
cells [142]. Indeed, MS post-mortem tissue studies have shown that a high number of
pro-inflammatory microglia/macrophages is associated with chronic inactive lesions,
where remyelination is poor [142, 236]. Further, in the EAE mouse model, an im-
balance in microglia/macrophage activation towards pro-inflammatory phenotypes
is associated with a more severe disease course [237]. Both human and experimen-
tal evidence suggests a persistence in pro-inflammatory immune cells can result in
poor outcomes in demyelinating lesions. Together, these data suggest that both age-
ing and lesion microenvironment may affect remyelination, particularly in the final
stages of maturation where oligodendrocytes fail to make myelin that subsequently
wraps in a compact manner around axons.
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1.4 Therapeutic targets for Multiple Sclerosis
1.4.1 Immunomodulatory therapies
As previously mentioned, MS is a complex and heterogenous disease; accord-
ingly, individual patient outcomes from the various available drugs vary, rendering
the selection of treatment a complex process. There are several disease-modifying
therapies (DMTs) currently approved for RRMS to reduce the rate of relapses. Each
have different mechanisms of action and considerations (i.e. efficacy, side effects, de-
livery route/frequency) that are taken into account by the physician and the patient
[238]. Therapies discussed in this section are summarized in Table 3.
The first generation DMTs (which new therapies are often compared to in clini-
cal trials) are Interferon-beta and Glatiramer acetate. These were common first-line
treatment options for individuals with RRMS, as they have good safety profiles and
clinical efficacy. Interferon-beta is thought to work by lowering levels of blood-brain
barrier disruption and regulating immune cell function, while Glatiramer acetate
likely modulates function of regulatory T cells [239]. Since the first Interferon-beta
drug was approved in 1993, a plethora of other more effective treatments have be-
come available, including orally administered DMTs (Fingolimod, Teriflunomide,
Dimethyl fumarate, Cladribine), and infusions (Natulizumab, Alemtuzumab, and
Ocrelizumab) [238, 240–242]. Depending on the severity of side effects, relevant
contra-indications, and recent MS activity, these may be recommended as first- or
second-line therapies for RRMS. Patient factors, such as drug preference/tolerability
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and adherence to dose regimen, are also considered when prescribing medications
[238].
Generally, physicians utilize a sequential DMT monotherapy strategy for RRMS
patients. After an appropriate DMT is selected, a patient will undergo surveillance
for a period of time to monitor clinical and radiological disease activity, as well
as drug tolerability, adherence, and safety [238]. Ideally, the patient would expe-
rience remission with no significant side effects, in which case the therapy would
continue with occasional reassessment. However, if disease continues to be active
(albeit slowly in some cases), patients will eventually relapse—likely due to the par-
tial efficacy of DMTs. At this time, the clinician is faced with a difficult decision
that often lacks concrete evidence-based support: has the drug failed, and is it time
to revise the treatment plan? As there is little research comparing specific DMTs,
or on the effects of using different DMTs sequentially, the clinical decision on which
DMT to prescribe next can be tough. Most DMTs, while effective in reducing relapse
rate, do not slow disease progression, and are not a cure. In a recent phase 3 trial,
however, Ocrelizumab showed promising results in slowing disability progression of
primary progressive MS patients compared to placebo controls. The authors found
that Ocrelizumab treatment lowered the risk of disability progression by 25%; fur-
ther, MRI scans revealed a decrease in total brain lesion volume in patients treated
with Ocrelizumab compared to an increase in patients treated with placebo [242].
While this B cell-depleting drug may be a promising avenue, it only focusses on
inflammatory aspects of the disease. None of these drugs target the underlying neu-
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rodegeneration and long-term demyelination. Developing drugs that target these
processes represents the greatest unmet need in multiple sclerosis therapeutics.
1.4.2 Clinical trials for remyelination therapies
A novel therapeutic approach that has been under investigation by several groups
is to target the underlying axonal degeneration by identifying pro-remyelination ther-
apies. Indeed, some pro-remyelination therapies for MS have undergone or are cur-
rently in clinical trials stage (e.g. anti-LINGO-1 antibody, bexarotene, clemastine)
[81, 88, 243]. LINGO-1 is a negative regulator of oligodendrocyte differentiation
and remyelination, and in an EAE mouse model, administration of an anti-LINGO-
1 antibody resulted in improved remyelination [88]. Unfortunately, anti-LINGO-1
antibody (developed under the name Opicinumab) recently failed to meet its pri-
mary endpoints in a Phase II clinical trial. There are several possible reasons for
this failed trial, including the use of an inappropriate patient population, the timing
of drug delivery, a short follow-up period, and questions regarding the antibody’s
efficacy in crossing the blood brain barrier. The complex results of this trial are
still being analysed, and at the very least will provide clues to improve clinical
trial design for remyelination outcomes [240, 244, 245]. More recently, clemastine
fumarate, an over-the-counter antihistamine with off-target, pro-remyelination anti-
muscarinic effects, has been tested in a small clinical trial. Two independent screens
identified clemastine as a compound with positive effects on oligodendrocyte dif-
ferentiation and myelination [243, 246]. Preclinical work validated these findings,
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showing that clemastine treatment reduced clinical severity, improved myelin area,
and exerted neuroprotective effects in an EAE mouse model [205]. Interestingly,
there was no change the number of infiltrating immune cells, suggesting this ef-
fect was not immune-mediated. Using knockout experiments, the authors identified
Chrm1 as the muscarinic receptor target of clemastine. Deletion of this receptor
resulted in enhanced differentiation and accelerated remyelination in a focal lesion
model [205]. When clemastine was tested in human cells, it was found to induce
OPC differentation and myelination [247]. These encouraging preclinical results led
to a randomised, controlled, double-blind crossover phase II clinical trial in 50 RRMS
patients with chronic demyelinating optic neuropathy. This is the first study to show
the efficacy of a pro-regenerative drug in the context of a chronic demyelinating dis-
ease; however, there was only a small increase in optic nerve conduction velocity and
no clinical change in vision. These measures are commonly used to assess myelin
damage and remyelination, and are discussed further below. Nevertheless, these re-
sults are promising and suggest that myelin repair is possible even after long-term
damage [247].
Two other interesting targets for myelin repair being developed include GSK239512
and MD1003 (high-dose biotin). Histamine H3 receptors expressed by neurons and
OPCs have been shown to play a role in OPC differentiation [243], and pre-clinical
studies showed that H3 antagonist/inverse agonist GSK239512 stimulates OPC dif-
ferentiation in vitro and promotes remyelination in a cuprizone mouse model. When
it was trialled in RRMS patients as an add-on therapy in conjuction with Interferon-
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beta or Glatiramer acetate, there was no visible impact in conventional MRI or
clinical assessments. However, an MRI marker of myelination called magnetisation
transfer ratio (MTR) showed a small positive effect of the drug compared to placebo
at 48 weeks [248]. It is possible that a longer follow-up study or the participation of
patients with more severe disease activity could yield interesting results for this drug.
Finally, high-dose biotin may boost myelin repair by stimulating fatty acid synthesis,
and may enhance neuroprotection via increased energy production in neurons [249,
250]. High-dose biotin (MD1003) was tested in a small randomised, double-blind,
placebo-controlled trial in patients with progressive MS after a pilot study showing
promising results [249, 251]. The new trial found that a significantly higher propor-
tion (13%) of patients in the biotin treatment arm showed disability improvement
at 9 and 12 months compared to the placebo arm. These results have led to a larger
study currently underway, and suggest that biotin treatment may help a subset of
progressive MS patients [251].
While these recent developments with pro-remyelinating drugs is encouraging,
given the heterogeneity of lesions both within and across patients [164], it is likely
that personalized medicine will play a role in future treatments of MS and different
combinations of disease-modifying therapies and pro-remyelinating and/or neuropro-
tective targets may be important for effective treatment of individuals.
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Table 3. Therapies for Multiple Sclerosis
Phase Therapy Mechanism of Action
Approved Interferon-beta Lowers levels of blood-brain barrier disruption
Regulates immune cell function
Glatiramer acetate Modulates function of T cells
Fingolimod Reduces exit of T and B cells from Lymph nodes
Teriflunomide Lowers inflammation
Reduces T cell infiltration
Dimethyl Fumerate Reduces inflammation
Cladribine Lowers T and B cell infiltration
Natulizumab Reduces T cell infiltration
Alemtuzumab Reduces T and B cell infiltration
Ocrelizumab Depletes B cells
Clinical trials Clemastine fumerate Anti-histamine with pro-regenerative effects
Induces OPC differentiation and myelination
GSK239512 Histamine H3 receptor agonist
Stimulates OPC differentiation/remyelination
MD1003 High-dose biotin
May improve myelin production/repair
1.4.3 Identifying targets for remyelination therapy
Although some progress has been made, there are still no approved remyelina-
tion therapies, hence a global effort spanning academia and industry is focused on
identifying regenerative therapy targets for multiple sclerosis. In order to do this,
researchers are taking a candidate approach and studying specific signals regulat-
ing oligodendrocye responses required for remyelination, or using unbiased high-
throughput screens allowing large libraries of small molecules or already approved
drugs to be tested for effects on oligodendrocyte responses [26, 252]. While it is en-
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couraging that these strategies have yielded several factors (some of which are listed
in Table 2) shown to promote oligodendrocyte responses in vitro, and even in animal
models, translating these preclinical findings to clinically relevant applications is a
challenge. With the latter strategy, drugs being tested are already approved, thus
easing their progression into clinical trials. The clemastine trial mentioned above
is a good example of a drug identified in one such screen quickly being moved into
relevant human testing [247]. In the former strategy, preclinical studies of candidate
targets are hampered by the lack of a single appropriate disease model. Without an
experimental animal model that recapitulates the intricate interactions between in-
flammation, regeneration, and neurodegeneration, promising preclinical targets can
often flounder in clinical trials [26].
As targeting remyelination is a recent development on the clinical stage, there
are a few aspects of trial design and outcome measurements that must be opti-
mized. Major hurdles include a lack of ability to accurately measure remyelination
in patients receiving therapy, as well as concerns about lesion heterogeneity and the
consequences on effect size. Currently, the preferred way to measure myelin damage
and repair in humans is through visually evoked potentials (VEP). This measure was
used in both the clemastine and anti-LINGO-1 trials described above, and is often
used as a diagnostic tool, even in patients without visual symptoms [253]. Since
myelinated axons fire up to 100 times faster than unmyelinated axons, researchers
can measure delays in firing responses to visual stimuli as an output of myelin dam-
age in the anterior visual pathway [253–255]. Clearly, this is not an ideal measure of
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remyelination, as it is indirect and focused only on one neuronal tract. To address
this, two promising approaches are currently being developed: MRI-based magne-
tization transfer ratio (MTR, mentioned above) [256–258], as well as PET-based
radiolabelled myelin-incorporating compounds [259, 260]. Additionally, identifying
types of lesions within and across patients is important to administer the appropriate
therapy. If a pro-differentiation drug is given to a patient with mostly lesions that
lack progenitor cells, it will likely fail (and vice-versa). As different patients given a
single treatment may have impairments at different stages of oligodendrocyte mat-
uration, a drug that is effective for some yet fails in a subset of the group could
contribute to an overall small effect size and a ‘failed’ trial. Advances in imaging
techniques that would allow patient group stratification based on lesion type would
greatly improve trial design and outcomes [26]. While strategies to improve these
aspects of clinical trials are underway, it is important to continue the preclinical
search for targets that may fulfil the unmet need of a regenerative therapy for MS.
One candidate approach for developing remyelination targets is identifying factors
secreted by immune cells that could be contributing to inhibitory or permissive le-
sion microenvironments. As mentioned in section 1.3.4, CNS-resident microglia and
peripherally-derived macrophages may exhibit anti-inflammatory, pro-regenerative
properties, depending on their phenotype [46, 142, 235, 261, 262]. Early work from
our lab showed that microglia and macrophages undergo a switch in phenotype dur-
ing remyelination—from pro-inflammatory to anti-inflammatory—and that this shift
drives OPC differentiation. The switch to anti-inflammatory factors is critical for
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OPC differentiation, and a dysregulation in efficacy or timing in this switch could un-
derlie the loss of remyelination potential in MS patients [142]. These findings suggest
that identifying anti-inflammatory macrophage-derived factors and their downstream
targets could be important for promoting remyelination.
1.5 Activin receptors and their ligands
1.5.1 Activin-A, the primary ligand for activin receptors, is an anti-
inflammatory macrophage-derived factor
Previous work by Miron and colleagues identified activin-A as an anti-inflammatory
macrophage-derived factor having a role in remyelination: i) its expression increases
during remyelination in vivo, ii) it promotes OPC differentiation in primary cul-
tures, and iii) blocking its action in microglia-conditioned media led to a reduction
in mature oligodendrocytes in ex vivo brain slice cultures [142, 263]. In addition to
promoting differentiation in primary OPC cultures, unpublished work from our lab
suggests that activin-A can also promote OPC proliferation and survival at different
concentrations. Further, activin-A is present in the cerebrospinal fluid of human MS
patients at a slightly increased concentration, indicating its possible relevance in the
neurodegenerative disease [264, 265].
Activin-A is a growth factor in the TGF-β superfamily; it is a homodimer com-
posed of two βA subunits linked by a single disulfide bond. Two other functional
activins exist: activin-B (two βB subunits) and activin-AB (a heterodimer of βA and
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βB subunits) [266]. These activins are structurally similar but functionally different,
as in vitro assays have demonstrated distinct potency and cellular outcomes [267].
Additionally, when transgenic mice with a βA knockout were modified to substitute
βB into the βA locus, some effects of βA knockout were rescued—albeit not fully,
suggesting that the βB subunit could not completely compensate for the functions
of βA [268]. Activin-A is the best characterized member of the activins, and while it
was originally identified as a reproductive factor, it has since been shown to be in-
volved in inflammation and repair in many systems [265, 269]. Specifically, activin-A
is expressed during inflammation and modulates the immune response via cytokine
release and production of nitric oxide [266].
In the CNS, activins and other TGF-β ligands are widely expressed and required
at many stages of development [270]; importantly, they have been shown to be rele-
vant during myelination and oligodendrocyte development (discussed further below)
[271, 272]. Activin-A has also been shown to be neuroprotective following oxygen-
glucose deprivation to a neuronal cell line in vitro [273], as well as essential for
neurogenesis following excitotoxic-induced neurodegeneration in vivo [274]. Further,
activin-A promotes astrocyte differentiation from CNS progenitors in vitro [275], as
well as supports neuronal differentiation of cortical neuronal progenitor cells [276].
In the healthy brain, activin signaling is involved in synaptic plasticity, cognition,
and behaviour (summarized in [277]). Impaired activin signaling has been associ-
ated with a variety of neurodegenerative diseases (summarized in [278]). Specifically,
mouse models of Huntington’s and Parkinson’s disease (excitotoxic quinolinic acid
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model and 6-hydroxydopamine model, respectively) treated with activin-A exhibited
neuroprotective effects [279, 280]. The mechanism underlying this neuroprotective
effect was found to be an important synergistic interaction between brain-derived
neurotrophic factor (BDNF) and activin-A. In essence, activity-dependent BDNF
signalling leads to increased production of activin-A via synaptic NMDA receptors,
which then negatively regulate extrasynaptic NMDA receptors. As neuronal health
is in part dictated by the balance between synaptic NMDA signalling (pro-survival)
and extrasynaptic NMDA signalling (pro-death), a disturbance in the interplay be-
tween BDNF and activin-A could lead to the neuronal pathogensis seen in these
disorders [278, 281].
Clearly, activin-A is an important growth factor during development and repair
in the CNS, and further study of its binding partners and downstream effects is key
to understanding its potential use in therapeutics.
1.5.2 Activin receptor expression and mechanism
Activin-A binds with high affinity to serine-threonine kinase type II activin re-
ceptors Acvr2a and Acvr2b. Once bound, this leads to the transphosphorylation
and activation of the type I co-receptor Acvr1b, which results in downstream sig-
nalling [270] involving pathways previously associated with driving OPC prolifera-
tion, differentiation, survival and myelination (including the canonical Smad2/3, and
non-canonical PI3K, p38, MAPK, ERK1/2, and Rac/Cdc42 pathways—see Figure
3) [272, 282–286]. Activin receptors are extensively expressed in the CNS and are
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important during development and injury. Specifically, activin receptors have been
shown to be expressed on axons during embryonic development and following exci-
totoxic injury in adult rodents, both in vitro and in vivo [274, 276]. Further, there
is in vivo experimental evidence showing that activin receptors 2a, 2b, and 1b are
expressed on OPCs and microglia/macrophages in remyelinating lesions [142], and
microarray data suggest that this expression is upregulated during remyelination
[81]. Taken together, this evidence indicates a potential role for activin receptors in
white matter neurodegenerative diseases.
Like many of the receptors of the TGF-β superfamily, activin receptor activity
is tightly regulated both by inhibitory ligands such as inhibin and follistatin, as well
as auto-inhibitory feedback mechanisms (inhibitory Smads, Smad6 and Smad7, see
Figure 4) [286, 287]. Inhibin is a heterodimer made up of two subunits (α and βA)
and directly competes with activin-A to bind the receptors and block downstream
signalling [288]. Follistatin works by sequestering the activin-A ligand and preventing
its binding to the activin receptors [287]. Therefore, blocking the activity of activin
receptors using these two different inhibitors can elucidate the role of the primary
ligand versus the role of the receptors.
Activin receptor subtypes have different binding affinities for ligands. Acvr2b
shows a higher affinity for activin-A compared to Acvr2a [304]; however, Activin
receptors can also bind other ligands in the TGF-β superfamily including myostatin,
bone morphogenic proteins (BMPs), growth and differentiation factors (GDFs), and
nodal (Table 4) [305]. Binding affinity of activin receptors for their many ligands
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Table 4. Ligands with affinity for activin receptors
Ligand Role in CNS Antagonists Mouse CNS Expression
A N O M E










X X X X
Activin-B Oligodendrocyte responses
Myelination [272]
Follistatin X X X X
Nodal Neural tube patterning
Forebrain maintenance







Maintenance & development of










Spinal cord patterning [294–296]








X X X X




BMP-7 Neuroprotective in stroke models
Eye development [300, 301]
Noggin X X X
BMP-15 None known None known X X X
All data in Mouse CNS Expression column reflects levels in P7 developing mouse brain and
was obtained from Barres RNASeq database [302] and from the literature [303]. A=Astroyctes,
N=Neurons, O=Oligodendrocyte lineage cells, M=microglia, E=Endothelial cells.
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Figure 3. Activin receptors drive signalling implicated in remyelination.
is not the only factor dictating downstream cellular responses. Several factors, in-
cluding availability and concentration of ligand, microenvironment, and endogenous
modulators of signalling are involved in the determining the many possible outcomes
of activin receptor activation.
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1.5.3 Determinants of TGF-β/activin receptor activation and outcome
The TGF-β superfamily is an enormously complex group of proteins, receptors,
co-receptors, and downstream effectors. Considering the family contains over 30
ligands—spanning transforming growth factors (TGFs), bone morphogenic proteins
(BMPs), and growth and differentiation factors (GDFs), among others—as well as
5 type II receptors and 7 type I receptors, there are an overwhelming number of
interaction possibilities [286, 306, 307]. Since their discovery nearly 40 years ago,
researchers have been working to dissect the many functions and roles of TGF-β
family members, which include cell proliferation, differentiation, and morphogenesis,
as well as tissue homeostasis and regeneration. Some of these roles seem paradox-
ical; indeed, many different and sometimes opposing effects have been reported for
the same TGF-β ligand [307]. The signalling mechanisms of TGF–β superfamily
receptor activation have been largely elucidated, and are relatively straight-forward:
a subset of oligomeric receptor-ligand complexes activate Smad1/5/8 phosphoryla-
tion (generally BMPs), and another subset activate Smad2/3 (generally activins,
GDFs, and TGF-βs). These Smads, termed receptor-activated Smads (R-Smads),
form a trimeric complex with a common Smad (Smad4) and translocate to the nu-
cleus, exerting downstream effects by regulating gene expression. As mentioned
above, Smad6/7 are auto-inhibitory Smads that disrupt these trimeric complexes
and polyubiquitinate Smad proteins and type I receptors for subsequent degradation
(Figure 4) [286, 307]. However, within this relatively simple mechanistic framework,
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the outcome can be one of many discrete cellular responses. Clearly, cellular context
is an important determinant of the response to TGF-β superfamily signalling.
Contextual features influencing TGF-β signalling include factors regulating signal
transduction, gene transcription, and epigenetic status. In terms of signal transduc-
tion, there are several extracellular variables that determine the degree of receptor
stimulation, including: level of ligand expression, ligand-trapping proteins (such as
follistatin [287], GASP-1, Sclerostin, and Noggin [308]), antagonistic ligands (such
as inhibin [288]), available receptor subtypes, and presence of accessory receptors
(such as betaglycan, which can present inhibin ligand to activin receptors [309]).
Transcription factors can also modulate TGF-β signalling, as availability of protein
binding partners determines which genes are targeted and how their expression is af-
fected. Finally, the epigenetic status of the cell, such as DNA methylation status and
histone modifications, will control which genes are amenable to expression changes.
For example, when a cell is differentiating, genes involved in differentiation will be
‘open’, allowing transcriptional machinery downstream of TGF-β signalling to en-
gage [307]. If this cell receives an aberrant input to activate proliferation genes, the
epigenetic landscape may hinder expression of those target genes. Taken together,
these contextual cues confer a level of specificity to the pleiotropic effects triggered
by members of this protein superfamily.
Several studies have been carried out to elucidate the many contextual possibil-
ities dictating the overall effect of activin receptor signalling on the cell [269, 277,
278, 288, 310, 311]. Table 4 lists all known ligands with binding affinity for activin
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receptors 2a and 2b, their CNS-specific roles, cell-type specific expression during de-
velopment, as well as known modulators of signalling. Given the level of complexity
of both intracellular and extracellular factors affecting signal transduction within
this superfamily, we must be careful not to generalize findings from the effects of
a ligand in one specific set of circumstances. It is important to clearly define the
conditions under which a TGF-β ligand is studied, and to understand that the same
ligand could have different—even opposing—effects under different conditions.
Figure 4. Agonists and antagonists of canonical TGF-β superfamily signalling.
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1.5.4 TGF-β superfamily in myelination and myelin disorders
In the CNS, some TGF-β ligand/receptor complexes have been shown to regulate
oligodendrocyte lineage cells and myelination [270, 312, 313]; specifically, recent
papers show that TGF-β and activins are important for developmental myelination
and oligodendrocyte maturation [271, 272].
TGF-β signalling in oligodendrocyte development
One study [272] sought to determine the role of TGF-β and activins in oligoden-
drocyte development and myelination. To address this, the authors first investigated
the expression of TGF-β ligands, receptors, and their canonical downstream effec-
tors in the developing mouse spinal cord by immunohistochemistry, and found that
in early embryonic development (E12.5), TGF-β1 ligand and both TGF-β receptor
2 (TGFβRII) and Acvr2b were present on Olig2+ oligodendrocytes in the periven-
tricular zone, accompanied by phosphorylated Smad3 (pSmad3, the active form of
Smad3 signalling). No activin-B or activin-A was detected at this time. By late
embryonic development (E14.5) and up to postnatal day 5 (P5), oligodendrocyte-
specific pSmad3 expression overlapped with both TGF-β1 and activin-B ligand, as
well as their respective receptors. This progressive overlap in Smad3 and ligand
expression suggests that TGF-β1 mediates Smad3 signalling in early oligodendro-
cyte development, and late development is mediated by both TGF-β1 and activin-B.
Indeed, these differences in expression are reflected in distinct signalling profiles in-
duced by the two ligands in oligodendrocyte cultures (both Oli-Neu cell lines and
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primary OPCs). Importantly, these signalling profiles also correlated with distinct
functional outcomes. Specifically, when primary OPC cultures were treated with
TGF-β1 alone, the authors observed a decrease in apoptosis (by caspase-3 staining),
an increase in BrdU+Olig2+ proliferating cells, as well as an increase in total num-
ber of Olig2+ oligodendrocytes. When cultures were treated with activin-B alone,
an increase in number of mature MBP+ oligodendrocytes was observed. When both
treatments were administered together, there was a combinatorial effect, includ-
ing a strong reduction in apoptosis, a higher number of total Olig2+ cells, and an
increase in both proliferating and mature oligodendrocytes. Further, in oligodendro-
cyte/neuron co-cultures, while activin-B treatment alone was sufficient to enhance
myelin formation, co-treatment with TGF-β resulted in an additive effect. Finally,
in activin-B (Inhbb−/−) knock-out mice, a transient impairment in embryonic oligo-
dendrocyte development was detected; however, by P5 there were no differences in
myelination. In Smad3−/− knock-out mice, a more severe phenotype was observed,
with delays in myelination persisting until P28. Together, these results provide a
potential model for TGF-β superfamily ligands contributing to oligodendrocyte de-
velopment in the spinal cord via Smad3 signalling [272].
The results of this study are supported by previous literature highlighting the
importance of TGF-β in oligodendrocyte development and myelination [270, 312,
313]. Interestingly, the the authors mentioned in their discussion that activin-A
treatment provided similar results to activin-B in their oligodendrocyte cell cultures,
which is divergent from two previous studies implicating activin-A and TGF-β1 in
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oligodendrocyte apoptosis [314, 315]. The reason behind this mismatch is unclear;
however, both of these studies focussed on cell culture assays, and given the pleitropic
and context-dependent effects of this superfamily, caution must be taken when in-
terpreting these results. An additional point to consider is the differences between
the activin-B and Smad3 knock-out animals [272]. It is possible that the activin-B
ligand knock-out had less severe effects due to compensatory effects from activin-A,
compared to the Smad3 knock-out which ablates signalling of both activins. Given
their results from treatment of oligodendrocyte cultures were similar across activins
(this data was not shown but mentioned in the discussion), it would have been inter-
esting to know whether activin-A is expressed post-natally in the developing spinal
cord, and to test whether a compensatory mechanism is responsible for the observed
differences between activin-B and Smad knock-out. Finally, while the authors pro-
vide good evidence for roles of different ligands in the TGF-β superfamily during
myelination, they do not directly manipulate the receptors, and thus do not address
the question of which receptor (TGF-β or activin) mediated the observed effects.
TGF-β signalling in oligodendrocyte differentiation
Interestingly, another study also found that TGF-β signalling was important for
oligodendrocyte development and myelination, but due to its effects on differentia-
tion, not proliferation [271]. Despite the differences in proposed mechanisms between
this study and the one discussed above—which could be due to distinct myelination
programs across brain regions [1] or embryonic vs post-natal differences—both stud-
ies confirm an important role for TGF-β in developmental myelination. Consistent
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with this study, there is much evidence for the anti-proliferation, pro-differentiation
role of TGF-β in many systems [316–320]. The authors elegantly demonstrated the
role of TGFβRII in promoting oligodendrocyte differentiation and myelination in
subcortical white matter via loss-of-function and gain-of-function experiments both
in vivo and in vitro [271]. Using PCR and Western blot techniques, the authors first
characterized the expression of TGF-β ligands, receptors, and downstream Smads
during subcortical white matter development in mice (between P8-P60), and found
that the expression profiles of these factors coincided with the transition of oligoden-
drocytes from progenitors to pre-myelinating cells. Next, the authors administered
TGF-β1 ligand to both OPCs in vitro and systemically to P5 mice, and observed ac-
celerated differentiation and myelination, along with higher levels of myelin proteins
MBP, CNP, and MOG. This effect was blocked when TGF-β1 treatment was ad-
ministered with a TGFβRII antagonist, suggesting this receptor mediates the effects
seen with TGF-β1. Further, when this receptor was genetically deleted in OPCs
using two different inducible Cre drivers (PDGFα-Cre and NG2-Cre), the authors
noted a decease in number of mature oligodendrocytes, an increase in OPCs, and a
decrease in mature myelin markers MBP, CNP, and MOG. Additional experiments
found that this effect was due to a regulation in cell cycle exit by TGF-β signalling—
specifically, Smad2/3 activation by TGF-β leads to nuclear localization via Smad4;
this complex then cooperates with transcription factors FoxO1 and Sp1 to modulate
transcription of anti-mitotic target genes (c-myc and p21 ) involved in regulating
cell cycle exit and differentiation. Importantly, the authors found that this effect
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was cell-autonomous: when TGF-β1 was administered to mice lacking TGF-βRII in
OPCs, there was no effect on oligodendrocyte differentiation or myelination, despite
the presence of these receptors on other cell types (microglia and astrocytes). All
together, this data suggests an important role for the TGF-β pathway in oligoden-
drocyte responses and developmental myelination. As such, it has been speculated
that disruption of these pathways could be involved in myelin and neurodegenerative
disorders of the CNS.
Negative myelination effects of some TGF-β ligands
Consistent with this, members of the TGF-β superfamily have been implicated
in myelin destruction and repair. Interestingly, BMP4 has been shown to have an
inhibitory effect on oligodendroglial differentiation in a cuprizone model of demyeli-
nation [321]. Specifically, the authors found that an increase in BMP signalling
(identified by pSmad1/5/8+ staining) following cuprizone-induced demyelination in
vivo was blocked by administration of Noggin, a BMP4 antagonist, and this re-
sulted in an increase in density of mature oligodendrocytes and improved remyelina-
tion. Conversely, exogenous BMP4 administration resulted in higher pSmad1/5/8
signalling, and an increase in BrdU+ proliferating oligodendrocytes during demyeli-
nation followed by a decrease in oligodendrocyte density during recovery. While the
authors observed increased numbers of astrocytes during recovery in BMP4 treated
animals, they found that these cells did not originate from the BrdU+ proliferat-
ing oligodendrocytes. Rather, their results suggest that BMP4 treatment promoted
oligodendrocyte apoptosis via caspase-3 during recovery. This evidence suggests that
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while BMP-driven Smad1/5/8 signalling seems to promote proliferation of OPCs, its
downregulation during myelin injury could be beneficial for oligodendrocyte differ-
entiation and myelination.
Additionally, a recent investigation into the effects of the coagulation factor
fibrinogen on oligodendrocyte progenitors and remyelination found that in vitro,
fibrinogen inhibits oligodendrocyte maturation and myelination via activation of
Smad1/5/8-mediated BMP signalling in OPCs [322]. These effects were reversed
using a BMP type I receptor (Acvr1) inhibitor, but not a BMP ligand inhibitor,
suggesting that fibrinogen exerts its effects in a BMP-ligand independent manner.
The authors also found that in vivo, fibrinogen depletion resulted in a decrease of
Smad1/5/8 accumulation in the nucleus and enhanced remyelination [322]. These
results are in line with previous research suggesting the inhibitory role of BMPs in
myelination and remyelination [323–326].
Addressing the pleiotropic effects of TGF-β signalling
Taken together, the results of these studies provide evidence for divergent ef-
fects of members of the TGF-β superfamily on oligdendrocyte lineage cells, myelina-
tion, and remyelination. Specifically, the evidence to date suggests opposing effects
on OPC proliferation and differentiation for Smad1/5/8-mediated signalling versus
Smad2/3-mediated signalling. However, as mentioned above, the ultimate cellular
response resulting from activation of either pathway is complicated by the many
regulatory mechanisms both upstream and downstream of Smad signalling. Start-
ing with the ligand-receptor interaction, there are several factors in the extracellular
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environment that determine whether a ligand will bind a particular receptor, includ-
ing availability of the ligand, concentration of the ligand compared to antagonists,
and concentration of competing ligands. Once a specific ligand has bound a type II
receptor, the downstream signalling events are mediated by a type I receptor, which
may activate either canonical (Smads) or non-canonical (see Figures 3 and 4) path-
ways, eliciting a number of potential responses. As mentioned above, Smad-mediated
pathways are controlled by inhibitory Smads (Smad6/7), which can negatively reg-
ulate signalling post ligand-binding. Taking into account the many roles identified
for TGF-βs, it is not surprising that these pathways are finely tuned—in fact, the
pleiotropic and context-dependent effects of this superfamily are likely a result of
this feature.
Therefore, given the diverse potential effects of TGF-β-mediated signalling, it is
crucial to understand the function and mechanism of these various protein/receptor
interactions and their downstream effectors in context. In terms of elucidating how
this superfamily influences myelination and remyelination, it is important not to
make assumptions or generalizations based on any individual model, receptor, or
ligand. While the previous literature has focused on a handful of ligands (activin-
B, BMP4, TGF-β1) and receptors (TGFβRII, BMPRII, Acvr1, Acvr1c), the role
of activin-A and its receptors (Acvr2a, Acvr2b, and Acvr1b) in myelination and
remyelination remains unexplored.
Our lab, including my own work, was the first to identify activin receptors 2a
and 2b as important regulators of oligodendrocyte lineage cell responses in health
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and disease across the lifespan [327]. Parts of this thesis have been published in our
paper (see Appendix), and results will be discussed in relevant chapters.
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1.6 Aims of Thesis
Given the evidence suggesting activin-A and activin receptors could have a re-
generative role in the CNS, and specifically in the regeneration of myelin, my PhD
project sought to determine whether activin receptor modulation could be a thera-
peutic target for regeneration in demyelinating diseases.
Hypothesis: Activin receptors are required to drive remyelination, and ligands bind-
ing these receptors can be used to enhance remyelination.
Aims:
1. Assess the requirement of activin receptors during remyelination
2. Identify alternative activin receptor ligands and elucidate their involvement in
remyelination
3. Determine the mechanism of action of activin receptors in remyelination
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2 Chapter 2: Materials and Methods
2.1 Animals used and ethics statements
CD1 wild-type mice were utilised for organotypic cerebellar slice culture experi-
ments. For in vivo lesioning experiments, 8-12 week old male C57Bl/6J mice from
Charles River Laboratories were purchased. Transgenic mice used include Smad2/3
reporter mice (pR26-228 AR8-TA-mCherry; henceforth described as AR8-mCherry)
purchased from Jackson Laboratories, as well as MacGreen macrophage/microglial
reporter mice (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J), which were bred to AR8-mCherry
mice and used for live imaging experiments (referred to as AR8-mCherry/MacGreen).
All experiments were of moderate severity, and performed under the UK Home Office
project licenses issued under the Animals (Scientific Procedures) Act. For in vivo
experiments, adult male mice were utilized to reduce hormonal effects. When using
osmotic pumps to administer compounds, animals were single-housed post surgery
in closed-top cages to minimize injury. In experiments where pumps were not used,
mice were group-housed, with 4-5 mice in each open-top cage. Mice were randomized
before surgery, and blinded post-perfusion. In all experiments a minimum of 3 and
a maximum of 6 mice were used per condition.
2.2 Genotyping
Genomic DNA was extracted from ear or tail tissue using the Wizard SV ge-
nomic purification system (Promega) according to the manufacturer’s instructions.
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AR8-mCherry mice were genotyped according to Jackson Laboratories’ instruc-
tions. Briefly, standard PCR was performed with primers 16938 (ACGTTTC-
CGACTTGAGTTGC) and 16939 (AATACTCCGAGGCGGATCAC). MacGreens
were genotyped using primers primers 79 (ATCATGGCCGACAAGCAGAAGAAC)
and 80 (GTACAGCTCGTCCATGCCGAGAGT).
2.3 Animal models of remyelination
Organotypic cerebellar slice cultures. Brains from P0-P3 wildtype CD1, AR8-
mCherry, and AR8-mCherry/MacGreen mouse pups were extracted followed by the
isolation of hindbrain and cerebellum, and sectioned into 300µm sagittal slices using
a McIlwain tissue chopper (as previously described in [142]). Six slices were plated
onto Millipore-Millicel-CM mesh insert (Fisher Scientific) placed into 6-well plates
with 1 ml slice culture media per well. Each well contained slices from one animal
only. Media was changed every 2-3 days, and composed of 50% minimum essential
media, 25% heat-inactivated horse serum, 25% Earles balanced salt solution (all
from GIBCO), 1% penicillin-streptomycin, 1% glutamax, and 6.5 mg ml−1 glucose
(all from Sigma). At 21 days in vitro, demyelination was induced via lysolecithin
(0.5 mg ml−1, Sigma) in media for 18-20 hours. Slices were washed in media for 10
minutes and left for 2 days to recover. Experiments were then either left untreated,
or treated with Activin receptor ligands (both inhibitors and stimulators of receptor
activity, all treatments listed in Table 5). Treatment was administered with every
media change until 7, 10, or 14 days post lysolecithin (dpl). Slices were then fixed
65
in 4% Paraformaldehyde (PFA) in PBS for 10 minutes.
Table 5. Treatments used in ex vivo and in vivo experiments.
Treatment Effect Control Concentration Company Cat No
Activin Acvr
agonist
4mM HCl 100 ng/ml R&D 338-AC-010
Inhibin Acvr
antagonist










Goat IgG 5 µg/ml R&D AF338
BMP6 Acvr
ligand





4mM HCl 100 ng/ml R&D 1958-GD-010
GDF1 Acvr
ligand















100 ng/ml R&D 994-LF-025
In vivo corpus callosum lesion model. 8-12 week old male C57BL/6J mice were
anaesthetised using Isofluorane and given an analgesic (Vetergesic/Rimadyl, mixed
at a 2:1 ratio, administered at 0.06ml subcutaneously per mouse). To prevent eye
dryness during surgery, animals were given one drop of a lubricating ointment (Lacri-
lube, Refresh) per eye. Using a diamond-tipped drill, a marker hole was made in
the skull at Bregma and a burr hole made at 1.2mm posterior and 0.5mm laterally
to the right. Demyelinating lesions were induced in the corpus callosum of mice
by stereotaxic injection of 1% lysolecithin using a Hamilton syringe. Sham lesions
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were induced by phosphate-buffered saline (PBS) injection. The Hamilton syringe
was loaded on the rig with either compound, and inserted into the burr hole at
1.4mm ventral to the surface of the skull. A total 2µl of compound was injected into
the brain at 0.5µl per minute. In experiments where mice were given a treatment
post-lesion, implantable osmotic infusion pumps were used (Alzet/Durect). Pumps
were inserted subcutaneously in a small pocket created by blunt dissection from an
incision between the scapulae. A polyethylene tube connected the micro-osmotic
pumps to a brain catheter, which was inserted into the lesion site and glued onto
the skull. Mice were then sutured using Mersilk 6-0 (Ethicon). The pumps released
0.11µl of compound per hour for up to 28 days. Treatments administered include
Activin-A, Inhibin, GASP-1, Sclerostin, and Lefty-1, with their respective controls
and at the same concentrations listed in Table 5. Mice were intracardially perfused
at 3, 7, 10, 14, and 21 days post lesion (dpl) with (i) PBS for subsequent lesion
dissection and RNA extraction, (ii) 4% paraformaldehyde (PFA, wt/vol, Sigma)
for immunohistochemical assays, or (iii) 4% PFA with 2% glutaraldehyde (vol/vol,
TAAB Laboratories) in 0.1M phosphate buffer for electron microscopy embedding.
2.4 Immunofluorescent staining and imaging
Organotypic cerebellar slice cultures. Fixed explants were blocked (0.3% Tri-
tonX and 5% heat-inactivated horse serum in PBS) for 1 hour at room temperature
and primary antibody applied for 2 nights overnight at 4°C. Primary antibodies used
are listed in Table 6. Slices were washed twice in PBS-0.1% TritonX before apply-
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ing fluorescently conjugated secondary antibodies (AlexaFluor, Life Technologies,
1:500) for 2 hours at room temperature. Following counterstaining with Hoechst for
10 minutes (1:1000), slices were washed 3 times in PBS-0.1% TritonX before being
mounted with Fluoromount-G (Southern Biotech) on glass slides and coverslipped,
or in 96-well plates with Coverglass base (Thermo). Z-stacks were captured using
the Olympus spinning disk confocal microscope (60x and 30x silicone oil objective)
and SlideBook software (3i). Images were cropped to 14 slices (0.59 µm/slice) in
SlideBook (3i) and exported as TIFFs. TIFF files were blinded and imported into
Volocity (Perkin Elmer) as an image sequence. A measurement protocol was used to
quantify voxels in each channel as well as overlapping voxels between channels. Re-
myelination index was calculated by normalizing colocalization values (MBP+NF+)
to NF+ voxel counts, and this value for treated slices was further normalized to vehi-
cle controls. All data was compiled and managed in Microsoft Excel, and statistical
analyses were performed in GraphPad Prism.
In vivo corpus callosum lesions. Brains from animals intracardially perfused
with 4% PFA (wt/vol, Sigma) were post-fixed overnight and cryoprotected in sucrose
prior to embedding in OCT (Tissue-Tech) and stored at −80°C. 10 µm tissue cryosec-
tions were air dried then blocked (0.3% TritonX and 5% heat-inactivated horse serum
in PBS) for 1 hour at room temperature. Primary antibodies were applied overnight
at 4°C (listed in Table 6). Sections were washed three times in PBS before apply-
ing fluorescently conjugated secondary antibodies (AlexaFluor, Life Technologies,
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1:500) for 2 hours at room temperature. Following counterstaining with Hoechst for
10 minutes (1:1000), sections were washed 3 times in PBS before being coverslipped
with Fluoromount-G (Southern Biotech). Single plane images were captured using
the Olympus spinning disk confocal microscope (60x and 30x silicone oil objective)
and SlideBook software (3i). Images were exported as TIFFs.
Human Multiple Sclerosis tissue. Post-mortem tissue from multiple sclerosis
patients and non-neurological controls were obtained. Diagnosis of multiple sclerosis
was confirmed by neuropathological means. Post-mortem delay (time from death
to tissue preservation) was 7-31 hours. Frozen unfixed tissue blocks (2x2x1 cm)
were cut at 10 µm and stored at −80 °C by laboratory technicians in the Williams,
ffrench-Constant (SCRM) and Miron groups. Multiple sclerosis lesions were clas-
sified by neurologist Anna Williams according to the International Classification of
Neurological Disease using luxol fast blue staining and CD68+ immunoreactivity. We
analyzed 4 control blocks and 10 tissue blocks from 8 multiple sclerosis patients; in
total, we analysed 7 active lesions, 10 chronic active lesions, 8 chronic inactive lesions
and 23 remyelinated lesions. See Table 7 for further details on human post-mortem
tissue. Sections were fixed in 4% PFA for 1 hour at room temperature, washed in
TBS, and permeabilized in methanol for 10 minutes at −20°C. Following washes
in 0.1% Tween20 (vol/vol) in TBS, sections were microwaved in Vector unmasking
solution for 10 minutes on medium power, washed once with TBS/Tween20 and
endogenous phosphatase and peroxidase activity blocked for 10 minutes (Bloxall,
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Vector). Primary antibody was prepared in 2.5% Normal Horse Serum (Vector) and
applied overnight in a humid chamber at 4°C. Primary antibodies used are listed in
Table 6. Following three washes in TBS, alkaline phosphatase-conjugated secondary
antibody to mouse or rabbit was applied for 30 minutes at room temperature in a
humid chamber. Sections were washed in TBS and stains were visualised by Vector
Blue substrate kit used as per the manufacturer’s instructions. After three further
TBS washes, the sections were blocked to quench any remaining phosphatase activity
(Bloxall, Vector) and the next primary antibody was applied as above. The second
primary antibody was developed using Vector Red substrate kit according to the
manufacturer’s instructions. Following washes in water, the sections were counter-
stained with Hoechst (1:10000) for one minute and coverslipped with Fluoromount-G.
Slides were imaged using Zeiss AxioScan SlideScanner. Images were prepared using
Zeiss Zen2 software. Lesions were identified using luxol fast blue maps of each tissue
(provided by Anna Williams). Fields of 360 µm x 360 µm were counted per lesion
and counts were multiplied to determine density of immunopositive cells per mm2.
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Table 6. Primary antibodies used for immunofluorescence.
Antigen Species Dilution Company Cat No
Myelin Basic Protein (MBP) Rat 1:250 AbD Serotec MCA409S
Olig2 Mouse 1:100 Millipore MABN50
Olig2 Rabbit 1:100 Abcam AB9610
Neurofilament-H Mouse 1:1000 EnCor MCA9B12
β-tubulinIII Mouse 1:400 Sigma-Aldrich T8578-200UL
Activin receptor IIA Rabbit 1:100 Invitrogen PA5-13886
Activin receptor IIB Rabbit 1:100 Invitrogen PA5-13888
Activin receptor IB Rabbit 1:100 Abnova PAB18053
CD68 [FA-11] Rat 1:100 Abcam AB53444
CD68 Mouse 1:100 Dako M0814
GFAP Chicken 1:1000 Covance Z0334
PU.1 [D-19] Goat 1:100 Santa Cruz SC5949
GDF1 Rabbit 1:50 Abcam AB139721
GDF11 Rabbit 1:100 Biorbyt ORB101175
BMP6 Rabbit 1:100 Novus NBP1-19733
Table 7. Postmortem Multiple Sclerosis lesion tissue.
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2.5 RNA extraction, reverse transcription, and RT-qPCR
Organotypic cerebellar slice cultures. Slices were washed with PBS, lysed
with RLT buffer supplemented with β-mercaptoethanol, scraped, and homogenized
with 21 gauge needles. RNA extraction was performed using the Qiagen minikit
(with on-column DNase treatment), and reverse transcription performed using the
Invitrogen Superscipt First-strand synthesis system for RT-PCR, both according to
the manufacturer’s instructions. A custom quantitative PCR array plate (Qiagen)
was designed to include genes for TGF-β family members that have a binding affinity
for Activin receptors. Quantitative PCR was carried out using the ABI7900HT
Standard. Ct values were obtained using the second derivative maximum method
and ∆Ct was calculated by subtracting average value from a housekeeping gene
(Actb). Expression is represented as 2−∆Ct.
In vivo corpus callosum lesions. Brains were dissected from PBS perfused mice
(as described above in 2.2) and using a brain matrix, a 2mm coronal section was
cut and placed in cold PBS. The lesion area was dissected and homogenized using
a glass dounce (Wheaton) and QIAshredder tubes (Qiagen). RNA extraction was
performed using the Qiagen All-Prep kit (with on-column DNase treatment), and
reverse transcription performed using the Invitrogen Superscript First-strand syn-
thesis system for RT-PCR, both according to manufacturer’s instructions. Custom
plates and qPCR methods were identical to the ones listed above.
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2.6 Protein extraction and Western blotting
Organotypic cerebellar slices were washed with PBS, scraped and collected in 1mL
4°C PBS, and homogenized with 21 gauge needles. Samples were immediately cen-
trifuged at 13,000 rpm for 7 minutes, supernatant was removed, and pellets were re-
suspended in RIPA buffer (Sigma-Aldrich) supplemented with protease and phospho-
tase inhibitors (1:100, Sigma-Aldrich). Samples were kept at -80 °C until total pro-
tein concentrations were determined using the Pierce BCA Protein Assay Kit as per
manufacturer’s instructions (Thermo Scientific). Samples were diluted in Laemmli
buffer (Bio-Rad), supplemented with 5% β-mercaptoethanol, heated at 95°C for 2
min, and 10 µg of protein was loaded onto a polyacrylamide gel (4-15%, Bio-Rad).
Gel electrophoresis was performed in a Tris-hydorxyethyl piperazineethanesulfonic
acid (HEPES)-sodium dodecyl sulfate (SDS) running buffer (Thermo Scientific) at
100V for 45 min. Proteins were transferred onto polyvinylidene difluoride (PVDF)
membranes (Thermo Scientific) for 2 h at 10V in 10% Pierce transfer buffer (Thermo
Scientific) and 20% methanol diluted in H2O. Membranes were blocked with 4%
bovine serum albumin (BSA) in Tris-buffered saline-0.1% Tween-20 (vol/vol) (TBST,
Thermo Scientific) for 1 hour at room temperature on an orbital shaker, and incu-
bated overnight at 4°C with rabbit anti-BMP6 (1:500, Novus Biologicals), rabbit
anti-GDF1 (1:1000, Abcam), and rabbit anti-GDF11 (1:1000, Biorbyt). Membranes
were washed three times in TBST for 10 minutes, and incubated with horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (Cell Signalling
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Technology, 1:2000) for 1 hour at room temperature. Chemiluminescent substrate
detection reagent ECL (Thermo Scientific) and digital imaging was performed us-
ing the LI-COR Odyssey Fc system. Membranes were re-blotted with antibody to
mouse Actin (1:20000, Cell Signalling Technology) and HRP-conjugated anti-mouse
IgG secondary antibody (LI-COR, 1:2000) as above for loading control purposes.
2.7 Resin embedding, semi-thin sections, and electron mi-
croscopy
Mice were intracardially perfused with 4% PFA (wt/vol) and 2% glutaraldehyde
(vol/vol; TAAB Laboratories) in 0.1 M phosphate buffer. Tissue was post-fixed
overnight at 4°C and transferred to 1% glutaraldehyde (vol/vol) until embedding. 1
mm tissue sections were processed into araldite resin blocks, followed by microtome
cutting of 1 µm sections. Sections were stained with a 1% toluidine blue/ 2% sodium
borate solution prior to bright field imaging at 100X magnification using a Zeiss Axio
microscope. Ultrathin sections (60 nm) were cut from corpus callosum, stained in
uranyl acetate and lead citrate, and grids imaged on a JEOL Transmission Electron
Microscope. Axon diameter and myelin thickness were calculated from measured
area based on assumption of circularity using Fiji/ImageJ (Fiji.sc), with a minimum
of 100 axons per animal analyzed. Standard g ratio analysis of myelin thickness was
calculated by determining the ratio of the inner axonal diameter to the total outer
diameter of the axon plus myelin. Myelinated axon density was counted blindly in
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8.62µm x 8.62µm images of the corpus callosum and scaled up to determine density
per mm2. A minimum of 3 images per animal were analyzed; each experimental
condition contained 3-5 animals. Measurements were compiled in Microsoft Excel
and organized using RStudio. ‘Proportion of myelinated axons’ by axon diameter
was determined by plotting the proportion of a sample of 100 myelinated axons
from each animal that were of a specific diameter, which was fitted with a best-
fit polynomial regression curve. To compare treatment and vehicle control curves,
a Kolmogorov-Smirnov test was used to test whether cumulative distributions of
myelinated axon diameters differed between conditions. To compare proportion of
myelinated axons by bin between treatments, data was plotted in Microsoft Excel
and a 2-way ANOVA with Bonferroni’s multiple comparisons test was carried out.
All statistical tests were done using GraphPad Prism 7.
2.8 Flow cytometry
Organotypic slice cultures from AR8-mCherry mice were pooled (3-6 slices per
sample) at 0, 2 and 7 days post lesion (dpl) and homogenised with a 2 ml dounce
tissue homogeniser. A Percoll (Sigma-Aldrich) gradient was used to isolate cells
from myelin debris. Samples were blocked with Fc-block (LEAF-purified anti-mouse
CD16/32 (Biolegend, 101321), then incubated with fluorochrome-conjugated anti-
bodies CD11b-AF647 (BioLegend 101218, 1:200) or PDGFRa-PE (BioLegend, 135905,
1:100), MAG-FITC (EMD Millipore, FCMAB337F, 1:100), and O4-APC (R&D,
FAB1326A, 1:100) for 30 minutes on ice. Following washes in buffer, samples were
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incubated with DAPI and run on the BD LSR Fortessa (6 laser) analyser, and anal-
ysed using FACSDiva software (BD). Gating was based on live (DAPI−) mCherry+
cells, followed by gating for singlet cells, and finally forward and side scatter to
eliminate cell debris and clusters. Cell populations were then gated for CD11b+
(microglia), PDGFRa+ (oligodendrocyte progenitors), O4+ (immature oligodendro-
cytes), and MAG+ (mature myelinating oligodendrocytes).
2.9 Live imaging
An insert with cultured cerebellar slices was adhered by the feet to a single 4
cm petri dish with molten wax and left briefly to dry. Media was first pipetted into
the petri dish to diffuse under the mesh then gently pipetted onto the surface of
mesh. Z-stacks were acquired as snapshots using a 20X wet-immersion objective on
the Olympus spinning disk confocal microscope, incubated at 37°C (high humidity)
and 5% CO2.
2.10 Statistics
All statistical tests were performed using GraphPad Prism 7, and power calcula-
tions performed using the free online tool OpenEpi. Statistical tests carried out for
each type of experiment will be discussed in turn.
Organotypic slice culture experiments. Slice culture experiments were analyzed
by treatment group and by time point. The goal was to compare differences between
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treatment and their respective controls at separate times during remyelination. To
do this, treatment values for each animal were normalized to the averaged control
value (n=3 for controls). Therefore, the control value is a hypothetical value of 1, and
changes with treatment are expressed as fold change. In order to determine whether
these changes are statistically significant, column statistics were used. Specifically,
a one-sample t-test compared to a theoretical mean of 1 (control) was performed. A
comparison of this method to a Kruskal-Wallis with Dunn’s Multiple comparisons
test on the raw data (where none of the data was averaged or normalized) revealed
similar results (see Figure 6 in Chapter 3). Since comparison between treatments is
better visualized when data is normalized to their respective vehicle controls, and
since this method is an accurate representation of the raw data, this was the chosen
method of data visualization for all further slice culture experiments. When data
was entered into OpenEpi to determine statistical power, all slice culture experiments
had at least 80% power. Group sizes for each experiment are between 3-6 animals
per treatment per time point and specifically stated in each figure.
In vivo lesioning experiments. In vivo experiments were analysed by treatment
group in order to compare each treatment to their respective vehicle controls during
remyelination. G ratios were analysed, both by individual axon counts (100 axons
per animal, 3-5 animals per group) and by animal averages. To compare G ratios,
a Mann-Whitney test was used, as data was unpaired and non-parametric. G ratio
was also analysed by axon diameter, and here an extra sum of squares F-test was
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used, as this test compares the goodness of fit between 2 models. As such, the line
of best fit of data points in the treatment group was compared to the control group.
Next, to determine whether the number of myelinated axons was different between
treatment and controls, two different analyses were carried out. First, myelinated
axons were counted per field in 10 images per animal, and the average for each ani-
mal was multiplied up to mm2. A Mann-Whitney test was used, as again data was
unpaired and non-parametric. Second, 100 myelinated axons were counted per ani-
mal and the axon diameter was measured for each axon. The relative percentages of
number of myelinated axons of specific diameters were then plotted. To compare the
distribution of axon diameters of treatment to vehicle control, a 4th-order polyno-
mial best-fit curve was plotted, and a Kolmogorov-Smirnov test was carried out. In
order to further compare treatment vs control across all axon diameters and within
each bin of diameter, a 2-way ANOVA with Bonferroni’s multiple comparisons test
was carried out. Many of these experiments did not reveal statistically significant
results, perhaps because they were underpowered.
Post-mortem human multiple sclerosis tissue analysis. To compare percent-
age of cells co-expressing markers for activin receptors or receptor ligands across
4 different lesion types and control tissue, a Kruskal-Wallis test was used. This is
a non-parametric test comparing 3 or more unmatched groups. Dunn’s multiple
comparisons test was performed to compare differences in the sum of ranks with
the expected difference based on number of groups and their size. Each lesion type
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was further compared to control tissue. N numbers for these experiments are stated
above, and presented in Table 7.
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3 Chapter 3: Activin receptors are required for
effective remyelination
3.1 Introduction
As described in detail in Chapter 1, myelin is an important component of the
central nervous system, providing insulation for electrical impulse conduction as
well as trophic and metabolic support to neurons [1, 2, 18, 22]. In diseases where
myelin is damaged and lost (such as multiple sclerosis), axons become vulnerable to
degeneration, leading to sensory and motor deficits. Myelin can be regenerated, and
requires oligodendrocyte progenitor cells (OPCs) to activate, migrate to the site of
injury, proliferate, and differentiate into mature myelin-making cells [24–26]. While
this process can be efficient early in MS, it often fails with disease progression [46,
166, 195, 208]. One proposed therapeutic strategy is to improve clinical outcome by
targeting the remyelination process. Promoting myelin regeneration would restore
support to axons, which may confer protection from neurodegeneration, ultimately
slowing or stopping disease progression. However, mechanisms underlying drivers of
remyelination and reasons for its failure in MS are not fully understood.
Previous work in our lab identified the TGF-β superfamily member activin-A
as being increased during remyelination in vivo and sufficient in stimulating ac-
tivin receptor-driven OPC differentiation in vitro [142]. However, it was not clear
whether activin receptor-mediated activity could directly influence remyelination.
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This chapter focusses on determining whether activin receptor signalling is required
for remyelination in focal demyelinating lesion models ex vivo and in vivo.
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3.2 Results
3.2.1 Creating a quantification method for remyelination in slices
The gold standard for quantifying remyelination in vivo is using electron mi-
croscopy to calculate g ratio (as described in section 1.2.2). As this is technically
difficult in ex vivo slices (protocol outlined in Figure 5a), an alternative method
for quantifying myelin regeneration was required. Using images from immunofluo-
rescently stained slices, a quantification method was developed for calculating area
of axons, area of myelin, and the area in which these two stains overlap. A theo-
retically simple idea was difficult to carry out in practice, as the axonal stain was
not robust in myelinated areas, potentially due to antibody penetration issues. It
is counter-productive to carry out a more effective tissue permeabilization proto-
col, as this would disrupt myelin structure. To acquire images of sufficient quality
for quantification, staining and image acquisition protocols were optimized. Then,
using image analysis software (Volocity, PerkinElmer), parameters were set for de-
termining objects in each stain: axons (neurofilament, NF) and myelin (myelin basic
protein, MBP). Filters were set for minimum object size, and a threshold was ap-
plied individually to blinded images. A mask was created for voxels in which the
two objects co-localize. The total voxel count for these three objects (NF, MBP, and
co-localized) was extracted. These numbers were used to calculate the remyelination
index: area of co-localization divided by area of axons (Figure 5). This new protocol
allowed for an objective quantification of myelin regeneration in slice cultures.
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Figure 5. Developing a method for quantifying remyelination ex vivo. a)
Protocol timeline for organotypic slice cultures. b) Sample image stained with Myelin
Basic Protein (MBP, red) and Neurofilament (NF, green). c) Masks of individual
stains and colocolization area of (b). All masks shown together in bottom right panel.
d) Formula for calculating remyelination index. e) Sample images of myelinated (top)
and demyelinated (bottom). f) Raw myelination indices of (e).
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3.2.2 Activin receptor stimulation can accelerate remyelination ex vivo
To examine whether stimulation of activin receptors affects remyelination, de-
myelinated ex vivo cerebellar slices were treated with activin-A, the primary ligand
for activin receptors. Activin-A has the highest binding affinity for activin receptors,
and once bound, activates downstream signalling pathways leading to expression of
target genes. Slices treated with activin-A significantly increased remyelination at
7 days post lesion compared to vehicle controls (Figure 6b, **P=0.0057). No sig-
nificant differences were observed in remyelination index at 10 and 14 days post
lesion, likely due to remyelination processes occurring efficiently in controls. Thus,
this data suggests that stimulating activin receptors using activin-A is sufficient to
accelerate remyelination. This result was published in our recent paper [327]. To
confirm whether normalized data was representative of raw data, raw data was plot-
ted and analysed (Figure 6d). Raw myelination index of activin-A treated slices
was significantly higher than vehicle control at 7dpl, but not at 10dpl or 14dpl.
Raw myelination index values for vehicle controls show that as myelin regeneration
proceeds with time, slices naturally become increasingly myelinated, and eventually
catch up to the accelerated remyelination seen with activin-A treatment. There-
fore, normalized data (as shown in Figure 6b) is representative of the raw data, and
is suitable for analysis of further slice culture remyelination index data within this
thesis.
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Figure 6. Activin-A accelerates remyelination in ex vivo cerebellar slices. a)
Activin-A binds with high affinity to activin receptors and activates downstream signalling
pathways. b) Mean remyelination index ± s.e.m. in activin-A treated ex vivo slices at 7,
10, and 14 days post lysolecithin (dpl) normalized to vehicle control from the respective
time point. n=3 animals, one-sample t-test compared to a theoretical mean of 1 (control),
**P=0.0057 at 7dpl. c) Representative images of slice cultures at 7dpl treated with
vehicle control or activin-A during remyelination, immunostained against myelin basic
protein (MBP, green) and axonal neurofilament-H (NF, red). Scale bar, 50 µm. d) Raw
myelination index data ± s.e.m. from (c) for activin-A (black bars) and vehicle controls
(grey bars) at 7, 10, and 14dpl. Kruskal-Wallis test (*P=0.0181) with Dunn’s multiple
comparisons (*P=0.0259 at 7dpl).
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3.2.3 Activin receptors are required for remyelination ex vivo
To determine whether activin receptors are required for remyelination, demyeli-
nated ex vivo cerebellar slices were treated with inhibin, an activin receptor inhibitor.
Inhibin competitively binds activin receptors, preventing binding of endogenous lig-
ands, and blocking downstream signalling (Figure 7a). Treatment with inhibin sig-
nificantly reduced remyelination at 7, 10, and 14 days post lesion compared to vehicle
controls (Figure 7b), suggesting for the first time that activin receptor signalling is
required for remyelination. This result was published in our recent paper [327].
3.2.4 Activin receptor modulation influences remyelination in a calibre-
dependent manner in vivo
To confirm whether modulating activin receptor activity using activin-A/inhibin
affects remyelination in an in vivo model, implantable osmotic mini-pumps with
attached brain cannula were used to supplement compounds directly to lysolecithin-
induced focal lesions in the corpus callosum (CC) of mice (Figure 8a). Lesion areas
were processed at 7 days post lesion (dpl) in activin-A treated mice, and at 14dpl
in inhibin treated mice. These time points were chosen based on results from the
above ex vivo experiments. Electron microscopy was then carried out to determine
effects on myelin thickness and density of myelinated axons. In activin-A treated
mice, there were no significant differences between treatment and control in terms
of g ratio (Figure 8b-d) or density of myelinated axons (Figure 8e). However, when
the data was stratified by axon diameter, a non-significant trend emerged in number
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Figure 7. Inhibin blocks remyelination in ex vivo cerebellar slices. a) Activin
receptor activity is blocked by inhibin, which competes with activin-A for the receptor
binding site. b) Mean remyelination index ± s.e.m. in inhibin treated ex vivo slices at 7,
10, and 14 days post lysolecithin (dpl) normalized to vehicle control from the respective
time point. n=3 animals, one-sample t-test compared to a theoretical mean of 1 (control),
*P=0.0165, *0.0374, **0.0004, respectively. c) Representative images of slice cultures at
14dpl treated with vehicle control or inhibin during remyelination, immunostained against
myelin basic protein (MBP, green) and axonal neurofilament-H (NF, red). Scale bar, 50
µm.
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of myelinated axons: a higher number of myelinated axons were observed in axons
smaller than 0.4 µm in diameter (Figure 8f). Representative images are shown in
Figure 8g.
In inhibin treated mice, there were no differences in overall g ratio between treat-
ment and control (Figure 9a,b). However, when g ratio was plotted against axon
diameter, slopes were significantly different (Figure 9c), suggesting distinct distribu-
tion of myelin thickness across axon diameters between inhibin and vehicle treated
lesions. While there were no differences between overall density of myelinated axons
(Figure 9d), when data was segmented by axon diameter, the cumulative distribu-
tions (represented by the curves in Figure 9e) were significantly different between
treatments. This data suggests that blocking activin receptors results in a shift in
the distribution of diameters of myelinated axons. Representative images are shown
in Figure 9f.
Taken together, this in vivo data corroborates the effect of activin receptor mod-
ulation on remyelination seen in the ex vivo model, albeit with an important caveat.
Axon diameter appears to be a potential determinant of how activin receptor mod-
ulation ultimately affects repair, suggesting there may be distinct mechanisms sup-
porting small versus large calibre axon remyelination.
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Figure 8. Activin-A treatment in focal lesions in vivo. a) Protocol diagram for
in vivo focal lesions. b) Overall g ratio ±s.d. of activin-A treated animals compared
to control, n=100 per animal, 3 animals per condition. Mann-Whitney test, no signifi-
cant differences. c) G ratio ±s.e.m. of Activin-A treated animals compared to control
averaged by animal. Mann-Whitney test, no significant differences. d) Dot plot of g
ratio and axon diameter in Activin-A treated (magenta) and vehicle controls (green).
Extra sum of squares F-test between slopes, non-significant. e) Mean of total number of
myelinated axons ±s.e.m. per mm2. Mann-Whitney test, non-significant. f) Proportion
of myelinated axons by axon diameter, in Activin-treated mice (magenta) and vehicle
control (green), overlaid with polynomial best-fit regression curves (Kolmogorov-Smirnov
test, non-significant). n=3 mice per condition, 100 axons measured per animal. 2-way
ANOVA with Bonferroni’s multiple comparisons test, non-significant. g) Representative
images of Activin-A and vehicle treated corpus callosum. Scale bar, 1µm.
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Figure 9. Inhibin treatment in focal lesions in vivo results in differences in
g ratio across axon diameters a) Overall g ratio ±s.d. of Inhibin-treated animals
compared to control, n=100 per animal, 3 animals per condition. Mann-Whitney test, no
significant differences. b) Mean of g ratio ±s.e.m. of Inhibin-treated animals compared to
control. Mann-Whitney test, non-significant. c) G-ratio versus axon diameter in Inhibin
treated (magenta) and vehicle controls (green). Extra sum of squares F-test between
slopes, *P<0.0001. d) Mean of total number of myelinated axons ±s.e.m. per mm2 in
Inhibin treated animals and vehicle controls. Mann-Whitney test, non-significant. e)
Proportion of myelinated axons by axon diameter, in Inhibin treated mice (magenta) and
vehicle control (green), overlaid with polynomial best-fit regression curves (Kolmogorov-
Smirnov test, ****P<0.0001). n=3 mice per condition, 100 axons measured per animal.
2-way ANOVA with Bonferroni’s multiple comparisons test, non-significant. f) Represen-
tative images of Inhibin and vehicle treated corpus callosum. Scale bar, 1µm.
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3.2.5 Activin-A ligand is not required for remyelination ex vivo
Since activin receptor activity was found to be important during remyelination
both ex vivo and in vivo, the requirement for its primary ligand, activin-A, was
subsequently examined. Activin-A activity was blocked in cerebellar slice cultures
using follistatin, a protein which sequesters activin-A with very high affinity and
prevents it from binding to its receptors. A separate control consisted of treatment
with an α-activin-A antibody (Figure 10a). Treatment with these blocking agents
did not affect the remyelination index (Figure 10b). Taken together, this data shows
that although activin receptors are required for remyelination ex vivo, the primary
ligand is not, indicating the likely activity of other ligands with binding capacity to
these receptors in the absence of activin-A.
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Figure 10. Activin-A is not required for remyelination in ex vivo cerebellar
slices. a) Activin-A activity is blocked by follistatin, which sequesters activin-A and
prevents it from binding to its receptor. b) Mean remyelination index ± s.e.m. in fol-
listatin treated ex vivo slices at 7, 10, and 14 days post lysolecithin (dpl) normalized
to vehicle control from the respective time point. n=3 animals, one-sample t-test com-
pared to a theoretical mean of 1 (control). No significant differences were observed. c)
Representative images of slice cultures at 14dpl treated with vehicle control or follistatin
during remyelination, immunostained against myelin basic protein (MBP, green) and
axonal neurofilament-H (NF, red). Follistatin results were confirmed using α-activin-A
antibody; representative image shown on right. Scale bar, 50 µm.
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3.3 Discussion
Activin receptor signalling is sufficient and required for remyelination
In this chapter, I reveal both a sufficiency and requirement for activin receptor
signalling during remyelination ex vivo. Treatment of cerebellar slice cultures with
activin receptor ligand activin-A resulted in an acceleration in remyelination, while
blocking activin receptors with inhibin hindered remyelination. This data is in line
with our previous work identifying activin-A as a pro-differentiation factor [142],
as well as previous literature suggesting a neuroprotective role for activin receptor
signalling [273, 274]. These results support the notion that specific ligand/receptor
complexes in the TGF-β superfamily must be carefully studied in context, as the
data in this chapter contradicts previous studies showing a negative effect of this
superfamily on remyelination. Importantly, these previous studies were on distinct
receptors (BMP receptor I, Acvr1) and downstream pathways (Smad1/5/8) [321,
322].
The data from Figures 6 and 7 were published in our recent paper alongside
developmental data implicating Activin receptors as regulators of the oligodendro-
cyte lineage across the lifespan. In the paper, we also deleted Activin receptor 1b
(the functional signalling receptor associated with Acvr2a/2b) from oligodendrocyte
progenitors (PDGFRα-Cre; Acvr1bfl/fl) in mice and observed hypomyelination, a
decrease in myelin-associated protein expression, and low numbers of differentiat-
ing and mature oligodendrocytes. This data, together with the observed phenotype
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associated with myelin abnormalities (tremor, hunched posture, stiff tail, juvenile
death) are evidence for the important role of Activin receptor signalling in devel-
opmental myelination. Clearly, signalling mediated by Acvr2a/Acvr2b/Acvr1b is
crucial during both development and regeneration.
Potential mechanism of action of activin receptors
To delve deeper into the underlying mechanism of activin signalling during re-
myelination, it would have been interesting to determine effects of activin-A/inhibin
treatment on oligodendrocyte lineage cells within cerebellar slices. While we have
determined that in vitro, different concentrations of activin-A treatment drives OPC
proliferation, maturation, and survival [142, 263, 327], we only observed effects on
oligodendrocyte differentiation in our in vivo assays. It is therefore not clear whether
one or all of these are driving remyelination ex vivo. A direct test for this would
have been to look for differences between treatment and controls in populations
of oligodendrocyte lineage cells using markers for each stage of maturation by im-
munohistochemistry. This experiment may have yielded interesting insight on which
oligodendrocyte responses are affected by activin receptor stimulation in the slices.
Given slice cultures were treated with 100 ng/ml activin-A, I would hypothesize a
greater effect on oligodendrocyte survival, as this is the response elicited by this
concentration of activin-A on OPC cultures [263]. Further, I would hypothesize
that inhibin treatment may affect all potential oligodendrocyte responses, as block-
ing activin-A’s access to receptors would prevent all of its effects. Interestingly, in
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our recent paper we also uncovered a role for activin receptors in driving oligoden-
drocyte membrane compaction during development. Mice lacking Acvr1b in OPCs
(PDGFRα-Cre; Acvr1bfl/fl) had enlarged inner tongue thickness compared to con-
trols, along with a lack of MBP in MAG+ sheaths, a mark of non-compact myelin.
Importantly, this compaction effect was not due to differences in membrane growth,
but rather membrane actin disassembly, a required step in myelin compaction [327].
To test for compaction effects following activin or inhibin treatment in the slice cul-
ture, electron microscopy would have had to be carried out. As mentioned above,
this is technically difficult in slices, so compaction effects were analyzed in the in
vivo focal demyelination model, discussed further below.
Differences between ex vivo and in vivo models
Given the redundancy of signals regulating remyelination (see Table 2), it is per-
haps surprising that blocking activin receptors ex vivo had such a significant effect.
This could be due to the isolated nature of the ex vivo culture system, reducing the
compensatory potential for expression of alternative receptors driving remyelination.
Indeed, the effects of inhibin treatment in the in vivo focal demyelination model are
less pronounced, perhaps due to other factors contributing to remyelination.
Overall, the in vivo results generally supported the ex vivo findings (although only
a trend was observed in axons under 0.4µm in diameter): treatment with activin-A
led to an increase, while inhibin treatment led to a decrease, in the number of myeli-
nated axons. However, the ex vivo effects were clearly more robust than in vivo, both
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in terms of variability and magnitude of effects. These discrepancies could be ac-
counted for by differences between models, such as compensatory potential described
above. This lack of potential ex vivo could affect the ‘adaptability’ of lesions during
repair, with increased input from other brain regions/periphery in vivo leading to
more flexibility in the regenerative response. Additionally, the nature of the lesion
itself could affect the resources available for orchestrating repair. Specifically, the
ex vivo model utilizes a global lesioning system: the entire slice is exposed to the
demyelinating toxin 21 days after the brain is dissected into 300 µm sections (a fairly
severe injury event alone). Conversely, the in vivo system is focal, and only a small
area of the corpus callosum is demyelinated in an otherwise intact animal, allowing
for resources such as immune cells and oligodendrocyte progenitors to migrate from
healthy brain regions or the periphery.
Further, there is a shift in the timeline of repair between these two models.
Previous research characterizing LPC-induced demyelination and remyelination in ex
vivo and in vivo models suggests that regeneration occurs faster in the former model,
with oligodendrocyte differentiation/early remyelination starting around 7dpl, and
being complete by 14dpl [45]. In vivo, this process is extended, with differentiation
and early remyelination starting at 10dpl and completing by 21dpl [142]. As an effect
with activin-A treatment was only observed early during remyelination—at 7dpl—in
our ex vivo model, it is possible that due to a shift in timing of repair, this effect
was missed when results were examined at 7dpl in vivo.
There is a fundamental difference between these two models in terms of age and
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brain region. The ex vivo model uses cerebellar brain slices from P0-P2 newborn
mice, and these slices are then grown in culture until myelination is complete (P21).
These P21 slices are considered ‘adult’ slices, as they have a fully myelinated cerebel-
lum similar to an adult mouse. However, adult mice used in in vivo experiments are
8 weeks old, and the lesioning is done in the corpus callosum, a different white matter
tract. As age has been implicated in modulating repair processes [26], it is possible
that this could, in part, account for discrepancies between models. Differences in
function, structure, and physiology have been reported between neonatal and adult
slice cultures [328]. While brains from younger animals are generally preferable in
organotypic cultures due to their enhanced viability and regenerative potential [329,
330], adult slices may have rendered more comparable results to our adult in vivo
lesioning. Indeed, previous research suggests that there are age-related differences
in remyelination speed and efficiency [221, 226, 331], as well as microglial cell popu-
lations [332, 333]. Further, the models are lesioned in separate white matter tracts
(corpus callosum and cerebellum). This could affect the repair process, as each tract
contains different neuronal cell types and thus different ranges of axon diameters and
properties, as well as some distinct populations of oligodendrocytes [334–336]
Axon diameter as a determinant of activin receptor signalling outcome
Additionally, axon calibre may be important for determining the outcome of ac-
tivin receptor modulation. In our paper, we found that all effects from our Acvr1b
conditional knock-out (PDGFRα-Cre; Acvr1bfl/fl) were observed only on small di-
97
ameter axons. At P16, myelin produced by cKO animals was shifted towards small
diameter axons compared to controls. The increase in inner tongue thickness was
also only observed in small calibre axons [327]. Taken together, this data suggests
that activin receptor-mediated myelination and remyelination effects are dependent
on axon calibre, potentially pointing towards differences in activin receptor ligand
expression across axon size. Consistent with this hypothesis, one study found that
upon experimentally enlarging axon diameter to support myelination, activin-A sub-
unit expression was increased [337]. To my knowledge, this is the first time an axon
calibre-dependent remyelination mechanism by a single receptor has been described.
This finding complicates future therapeutic potential, as targeting an activin recep-
tor ligand to axons of specific diameters would be a complex pharmacological task.
Nevertheless, it is important to first understand the mechanisms underlying myelin
regeneration in health and disease to develop appropriate therapeutics.
Alternative activin receptor ligands may also drive remyelination
Finally, blocking activin-A activity in ex vivo slice cultures with Follistatin and
anti-activin-A antibody did not affect remyelination, suggesting that in the absence
of activin-A, other TGF-β ligands may bind activin receptors and drive remyelina-
tion. Previous research on the promiscuity of TGF-β superfamily binding partners
supports this hypothesis [338–343]. First, it is important to note that while this
superfamily contains over 30 ligands, there are only five type II receptors and seven
type I receptors. As such, it is clear that one receptor can bind more than one lig-
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and, and we cannot assume a one factor - one receptor - one function mechanism.
Activin receptors 2a and 2b in particular are among the most promiscuous, binding
members of the TGF-β, GDF, and BMP subfamilies [342]. Additionally, knock-out
studies of single ligands or receptors within the superfamily vary in their phenotypic
severity, suggesting that in the absence of one protein, another within the family can
compensate [343].
Figure 11. Hypothetical model of how Activin receptors and their ligands in-
fluence remyelination. When activin receptors are stimulated with activin-A, remyeli-
nation is accelerated. When activin receptors are blocked using Inhibin, remyelination fails.
However, if activin-A is blocked, normal remyelination occurs, hinting at the involvement
of alternate ligands.
This proposed compensation mechanism by other TGF-β proteins in the absence
of activin-A highlights the importance of this regenerative process. Given the pre-
viously established requirement of activin receptors during ex vivo remyelination, it
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follows that other activin receptor ligands must be present in the slice (see Figure
11 for summary). There are several candidate proteins within the TGF-β superfam-
ily with binding affinity for activin receptors, many with functions in development
and progenitor cell differentiation (see Table 4). The role of these candidates in
remyelination is explored in the following chapter.
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4 Chapter 4: Alternative activin receptor ligands
influence remyelination
4.1 Introduction
As introduced in Section 1.5, the TGF-β superfamily is a large, complex, and
interacting group of agonists, antagonists, and receptors. The ultimate effects of
receptor activity depend on ligand availability and concentration, cellular context,
concentration of antagonists, and downstream regulatory factors. Importantly, this
superfamily is known for a myriad of functions, including cell proliferation, differ-
entiation, and morphogenesis, as well as tissue homeostasis and regeneration [306,
307]. Such a wide variety in cellular responses hints at the complexity of signalling
within this superfamily, and rejects the simple idea of one ligand - one receptor - one
function.
Activin receptors 2a and 2b comprise two of the five type II receptors, and are
among the most promiscuous in terms of ligand binding [342]. Table 4 lists all lig-
ands with binding affinity for activin receptors, their roles in the CNS, their main
antagonists, and their cell-specific expression in the developing mouse brain. Of
these ligands, only three (activin-A, activin-B, and BMP-2) have been previously
implicated in regulating oligodendrocyte responses. Activin-A’s involvement in re-
myelination was primarily studied in our lab and has been covered in the previous
chapter. Work on activin-B and BMP-2 as a driver and inhibitor of oligodendrocyte
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development (respectively) focussed on developmental myelination. None of the lig-
ands in Table 4 (with the exception of activin-A) have been studied in the context
of remyelination. In this chapter, I identified activin receptor ligands expressed dur-
ing remyelination, and used both gain-of-function and loss-of-function strategies to
determine their sufficiency and requirement for myelin regeneration.
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4.2 Results
4.2.1 Alternative activin receptor ligands are differentially expressed
during remyelination ex vivo and in vivo
Since work from Chapter 3 suggested that activin receptors are required for re-
myelination ex vivo, but the primary ligand activin-A is not, I next sought to de-
termine which activin receptor binding ligands (see Table 4) are present in both the
organotypic slice culture and the in vivo focal lesioning models. To investigate which
of these ligands are endogenously present in our ex vivo model, I used quantitative
real-time PCR (qPCR) to establish the relative quantities of ligand mRNA in the
slices at important time points (Figure 12a). Figure 12b shows a heat map of ligand
mRNA expression at myelination (21 days in vitro, div), demyelination (2 days post
lysolecithin, dpl), and remyelination (7 and 14dpl). Interestingly, I found that while
some ligands are expressed differentially during myelination, demyelination, and re-
myelination, others are not expressed at all (Figure 12b). Importantly, while GDF1,
GDF11, BMP6, and activin-A (gene name Inhba) are highly expressed at myeli-
nation, they are re-expressed at different times during remyelination. Specifically,
GDF1, GDF11, and BMP6 are upregulated at 14dpl, and activin-A is upregulated
earlier at 7dpl, suggesting that these ligands may have distinct functions during en-
dogenous remyelination. Many ligands, such as myostatin, nodal, and GDF5, are
not expressed at all, indicative of their lack of involvement in remyelination in this
model. As qPCR data only reveals the relative quantities of mRNA, I next per-
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formed Western blots using slice culture lysates to determine whether the top hits
from the qPCR experiment were expressed at the protein level. Here, I saw that
all three top hits (GDF1, GDF11, and BMP6) were indeed expressed at the protein
level at 7 and 14dpl (Figure 12c). It was intriguing to note that while the mRNA-
level expression changes between these two time points, the protein-level expression
is stable. This suggests that there may be post-transcriptional feedback mechanisms
regulating protein expression during repair.
Next, I investigated whether ligands expressed in the ex vivo slice culture paral-
leled those expressed during in vivo remyelination. To do this, I extracted RNA from
lysolecithin-induced focal corpus callosum lesions and ran quantitative real-time PCR
to determine relative quantities of mRNA, as above (Figure 13a). Figure 13b shows
a heat map of ligand mRNA expression at important time points during remyeli-
nation in vivo, including when oligodendrocyte differentiation/ensheathment begins
(10dpl), is underway (14dpl), and is complete (21dpl). Consistent with the ex vivo
results, ligands highly expressed during in vivo remyelination were GDF1, GDF11,
and BMP6. Surprisingly, activin-A was not highly expressed during remyelination.
However, previous work from our lab [142] confirmed activin-A protein expression in
remyelinating lesions, suggesting post-transcriptional regulation mechanisms are at
work. To confirm protein-level expression of alternative ligands, I analyzed GDF1,
GDF11, and BMP6 expression in lesions by immunohistochemistry, and found that
all three ligands were present within the lesion area (Figure 13c).
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Figure 12. Activin receptor ligand expression during remyelination ex vivo.
a) Slice culture processing protocol for qPCR analysis. b) Heat map of relative mRNA
expression of activin receptor-binding ligands during myelination, demyelination, and
remyelination. Scale is shown on left. Darker colours indicate higher 2-∆Ct values, and
thus higher expression. Values shown are an average of 4 separate experiments, with 6
slices (1 well) per lysate. c) Western blot of top 3 hits from (b) to confirm protein-level
expression at 7dpl and 14dpl.
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Figure 13. Activin receptor ligand expression during remyelination in vivo. a)
In vivo lesioning protocol for qPCR analysis. b) Heat map of relative mRNA expression
of activin receptor-binding ligands during remyelination. Scale is shown on left. Darker
colours indicate higher 2-∆Ct values, and thus higher expression. Values shown are an
average of 3 separate experiments. c) Immunohistochemistry of top 3 hits from (b) to
confirm protein-level expression in focal lesions at 14dpl with isotype control (rabbit IgG,
green). Dotted lines indicate lesion areas. Scale bar, 50µm.
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4.2.2 GDF1 is important during late remyelination ex vivo
Since previous work pointed towards a requirement for activin receptors, but
not the primary ligand (activin-A) during remyelination, I next sought to determine
whether any of the other highly expressed activin-receptor binding ligands identified
in Figures 12 and 13 were required for remyelination. The first ligand tested was
GDF1. To block GDF1 action in ex vivo slices, Lefty-1 was used, a protein which
blocks a required co-receptor for GDF1’s binding to activin receptors (Figure 14a).
While remyelination index was not significantly affected at 7dpl or 14dpl in Lefty-1
treated slices compared to controls, there was a trend decrease in remyelination at
14dpl. This is supported by the representative images in Figure 14b, where there
is a clear reduction in myelin basic protein immunostaining. Surprisingly, at 7dpl,
there is a slight increase in the remyelination index. Lefty-1 works by inhibiting an
EGF-CFC (Embryonic Growth Factor-Cripto/FRL-1/Cryptic) co-receptor, which is
required for GDF1 binding to activin receptors; however, this co-receptor also blocks
activin-A’s access to activin receptors [344, 345]. As such, the slight increase in
remyelination at 7dpl with Lefty-1 treatment may be due to a disinhibitory effect
on activin-A mediated activin receptor signalling. It is possible that this signalling
is only important early (at 7dpl), as a disinhibitory effect is not apparent later at
14dpl.
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Figure 14. GDF1 inhibition has a slight effect on late remyelination. a) GDF1 is
blocked by Lefty-1, which inhibits a required co-receptor (EGF-CFC) and prevents GDF1
from binding Activin receptors. b) Representative images of slice cultures at 14dpl treated
with vehicle control or Lefty-1 during remyelination, immunostained against myelin basic
protein (MBP, green) and axonal neurofilament-H (NF, red). Scale bar, 50 µm. c)
Mean remyelination index ±s.e.m. in Lefty-1 treated ex vivo slices at 7 and 14 days
post lysolecithin (dpl) normalized to vehicle control from the respective time point. n=3
animals, one-sample t-test compared to a theoretical mean of 1 (control). No significant
differences were observed.
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Next, to determine whether a combination of activin receptor ligands were re-
quired for remyelination, I blocked both activin-A and GDF1 together during re-
myelination in ex vivo slice cultures (Figure 15a). Activin-A was blocked by Fol-
listatin (as in Chapter 3), and GDF1 was blocked by Lefty-1. Interestingly, when
both ligands were blocked together, there was a significant reduction in remyelina-
tion at 14dpl (Figure 15b,c), suggesting that together, the ligands are important for
late remyelination. At 7dpl, remyelination was ‘reduced’ back to vehicle levels with
Follistatin and Lefty-1 treatment compared to Lefty-1 treatment alone (Figure 14c).
This is consistent with the disinhibition effect hypothesis stated above: when EGF-
CFC co-receptors are blocked by Lefty-1, activin-A has increased access to activin
receptors, thereby resulting in increased remyelination. If activin-A is also blocked
using follistatin, however, remyelination returns to baseline (Figure 15c).
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Figure 15. Blocking GDF1 and activin-A together inhibits late remyelination.
a) GDF1 and activin-A are blocked by Lefty-1 and Follistatin. b) Representative images
of slice cultures at 14dpl treated with vehicle control or Follistatin (FS) + Lefty-1 during
remyelination, immunostained against myelin basic protein (MBP, green) and axonal
neurofilament-H (NF, red). Scale bar, 50 µm. c) Mean remyelination index ±s.e.m. in
Follistatin (FS) + Lefty-1 treated ex vivo slices at 7 and 14 days post lysolecithin (dpl)
normalized to vehicle control from the respective time point. n=3 animals, one-sample
t-test compared to a theoretical mean of 1 (control), *P=0.0385 at 14dpl.
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4.2.3 GDF1 inhibition in vivo affects g ratio and number of myelinated
axons
As blocking GDF1 had a negative effect during late remyelination ex vivo, I next
wanted to determine whether this was also reflected in an in vivo model of remyelina-
tion. To do this, implantable osmotic mini-pumps with attached brain cannula were
used to supplement Lefty-1 or vehicle control directly to lysolecithin-induced focal
lesions in the corpus callosum of mice. Lesion areas were processed at 14dpl based
on the above ex vivo results. Electron microscopy imaging was then carried out to
determine effects on myelin thickness and density of myelinated axons. There were
no significant differences in overall or average g ratio (Figure 16a, b); however, when
g ratio was plotted against axon diameter, slopes were significantly different (Figure
16c), suggesting differences in myelin thickness by axon diameter between Lefty-1
treatment and controls. Interestingly, the overall number of myelinated axons was
significantly higher in Lefty-1 treated animals compared to controls (Figure 16d).
When number of myelinated axons was stratified by axon diameter, there were non-
significant trends, with Lefty-1 mostly increasing number of myelinated axons below
0.4 µm and between 0.7-0.8 µm in diameter (Figure 16e). Together, this data sug-
gests that blocking GDF1 in vivo has calibre-dependent effects on myelin thickness
and increases the overall number of myelinated axons.
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Figure 16. Inhibiting GDF1 in focal lesions in vivo affects g ratio and num-
ber of myelinated axons. a) Overall g ratio ±s.d. of Lefty-1 treated animals com-
pared to control, n=100 per animal, 4-5 animals per condition. Mann-Whitney test,
non-significant. b) Mean of g ratio ±s.e.m. of Lefty-1 treated animals compared to con-
trol. Mann-Whitney test, non-significant. c) G ratio versus axon diameter in Lefty-1
treated (magenta) and vehicle controls (green). Extra sum of squares F-test between
slopes, *P<0.0001. d) Mean of total number of myelinated axons ±s.e.m. in Lefty-1
treated animals and vehicle controls, Mann-Whitney test, *P=0.0286. e) Proportion of
myelinated axons by axon diameter in Lefty-1 treated mice (magenta) and vehicle control
(green), overlaid with polynomial best-fit regression curves (Kolmogorov-Smirnov test,
non-significant). n=4-5 animals per condition, 100 axons per animal. 2-way ANOVA
with Bonferroni’s multiple comparisons test, non-significant. f) Representative images of
Lefty-1 and vehicle treated corpus callosum. Scale bar, 1µm.
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4.2.4 GDF11 is required during early and late remyelination ex vivo
The next activin receptor ligand tested for effects on remyelination was GDF11.
To block GDF11 activity, GASP-1 was administered to organotypic slice cultures
(Figure 17a). GASP-1 works as a ligand trap and prevents GDF11 from binding to
receptors. Blocking GDF11 significantly impaired remyelination both at 7dpl and
14dpl (Figure 17c). Representative images (Figure 17b) show reduced myelin basic
protein (MBP, green) immunostaining at 7dpl in GASP-1 treated slices compared to
control. Here, it is interesting to note the morphology of the MBP stain. Specifically,
the MBP looks to be mostly surrounding cell bodies, and not running along axons,
pointing to an inhibitory effect on terminal oligodendrocyte differentiation.
To determine whether blocking GDF11 and activin-A together affects remyeli-
nation, Follistatin and GASP-1 were administered to ex vivo slice cultures (Figure
18a). Remyelination was significantly impaired both at 7dpl and 14dpl (Figure 18b,
c). The morphology of the MBP stain here is similar to that of Figure 17b; however,
there looks to be overall less myelin, suggesting this potential effect on oligodendro-
cyte differentiation is consistent.
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Figure 17. GDF11 inhibition strongly blocks early and late remyelination. a)
GDF11 is blocked by GASP-1, which works as a ligand trap and prevents GDF11 from
binding its receptors. b) Representative images of slice cultures at 7dpl treated with
vehicle control or GASP-1 during remyelination, immunostained against myelin basic
protein (MBP, green) and axonal neurofilament-H (NF, red). Scale bar, 50 µm. c)
Mean remyelination index ±s.e.m. in GASP-1 treated ex vivo slices at 7 and 14 days
post lysolecithin (dpl) normalized to vehicle control from the respective time point. n=3
animals, one-sample t-test compared to a theoretical mean of 1 (control), ***P=0.0003
and ***P=0.001 at 7dpl and 14dpl, respectively.
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Figure 18. Blocking GDF11 and activin-A together inhibits early and late
remyelination. a) GDF11 and activin-A are blocked by GASP-1 and Follistatin. b)
Representative images of slice cultures at 14dpl treated with vehicle control or Follistatin
(FS) + GASP-1 during remyelination, immunostained against myelin basic protein (MBP,
green) and axonal neurofilament-H (NF, red). Scale bar, 50 µm. c) Mean remyelination
index ±s.e.m. in Follistatin + GASP-1 treated ex vivo slices at 7 and 14 days post
lysolecithin (dpl) normalized to vehicle control from the respective time point. n=3
animals, one-sample t-test compared to a theoretical mean of 1 (control), *P=0.0449 and
*P=0.0253 at 7dpl and 14dpl, respectively.
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4.2.5 Blocking GDF11 in vivo affects number of myelinated axons by
diameter
To determine whether blocking GDF11 affects remyelination in vivo, implantable
osmotic mini-pumps with attached brain cannula were used to supplement GASP-1
or vehicle control directly to lysolecithin-induced focal lesions in the corpus callosum
of mice. Lesion areas were processed at 14dpl based on the above ex vivo results.
Electron microscopy was then carried out to determine effects on myelin thickness
and density of myelinated axons. There were no differences between GASP-1 treated
and vehicle controls in terms of overall or average g ratio (Figure 19a, b). Addition-
ally, when g ratio was plotted by axon diameter, slopes were not significantly differ-
ent between treatments (Figure 19c). GASP-1 treated animals had a slightly (non-
significant) lower number of overall myelinated axons; however, when this data was
stratified by axon diameter, there was a significantly higher number of small diame-
ter (<0.4 µm) myelinated axons. Further, the cumulative distribution of myelinated
axon diameters (represented by the curves in Figure 19e) were significantly different
between treatments. This data suggests that blocking GDF11 in an in vivo focal
demyelinating model affects the number of myelinated axons in a calibre-dependent
manner.
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Figure 19. Blocking GDF11 in focal lesions in vivo results in differences in
number of myelinated axons by diameter. a) Overall g ratio ±s.d. of GASP-
1 treated animals compared to control, n=100 per animal, 4-5 animals per condition.
Mann-Whitney test, non-significant. b) Mean of g ratio ±s.e.m. of GASP-1 treated
animals compared to control. Mann-Whitney test, non-significant. c) G ratio versus
axon diameter in GASP-1 treated (magenta) and vehicle controls (green). Extra sum of
squares F-test between slopes, non-significant. d) Mean of total number of myelinated
axons ±s.e.m. in GASP-1 treated animals and vehicle controls. Mann-Whitney test, non-
signifcant. e) Analysis of distribution of number of myelinated axons in relation to axon
diameter, in GASP-1 treated mice (magenta) and vehicle control (green), overlaid with
polynomial best-fit regression curves (Kolmogorov-Smirnov test, ****P<0.0001). n=4-5
animals per condition, 100 axons measured per animal. 2-way ANOVA with Bonferroni’s
multiple comparisons test, ***P=0.0004 at 0-0.4 µm diameter. f) Representative images
of GASP-1 and vehicle treated corpus callosum. Scale bar, 1µm.
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4.2.6 BMP6 is required during late remyelination ex vivo
The final activin receptor ligand tested was bone morphogenic protein (BMP) 6.
To block BMP6, Sclerostin (SOST), a BMP6-specific ligand trap, was used (Figure
20a). Supplementing SOST to ex vivo slice cultures resulted in a significant impair-
ment in remyelination at 14dpl (Figure 20b, c). This data suggests BMP6 is required
during late remyelination.
To determine whether blocking a combination of activin receptor ligands affects
remyelination, Follistatin and SOST were administered to ex vivo remyelinating slice
cultures (Figure 21a). Here, blocking BMP6 and activin-A together resulted in a sig-
nificant reduction in remyelination at both 7dpl and 14dpl (Figure 21b, c). Together,
these results implicate an early synergistic effect between BMP6 and activin-A: while
alone, neither is required at 7dpl, loss of both impairs remyelination at this time
point.
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Figure 20. BMP6 inhibition blocks late remyelination. a) BMP6 is blocked
by Sclerostin (SOST) which works as a ligand trap and prevents BMP6 from binding
its receptors. b) Representative images of slice cultures at 14dpl treated with vehicle
control or SOST during remyelination, immunostained against myelin basic protein (MBP,
green) and axonal neurofilament-H (NF, red). Scale bar, 50 µm. c) Mean remyelination
index ±s.e.m. in SOST treated ex vivo slices at 7 and 14 days post lysolecithin (dpl)
normalized to vehicle control from the respective time point. n=3 animals, one-sample
t-test compared to a theoretical mean of 1 (control), **P=0.005 at 14dpl.
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Figure 21. Blocking BMP6 and activin-A together inhibits early and late
remyelination. a) BMP6 and activin-A are inhibited by SOST and Follistatin. b) Rep-
resentative images of slice cultures at 14dpl treated with vehicle control or Follistatin (FS)
+ SOST during remyelination, immunostained against myelin basic protein (MBP, green)
and axonal neurofilament-H (NF, red). Scale bar, 50 µm. c) Mean remyelination index
±s.e.m. in Follistatin + SOST treated ex vivo slices at 7 and 14 days post lysolecithin
(dpl) normalized to vehicle control from the respective time point. n=3 animals, one-
sample t-test compared to a theoretical mean of 1 (control), *P=0.0262 and **P=0.0055
at 7dpl and 14dpl, respectively.
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4.2.7 Inhibition of BMP6 in vivo does not affect remyelination
To determine whether blocking BMP6 in vivo reflected the observed effects in
the ex vivo model, implantable osmotic mini-pumps with attached brain cannula
were used to supplement SOST or vehicle control directly to lysolecithin-induced
focal lesions in the corpus callosum of mice. Lesion areas were processed at 14dpl
based on the above ex vivo results. Electron microscopy was then carried out to
determine effects on myelin thickness and density of myelinated axons. There were
no significant differences between SOST treated and controls in terms of overall or
average g ratio (Figure 22a, b). Additionally, when g ratio was plotted by axon
diameter, the slopes were not different between treatment and control (Figure 22c),
suggesting myelin thickness by axon calibre is not affected by BMP6 inhibition. In
terms of number of myelinated axons, there were no overall or axon calibre-dependent
differences in SOST treated animals compared to controls; however, there was a small
trend in the number of myelinated small-calibre axons (<0.4µm), with slightly higher
numbers in SOST treated animals (Figure 22d, e). These results show that although
remyelination was significantly reduced upon blocking BMP6 ex vivo, this was not
reflected in the in vivo model.
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Figure 22. Blocking BMP6 in focal lesions in vivo does not affect remyeli-
nation. a) Overall g ratio ±s.d. of SOST-treated animals compared to control, n=100
per animal, 4-5 animals per condition. Mann-Whitney test, non-significant. b) Mean
of g ratio ±s.e.m. of SOST-treated animals compared to control. Mann-Whitney test,
non-significant. c) G ratio versus axon diameter in SOST treated (magenta) and vehicle
controls (green). Extra sum of squares F-test between slopes, non-significant. d) Mean of
total number of myelinated axons ±s.e.m. in SOST treated animals and vehicle controls.
Mann-Whitney test, non-significant. e) Proportion of myelinated axons by axon diameter
in SOST treated mice (magenta) and vehicle control (green), overlaid with polynomial
best-fit regression curves (Kolmogorov-Smirnov test, non-significant). n=4-5 animals per
condition, 100 axons measured per animal. 2-way ANOVA with Bonferroni’s multiple
comparisons test, non-significant. f) Representative images of SOST and vehicle treated
corpus callosum. Scale bar, 1µm.
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4.2.8 Supplementing activin receptor ligands other than activin-A does
not affect remyelination ex vivo
To investigate whether activin receptor activity can be modulated during remyeli-
nation by ligands other than activin-A, GDF1, GDF11, and BMP6 recombinant
proteins were supplemented to ex vivo cerebellar slice cultures during remyelination
(Figure 23a). Here, there were no significant differences in remyelination at 7dpl,
compared to the significant (>2 fold) increase in remyelination upon treatment with
activin-A (Figure 23b, c). These results demonstrate that while the presence of
some of these ligands is important for remyelination ex vivo, none are sufficient to
accelerate remyelination.
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Figure 23. Supplementing GDF1, GDF11, and BMP6 to slice cultures did
not improve remyelination. a) GDF1, GDF11, and BMP6 were added to ex vivo
slice cultures individually during remyelination. b) Mean remyelination index ±s.e.m.
in GDF1, GDF11, and BMP6 treated ex vivo slices at 7 days post lysolecithin (dpl)
normalized to vehicle control from the respective time point. n=3 animals, one-sample
t-test compared to a theoretical mean of 1 (control). Activin-A treated condition shown
as comparison of highly significant effect (**P=0.0057). Activin-A treated condition data
taken from Figure 6 in Chapter 3. c) Representative images of slice cultures at 7dpl treated
with ligands (GDF1, GDF11, BMP6) and their vehicle controls during remyelination,
immunostained against myelin basic protein (MBP, green) and axonal neurofilament-H
(NF, red). Scale bar, 50 µm.
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4.3 Discussion
Activin receptor ligands are dynamically expressed during remyelination
In this chapter, I identified three novel proteins within the TGF-β superfamily
with roles in remyelination. Data from a panel of 11 activin receptor ligands revealed
dynamic mRNA expression during remyelination in both ex vivo and in vivo models.
From the 11 initial proteins, the top three hits were chosen for further investigation.
Their expression was confirmed at the protein level by Western blot and immmuno-
histochemistry. It was encouraging that across both ex vivo and in vivo lesioning
models, the same three proteins came up as top hits during remyelination. This
suggests that despite many differences between these models (such as age and brain
region), the expression of proteins relevant in myelin regeneration is conserved.
Interestingly, the dynamic mRNA-level expression was not reflected at the protein
level in the ex vivo model. This could be due to the tight regulatory systems con-
trolling TGF-β protein activity, or general regulatory mechanisms controlling post-
transcriptional, translational, and protein degradation processes. Indeed, a poor
correlation between mRNA and protein-level expression has been widely reported
[346–348]. In this superfamily of proteins, where activity is strictly controlled by
several mechanisms (such as precursor cleavage into mature peptides and ligand-
binding proteins [306, 307]), it is perhaps not surprising that protein expression is
more stable than the relative mRNA transcript levels may suggest.
The low expression of activin-A mRNA during remyelination in ex vivo and in
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vivo models was unexpected. As mentioned above, mRNA transcript expression
may not reflect protein levels; therefore, it would have been interesting to confirm
protein-level expression for activin-A during remyelination in the slices. Given previ-
ous research, I would hypothesize that activin-A is expressed at the protein level after
a demyelinating injury. Indeed, activin-A protein has been detected by immunohis-
tochemistry at 10dpl in an in vivo remyelination model [142]. Further, activin-A is
expressed in human perinatal white matter injury areas and in acute active lesions
of MS patients [327], pointing to its role in inflammation and repair in human dis-
ease. Therefore, the dynamic expression of activin-A mRNA ex vivo and its lack of
expression in vivo may not reflect protein-level expression and activity.
Importantly, all three of the proteins identified in qPCR screens were expressed
at the protein level in both ex vivo and in vivo models during remyelination. To
confirm their relevance for remyelination, I then tested whether modulating each
protein’s activity had any effects on this regenerative process.
GDF1, GDF11, and BMP6 can modulate remyelination
Each of the three novel candidates tested for potential effects on remyelination
revealed unique effects. Each ligand was inhibited (both alone and with activin-A
inhibitor) and supplemented to the ex vivo model. To determine whether ex vivo
results are similar across models, each ligand was also blocked in vivo. The observed
effects of each ligand will be discussed in turn (see Figure 24 for summary of ex
vivo effects). A general limitation that applies to the blocking strategy used in
126
this chapter is that the pharmacokinetics and pharmacodynamics of these blocking
agents were not established within the models used. It may have been interesting
to determine whether blocking agents were indeed binding to their targets using
fluorescent tagging or immunohistochemistry.
GDF1
GDF1 is a recently characterized member of the TGF-β superfamily found mainly
in the central nervous system, with important functions during forebrain develop-
ment [290, 349], and no previously reported associations with remyelination. When
Lefty-1, a GDF1 inhibitor, was administered to organotypic slice cultures alone,
there was a non-significant increase in remyelination at 7dpl followed by a decrease at
14dpl. When slices were treated with Lefty-1 combined with Follistatin (an activin-A
inhibitor), the slight increase at 7dpl with Lefty-1 alone returned to baseline, and the
decrease in remyelination at 14dpl became significant. When in vivo focal demyeli-
nating lesions were treated with Lefty-1, there was an overall increase in the number
of myelinated axons at 14dpl, notably in axons <0.4µm and between 0.7-0.8µm in
diameter. However, the proportion of myelinated axons between Lefty-1 and controls
were not significantly different within axon diameter bins. Further, while there were
no overall differences in g ratio, the slopes between treatments were significantly dif-
ferent when plotted against axon diameter, suggesting that myelin thickness across
axon diameter is affected by Lefty-1 treatment.
This is in line with previous work on interactions between EGF-CFC co-receptors,
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activin-A, GDF1, and Lefty-1. There is substantial evidence for the requirement of
EGF-CFC co-receptors (such as Cripto) for complex formation of GDF1 with activin
receptors 2a and 2b [344, 345, 350]. Cripto is able to bind Acvr1b and facilitate
signalling of GDF1 via Acvr2a/2b. Activin-A, however, does not require EGF-CFC
co-receptors to bind Acvr2a/2b. Researchers found that differences in a 14 amino
acid sequence between activin-A and GDF1 determines EGF-CFC dependence [345].
In fact, not only is activin-A able to signal independently of Cripto, the presence of
this co-receptor can actually inhibit activin signalling. There is evidence indicating
that an activin-A-Cripto-Acvr2a/2b complex is mutually exclusive with an activin-
A-Acvr2a/2b-Acvr1b complex. Additionally, when cells are transfected with Cripto,
activin-A mediated signalling is inhibited [344]. An additional layer of complexity is
added when we consider inhibitors of EGF-CFC co-receptors, such as Lefty-1. Lefty
proteins are monomers that have been shown to inhibit EGF-CFC co-receptors, and
therefore GDF1 activity, in xenopus and zebrafish studies [345]. Taken together,
the evidence points towards an inhibitory role for EGF-CFC in activin-A-mediated
signalling, which is disinhibited by Lefty-1.
The complex functions of Lefty-1 are consistent with the varied results from Lefty-
1 treatment on remyelination both ex vivo and in vivo. Specifically, remyelination is
increased then decreased with Lefty-1 treatment alone in slice cultures, suggesting
that an early disinhibition of activin-A is beneficial, while a late inhibition of GDF1
is detrimental. Indeed, when activin-A was blocked together with GDF1, the early
beneficial effects of Lefty-1 treatment disappeared, and the late detrimental effects
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were more severe. Interestingly, in vivo Lefty-1 administration resulted in a higher
number of myelinated axons. This could reflect an early disinhibitory function of
Lefty-1 on activin-A mediated signalling, rather than the inhibitory effect of GDF1.
To test this, an immunohistochemistry-based technique (proximity ligation assay,
PLA) may have been used to detect whether there is more activin-A bound to activin
receptors with Lefty-1 treatment at 14dpl compared to controls. Further, analysis of
number of myelinated axons at later times (21dpl, roughly parallel to 14dpl ex vivo)
may have revealed results more reflective of GDF1 inhibition. Finally, it would have
been interesting to characterize the expression of EGF-CFC co-receptors in both
models, as differences in frequency of these proteins may affect Lefty-1 efficiency.
GDF11
GDF11 is expressed in astrocytes, neurons, and oligodendrocytes during devel-
opment and has many roles within the CNS, including spinal cord patterning, neu-
rogenesis, and cerebral vascular remodeling [294–296]. GASP-1 (GDF-Associated
Serum Protein-1) is a strong inhibitor of GDF11, and works by preventing GDF11
from binding to activin receptors. Specifically, there is both in vitro and in vivo
evidence for GASP-1 inhibiting the activity of GDF11 and the closely related pro-
tein myostatin/GDF8 [351, 352]. Despite the high similarity between GDF11 and
myostatin, they are not functionally equivalent: GDF11 can promote Smad2/3 sig-
nalling via Acvr1b more effectively than myostatin [352]. Importantly, I found that
myostatin/GDF8 is not highly expressed during remyelination (Figures 12, 13).
129
GDF11 has not been previously associated with remyelination. Here, when
GDF11 was inhibited via GASP-1 administration in slice cultures, a strong and
significant reduction in remyelination at both 7dpl and 14dpl was observed. When
GDF11 was blocked in conjunction with activin-A, this strong reduction in remyeli-
nation persisted across both time points. Inhibition of GDF11 in vivo had no overall
or calibre-dependent effects on g ratio, suggesting myelin thickness is not regulated
by GDF11. While there was only a non-significant trend to a lower number of over-
all myelinated axons with GASP-1 treatment, the distribution of myelinated axons
across diameters was different between treatments. Specifically, GASP-1 treatment
resulted in a (non-significant) reduction in numbers of myelinated axons between
0.5-1 µm in diameter, and a significant increase in number of myelinated axons with
diameters smaller than 0.4µm. This suggests that GDF11 mediated activin receptor
signalling could regulate calibre-dependent myelination.
The strong effects observed in ex vivo blocking experiments may reflect the lack
of circulation in this model. Given GDF11 is abundant in the blood [353], a possible
reason for such strong effects in the ex vivo model is the lack of available protein
source. The much more subtle in vivo effects could therefore be due to input from the
circulation providing additional GDF11 to the lesion area as a response to GASP-1
treatment. This hypothesis could have been tested either by co-immunoprecipitation
or by PLA to determine differences in the amount of GDF11 bound to activin recep-
tors in GASP-1 treated animals compared to controls. As GASP-1 prevents GDF11
from binding to its receptors, I would expect to find less GDF11 bound to recep-
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tors in the GASP-1 treated animals; however, if additional GDF11 is coming in, the
amount of GDF11 bound to activin receptors may be stable across conditions.
BMP6
BMP6 is expressed by neurons and oligodendrocytes in the developing CNS.
Conflicting roles have been reported for this ligand, such as improvement of ischemic
brain injury and defective neurogenesis [298, 299]. Importantly, members of the
BMP subfamily generally have been shown to be involved in negative regulation of
oligodendrocyte maturation, and inducing astrogliogenesis instead [323, 325]. BMP6
has been specifically shown to be upregulated in demyelinating lesions in EAE mice;
however, this was only shown for the mRNA level and was not followed up on, as other
BMPs (BMP4 in particular) showed a much higher expression in this study [326].
As stated previously, it is important to investigate specific ligand-receptor-pathway
interactions within each context, as the effects of TGF-β ligands vary based on
environment. While BMP6 can bind Activin receptors 2a/2b as well as BMP receptor
2 (BMPRII), BMP4 can only bind BMPRII [308]. It is therefore not advisable to
generalize findings across members of the BMP subfamily.
BMP6 activity can be blocked by Sclerostin (SOST), a recently identified BMP
inhibitor. It has been reported to strongly inhibit BMP6, and weakly inhibit BMP2,
BMP4, and BMP7 [308, 354, 355]. While its mechanism of action remains to be fully
elucidated, studies have shown that SOST may work via inhibition of BMP-induced
Smad phosphorylation [356, 357]. Treatment of ex vivo slice cultures with SOST
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resulted in impaired late remyelination (14dpl). When SOST was combined with
Follistatin (an activin-A inhibitor), remyelination was impaired both early (7dpl)
and late (14dpl), pointing to a synergistic effect of BMP6 and activin-A during
early remyelination. Indeed, synergism between TGF-β family members and their
downstream signalling pathways has been observed in several contexts, including
regulatory T cell development and photoreceptor activity in the retina [358–360]. In
vivo, BMP6 inhibition had no significant effects on remyelination (both in terms of
number of myelinated axons and myelin thickness), but a slight increase in number
of myelinated axons below 0.4µm in diameter was observed.
The ex vivo and in vivo systems may have distinct levels of activin receptors
vs other ligand-binding receptors, which may influence the differences observed in
BMP6 inhibition between models. For example, if BMP receptors are more abundant
in vivo than ex vivo, then BMP6 may be binding BMPRII more than Acvr2a/2b in
vivo. If this is the case, then blocking BMP6 using SOST in vivo may reflect inhi-
bition of BMPRII-mediated signalling more so than Acvr2a/2b-mediated signalling.
This could have been tested by techniques which determine ligand-receptor binding
(such as PLA or co-immunoprecipitation experiments discussed above), as well as
determining expression of BMPRII in each model.
While blocking GDF1, GDF11, and BMP6 all yielded interesting inhibitory ef-
fects, supplementing these proteins to ex vivo slices did not accelerate or improve
remyelination. Since activin-A has a high affinity for activin receptors, this apparent
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lack of effect may be due to activin-A outcompeting these other three ligands for
receptor binding. Additionally, a lack of effect may be due to endogenous ligands
being plentiful and receptors being saturated. Further, it is possible that the concen-
tration at which the proteins were administered to slices was not sufficient to induce
activin receptor signalling. To account for this, higher concentrations of these ligands
could have been tested to determine the optimal dosage. While GDF1 and GDF11
are only able to bind activin receptors, BMP6 may also bind BMPRII. Therefore,
supplementing BMP6 may not have directly affected activin receptor signalling, as
it may have activated distinct receptors. As mentioned above, it would be useful
to carry out PLA or co-immunoprecipitation experiments to know which receptor
BMP6 is more frequently bound to, as well as immunohistochemistry to determine
whether BMPRII is widely expressed during remyelination.
It is surprising that blocking the highest affinity activin receptor ligand (activin-
A) in ex vivo slice cultures yielded no differences in remyelination, but blocking lower
affinity ligands (GDF1, GDF11, BMP6) hindered remyelination. This could be due
to efficacy of inhibitors: though Follistatin has a very high binding affinity for activin-
A, it was not explicitly shown to sequester activin-A in these experiments. However,
an additional experiment using anti-activin-A antibody also resulted in no effect on
remyelination, bolstering the original Follistatin results. Nevertheless, to irrefutably
confirm Follistatin’s function in blocking activin-A, either a co-immunoprecipitation
experiment or a proximity ligation assay could have been carried out. Another
potential reason for this surprising result could be the delicate balance of TGF-β
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ligand and receptor interactions. It is possible that there are more abundant stores
of activin-A ligand post-injury than that of GDF1, GDF11, or BMP6. Therefore, re-
ducing available activin-A would have a less pronounced effect than depleting all the
available GDF1, GDF11, and BMP6. Alternatively, it is also possible that activin-
A levels are endogenously very low in slices, and therefore blocking its action does
not affect remyelination. Quantitative comparisons of ligand expression by Western
blot or immunohistochemistry in the ex vivo model may have shed light on this hy-
pothesis. Finally, to corroborate results from ligand-specific antagonists, a genetic
approach to induce global deletion of ligand genes (driven by a ROSA26 promoter)
after a demyelinating insult may have been useful. As this superfamily is important
during development, many TGF-β null experimental animals die prematurely, so it
would be important to control the timing of deletion.
Discrepancies between ex vivo and in vivo results
While each ligand inhibitor had strong effects on remyelination ex vivo, effects
were much more subtle in the in vivo model. This is not surprising: given that
blocking the activin receptor in vivo (Chapter 3) did not strongly affect remyeli-
nation potential, it follows that inhibiting any of the activin receptor ligands would
have similarly subtle effects. However, these discrepancies could also be due to major
differences between models as discussed in Chapter 3. Further, there may be addi-
tional differences between models in the regulation of TGF-β superfamily signalling.
For example, it is possible that in vivo, activin-A is better able to compensate for
the loss of GDF1, GDF11, and BMP6, resulting in no major differences between
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ligand inhibitors and controls. To account for this possibility, it would have been
interesting to first compare relative protein levels of activin-A in the slice and in
vivo. To further test this theory, Follistatin (activin-A inhibitor) may have been
administered to in vivo lesions in conjunction with each ligand inhibitor, as well as
all 4 ligand inhibitors together. Results from this experiment would inform whether
activin-A is responsible for compensatory effects in the absence of each ligand, and
whether all 4 ligands work together to support remyelination.
Interestingly, there is a similarity between ligand inhibitor and activin-A treated
animals in terms of calibre-specific in vivo results. In axons smaller than 0.4µm
in diameter, there were slightly higher numbers of myelinated axons when each lig-
and was blocked compared to their vehicle controls, similarly to when activin-A
was administered in Chapter 3. A potential cause for this similarity may be that
blocking these ligands is actually ‘freeing up’ the receptors for activin-A to bind.
To test this hypothesis, a co-immunoprecipitation experiment may be carried out to
determine whether more activin-A-Acvr2a/2b complexes are observed in conditions
where alternative ligands are blocked. Further, the experiment described above,
where Follistatin is used in conjunction with ligand antagonists, would be helpful in
determining whether this proposed mechanism is driving the axon calibre-dependent
increase in number of myelinated axons.
Ligand-specific effects on oligodendrocyte lineage cells
In addition to the quantified differences between ligand blocking treatments
and controls discussed above, there were also clear qualitative differences between
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conditions in the ex vivo model. When investigating differences in morphology
of myelin immunostains between control remyelinated slices and poor remyelina-
tion in ligand blocking treatment, it is evident that each ligand inhibitor has a
distinct effect. Blocking GDF1 appeared to have an effect on overall amount of
myelin membrane being made, GDF11 inhibition appeared to affect oligodendro-
cyte maturation, and BMP6 inhibition may have had an effect on myelin membrane
compaction/ensheathment (see Figure 24 for summary). Based on these qualita-
tive observations, a good follow-up experiment would be to test whether block-
ing each of these ligands in cell cultures (oligodendrocyte progenitor cell cultures,
oligodendrocyte-neuronal co-cultures, or oligodendrocyte-microfibre cultures) results
in similar effects.
Further, although few effects were observed in the in vivo model at the ultra-
structural level, it would have been interesting to immunostain brain sections for
oligodendrocyte lineage cell markers to determine whether inhibiting GDF1, GDF11,
and BMP6 had any direct effects on oligodendrocyte maturation.
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Figure 24. Inhibition of GDF1, GDF11, and BMP6 have distinct effects on remyelination
ex vivo.
Overall, results from this chapter yield a number of additional questions regard-
ing the role of TGF-β superfamily members during remyelination. Clearly, there is
a complex role for these secreted proteins in driving remyelination via activin recep-
tors. However, it is not known which cell types are expressing these ligands during
remyelination, or which cells are mediating activin receptor signalling. Further, it
is not clear whether these ligands are relevant in human disease. These important
outstanding questions will be investigated in the following chapter.
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5 Chapter 5: Microglia/macrophages and oligo-
dendrocytes mediate activin receptor signalling
during remyelination
5.1 Introduction
To consider activin receptors as a potential target for clinical intervention in
Multiple Sclerosis, we must first elucidate their mechanism of action. Given the
many functions of activin receptor ligands, especially during development and injury
[270], it is important to understand the cell types expressing these ligands, as well
as the cells and downstream pathways through which they are actively signalling, in
a context-specific manner.
This information is crucial for a) developing therapies targeted to specific cell
types, b) understanding whether observed changes in remyelination are due to direct
or indirect effects on oligodendrocytes, and c) providing clues as to what the cellular
source of ligands is within lesion areas. Previously, activin receptor expression has
been reported on axons during development and following excitotoxic injury in ro-
dents [274, 276]. Further, work by Miron and colleagues showed that during remyeli-
nation in vivo, NG2+ oligodendrocyte progenitor cells and microglia/macrophages
expressed both ligand-binding receptors (Acvr2a/2b) and the signal-transducing re-
ceptor Acvr1b. Importantly, microglia/macrophages also expressed activin-A, the
primary ligand for these receptors [142]. Developmental data for alternative activin
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receptor binding ligands identified in Chapter 4 revealed expression on neurons, as-
trocytes, and oligodendrocytes [302].
Given the significant contribution of cellular and microenvironmental context
to ultimate signalling outcome in this superfamily of ligands and receptors, several
unexplored questions remain regarding the mechanism of action of activin receptors
during remyelination. In this chapter, I determined whether GDF1, GDF11, and
BMP6 are relevant in human disease, and what cell types express these proteins
within MS lesions. Results from human tissue were then confirmed in remyelinating
mouse tissue. Additionally, reporter mice (described in detail below) were used to
identify cell types actively signalling through activin receptors. Finally, cell-specific
activin receptor expression in human tissue was elucidated, uncovering a potential
receptor subtype specific effect.
139
5.2 Results
5.2.1 Ligands are expressed on microglia in active MS lesions
To determine whether the activin receptor binding proteins identified in Chapter
4 were relevant in human disease, immunohistochemistry was carried out on post-
mortem MS tissue to investigate a) whether GDF1, GDF11, and BMP6 are expressed
in lesions, and b) which cell types express these proteins. Post-mortem tissue is
characterized using Luxol Fast Blue (LFB) staining to delineate white matter (WM,
dark blue) from grey matter (GM, light blue). White matter lesions are then patho-
logically characterized according to the International Classification of Neurological
Diseases, again using LFB to stain intact myelin and Oil Red O (ORO) to identify
myelin debris (Figure 25a-b). Remyelinated lesions are characterized by intermedi-
ate LFB staining (often called a ‘shadow plaque’), and little myelin debris. Acute
active lesions exhibit a diffuse LFB border, demyelination, and ample amounts of
myelin debris. Chronic active lesions show a lack of LFB staining and some myelin
debris. Chronic inactive lesions show significant loss of LFB and no myelin debris.
Lesion types have different likelihoods of repairing: chronic inactive are least likely
to remyelinate, chronic active is moderately likely to repair, and acute active have a
good remyelination potential (see Figure 25c for schematic).
Post-mortem tissue was co-stained for each ligand (GDF1, GDF11, and BMP6)
and CD68, an activated microglia/macrophage marker (Figure 25d-e). Figure 25d
shows the proportion of total ligand+ cells which are also CD68+. In acute active le-
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sions, between 70-100% of all ligand expressing cells are CD68+ microglia/macrophages,
a significant difference compared to control sections (Dunn’s multiple comparisons
test, *P=0.0404, **P=0.0011, *P=0.0266 for GDF1, GDF11, and BMP6, respec-
tively). Interestingly, microglia/macrophages make up only about 50% of ligand-
expressing cells in chronic active, chronic inactive, and remyelinated lesions, sug-
gesting that this is likely an acute post-injury response. Figure 25e shows represen-
tative images of GDF1+, GDF11+, and BMP6+ cells co-stained with CD68. Taken
together, this data suggests that microglia/macrophages are the major activin recep-
tor ligand expressing cells within active MS lesions. This co-expression data could
either indicate that microliga/macrophages are upregulating and producing these
ligands, or that the ligands are binding to receptors on microglia and activating
downstream signalling. Tissue stains and cell counts in Figure 25 were carried out
by an ERASMUS student, Dawid Kargul. Panels a) and b) were published in our
recent paper [327].
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Figure 25. GDF1, GDF11, and BMP6 are highly expressed on mi-
croglia/macrophages in active MS lesions. a) Luxol Fast Blue (LFB, blue) staining
was used to clearly distinguish white matter (WM) from grey matter (GM). MS lesions
were digitally annotated (red circles) in Zen software to ensure that the same area was
quantified for various readouts. Scale bar, 2000 µm. b) MS lesions were pathologically
characterized according to the International Classification of Neurological Diseases, using
LFB to stain intact myelin (blue) and Oil Red O (ORO) to stain myelin debris (brown).
Healthy control tissue shows intact myelin and no myelin debris. Fully remyelinated
lesions show intermediate intensity of LFB (‘shadow plaque’) with little to no myelin
debris. Acute active lesions show a diffuse LFB border with demyelination and an abun-
dance of myelin debris throughout the lesion. Chronic Active lesions show loss of LFB
and some myelin debris. Chronic Inactive lesions show significant demyelination and no
myelin debris. Scale bar, 500 µm. c) Schematic of remyelination potential by lesion
type. From low to high: chronic inactive (red), chronic active (orange), acute active (yel-
low), and remyelinated (green). d) Proportion of GDF1+, GDF11+, and BMP6+ cells
(±s.d.) expressing CD68 in MS lesions and controls. Kruskal-Wallis test with Dunn’s
multiple comparisons: GDF1 (*P=0.0404), GDF11 (**P=0.0011, ***P=0.0003), BMP6
(*P=0.0124, *P=0.0266). e) CD68+ (red) and GDF1+, GDF11+, and BMP6+ (blue)
double positive cells in MS lesions. DAPI shown in light blue. Scale bar, 5 µm.
142
5.2.2 Ligands are expressed on microglia in remyelinating mouse tissue
To determine whether microglia/macrophage specific ligand expression observed
in MS tissue was paralleled in the in vivo remyelinating mouse model, 14 days post
lesion (dpl) tissue was immunostained for GDF1, GDF11, BMP6, and microglial
markers (either CD68 or PU.1). Within the lesion area (delineated by dotted lines,
Figure 26b), microglia/macrophage-specific ligand expression was observed. CD68
was used as a microglia/macrophage cytoplasmic marker for GDF1 and BMP6 co-
stains, as these ligands were expressed mostly in the cytoplasm. However, GDF11
expression looked to be nuclear; therefore, PU.1 (a nuclear microglia/macrophage
marker) was used for this co-stain. Notably, GDF11 was also expressed on NeuN+
neuronal cell bodies outside of the lesion area. Within the lesion area, however, all
three ligands were clearly co-localized with microliga/macrophages, suggesting that
findings from the active MS lesions in Figure 25 are reflected in the in vivo focal
lesioning model.
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Figure 26. GDF1, GDF11, and BMP6 are expressed on microglia in remyeli-
nating lesions in vivo. a) Diagram of in vivo focal demyelinating lesion model. b)
Images of focal lesions at 14 days post lesion (dpl), dotted lines delineate corpus callo-
sum lesion. CD68+ (magenta) or PU.1+ (red) microglia/macrophages expressing GDF1,
GDF11, or BMP6 (green), counterstained with DAPI. Close-up images of individual cells
shown on right. Scale bar, 50 µm.
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5.2.3 Canonical activin receptor signalling occurs through microglia and
oligodendrocytes during remyelination
Given that activin receptor ligands are important during remyelination and their
expression within acute lesions is abundant on microglia/macrophages, and as our
previous work identified activin receptors on oligodendrocytes [142, 327], I next
wanted to determine whether these same cells were also mediating activin receptor
signalling. To do this, I used an AR8-mCherry reporter mouse line, where mCherry
expression is under the control of an activin response element (AR8) and is expressed
in cells that receive Smad2/3 mediated signalling (for schematic, see Figure 27a).
Remyelinating organotypic cerebellar slices from AR8-mCherry mice were collected
at 0dpl, 2dpl and 7dpl for Flow cytometry analysis (Figure 27b-d). Cells from
slice lysates were either stained with CD11b (microglia) or with oligodendrocyte
lineage markers PDGFRα (progenitors), O4 (immature oligodendrocytes), and MAG
(mature oligodendrocytes). Cells were first gated for mCherry+ DAPI− live cells,
then for single cells. Finally, mCherry was plotted against either CD11b (Figure
27b), and side scatter was plotted against each of the oligodendrocyte lineage markers
(Figure 27c) to determine the percentage of total mCherry+ population that was also
positive for each cellular marker (Figure 27d).
Surprisingly, the majority of mCherry+ cells do not express CD11b or oligoden-
drocyte lineage cell markers at any time. At 0dpl (before demyelination), 18.33%
(±1.097) of mCherry+ cells are CD11b+. However, shortly after demyelination
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(2dpl), there are only 2.925% (±1.64) mCherry+CD11b+ cells, subsequently rising
slightly to 7.125% (±2.572) by 7dpl. Interestingly, when inhibin was administered to
remyelinating slice cultures and mCherry expression subsequently analyzed by Flow,
the percentage of mCherry+CD11b+ cells remained unchanged (6.475% ±1.729).
At all time points analyzed (0, 2, 7dpl), percentage of mCherry+ cells expressing
any oligodendrocyte lineage cell marker remained below 5%. Taken together, this
data suggests that only a small proportion of Smad2/3-mediated activin receptor sig-
nalling occurs through microglia and oligodendrocyte lineage cells in the slice culture
model, but does confirm that these cells do signal through activin receptors.
To determine whether Flow cytometry results in Figure 27 are also observed us-
ing other techniques, AR8-mCherry slices were fixed at 7dpl and stained with CD68,
a microglial marker (Figure 28b). Here, abundant co-localization between mCherry
and CD68 can be observed, suggesting a much higher proportion of mCherry+ cells
are microglia than the Flow experiment may have indicated. To check whether cells
expressing both mCherry and microglial markers could be detected in live tissue,
AR8-mCherry mice were bred to MacGreen mice (macrophage/microglia reporter
mice described in Chapter 2) and live imaging snapshots of organotypic slices were
taken at 7dpl. Figure 28c shows images of a live mCherry+MacGreen+ cell, con-
firming that microglia do actively signal through Smad2/3 during remyelination.
Finally, to determine whether the functional activin receptor (Acvr1b) was also ex-
pressed on microglia, and whether its expression could be observed on other cell
types, wild-type cerebellar slices were stained at 7dpl for Acvr1b, and co-stained
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with either β-tubulinIII (neurons) and CD68 (microglia, Figure 28a, top row); or
GFAP (reactive astrocytes) and Olig2 (oligodendrocytes, Figure 28a, bottom row).
Here, Acvr1b expression was observed only on CD68+ microglia and Olig2+ cells
(indicated by white arrows in Figure 28a). Interestingly, some Acvr1b+ cells were
not positive for either microglia or oligodendrocyte lineage cell markers, suggesting
that other cell types (such as neural progenitor cells, endothelial cells, or pericytes)
may also signal through Acvr1b during remyelination.
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Figure 27. Activin receptors signal partly through microglia during remyeli-
nation. a) Schematic of activin response element-driven mCherry expression in AR8-
mCherry mice. Once ligand is bound, Smad2/3 is phosphorylated and binds to Smad4.
This complex is translocated to the nucleus and binds activin response element which
drives mCherry expression. b) Gating strategy for analysing mCherry+CD11b+ cells.
Live mCherry+ DAPI− cells were gated first, followed by singlet cells, and finally forward
scatter (FSC-A) and side scatter (SSC-A) to eliminate cell debris and clusters. AF647-
CD11b (x axis) was plotted against mCherry (y axis) to determine CD11b+ and CD11b−
mCherry cell populations. c) Gating strategy for analysing mCherry+ and PDGFRa+,
O4+, or MAG+ cells. Live mCherry+ DAPI− cells were gated first, followed by sin-
glet cells, and finally forward and side scatter to eliminate cell debris and clusters. Single
stained samples were used to set PDGFRa, O4, and MAG gates (bottom row of plots). d)
Proportion of mCherry+ cells expressing CD11b and Oligodendrocyte lineage cell markers
(±s.e.m.), n=3-4 experiments per time point.
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Figure 28. Functional activin receptor Acvr1b and downstream Activin Re-
sponse Element-driven mCherry expression on microglia and oligodendro-
cytes. a) Images of remyelinating ex vivo mouse tissue at 7dpl showing Acvr1b+ (red,
both rows), β-TubulinIII+ (white, top row), CD68+ (green, top row), GFAP+ (white,
bottom row), and Olig2+ (green, bottom row) cells. Acvr1b+ CD68+ double positive
cells (top row) and Acvr1b+ Olig2+ double positive cells (bottom row) indicated by
white arrows. Scale bar, 50 µm. b) Images of fixed remyelinating ex vivo AR8-mCherry
mouse tissue at 7dpl. mCherry+ (red) CD68+ (green) double positive cells were observed.
Scale bar, 50 µm. c) Live imaging snapshot of AR8-mCherry/MacGreen mouse explants,
showing mCherry+ MacGreen+ double positive cell. Scale bar, 5 µm.
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5.2.4 Activin receptors 2a/2b are expressed on oligodendrocytes and
microglia in MS tissue
Given activin receptor ligands are expressed on microglia/macrophages (GDF1,
GDF11, BMP6) and oligodendrocyte lineage cells (activin-A, [327]) in MS lesions, I
next determined cell-specific ligand-binding activin receptor expression in human tis-
sue. Tissue was characterised as above (Figure 25a), and stained for activin receptors
2a/2b and either CD68 (microglia) or Olig2 (oligodendrocytes). Activin receptors
2a and 2b were observed on both oligodendrocytes and microglia/macrophages (Fig-
ure 29c-d). When percentage of total oligodendrocytes expressing either Acvr2a or
Acvr2b was quantified, an interesting difference between receptor subtype expression
within lesion types emerged. Specifically, in lesions with good remyelinating poten-
tial (acute active and chronic active, Figure 29a), there was a higher proportion of
Acvr2a+Olig2+ cells compared to Acvr2b+Olig2+ cells (Figure 29b). However, in
chronic inactive lesions, which have a very low remyelinating potential (Figure 29a),
the proportion of Acvr2b+Olig2+ cells is increased. Taken together, this increase in
Acvr2b expression within oligodendrocyte lineage cells combined with its relatively
higher affinity for activin-A [304] may suggest that this receptor subtype sequesters
the ligand and restricts Acvr2a-mediated signalling in oligodendrocytes. The activin
receptor/oligodendrocyte co-expression data was published in our recent paper [327].
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Figure 29. Activin receptors 2a/2b are expressed on oligodendrocytes
and microglia/macrophages in MS tissue. a) Proportion of Acvr2a+Olig2+ or
Acvr2b+Olig2+ from total Olig2+ cells (±s.d.) in healthy control tissue or MS lesions
(remyelinated, acute active, chronic active, chronic inactive). N for each lesion type indi-
cated in Chapter 2. Kruskal-Wallis test and Dunn’s multiple comparison test, *P<0.05.
b) Acvr2a+ (top row, red) or Acvr2b+ (bottom row, red) and Olig2+ (blue) double posi-
tive cells in MS lesions. Scale bar, 5 µm. c) Acvr2a+ (top row, red) or Acvr2b+ (bottom
row, red) and CD68+ (blue) double positive cells in MS lesions. Scale bar, 5 µm.
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5.3 Discussion
Activin receptor ligands are expressed on microglia/macrophages
In this chapter, I established that activin receptor ligands important during re-
myelination (GDF1, GDF11, and BMP6) are expressed on microglia/macrophages
both in MS tissue and in a remyelinating mouse model. This is consistent with
previous work which identified activin-A (the primary ligand for activin receptors)
as a factor released by microglia/macrophages during remyelination [142]. In our
recent paper, we also showed that activin-A expression was upregulated in active
MS lesions compared to non-injured controls [327]. Here, I found that expression of
alternative ligands in microglia/macrophages was dynamic between lesions. Almost
100% of ligand-expressing cells in active MS lesions were microglia/macrophages,
while in other lesions and controls, this number dropped to 50% or less. This may
suggest a microglia/macrophage-specific upregulation of GDF1, GDF11, and BMP6
in acute active lesions, hinting at the involvement of these ligands in post-injury
inflammation. Alternatively, other lesion types may contain higher numbers of cells
other than microglia expressing these ligands, which would influence the proportion
of total ligand+ cells which are microglia/macrophages. An important caveat to this
expression data is that it does not elucidate whether these ligands are being up-
regulated and produced by microglia/macrophages themselves, or if the ligands are
simply found on microglia/macrophages because they are binding to receptors on
those cells. To address this, conditioned media from microglial cell cultures induced
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to either pro-inflammatory or anti-inflammatory phenotypes could be analysed by
ELISA to determine whether each ligand is present in the media. If GDF1, GDF11,
or BMP6 were detected, it would suggest that the microglia of a certain phenotype
may produce these proteins. Further, in situ hybridization may be used to determine
whether microglia/macrophages express ligand mRNA, which would also show that
these cells are producing the proteins.
In remyelinating in vivo mouse tissue, activin receptor binding ligands were also
observed to be expressed on microglia/macrophages. Additionally, GDF11 was ex-
pressed on neuronal cell bodies adjacent to the corpus callosum lesion area. There-
fore, while GDF1 and BMP6 seem to be exclusively expressed on microglia during
remyelination, GDF11 can also be expressed on neurons, suggesting that it may have
neuronal-specific effects. Importantly, differences between cell-specific developmental
expression (outlined in Table 4) and adult post-injury expression (determined here)
support the notion that TGF-β ligand function/expression may change depending
on contextual factors such as age and healthy or diseased microenvironment.
Activin receptors signal through microglia and oligodendrocytes during
remyelination
Results from this chapter suggest that activin receptors signal, at least in part,
through microglia and oligodendrocytes. Evidence from both Flow cytometry and
immunohistochemical experiments using AR8-mCherry reporter mice show that ac-
tivin receptor-driven Smad2/3 signalling is present in CD11b+, CD68+, and MacGreen+
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microglia. As these experiments used organotypic slice cultures, there is no contri-
bution from the periphery, and therefore cells detected by microglia/macrophage
markers can be assumed to be only microglia. Surprisingly, there were some dis-
crepancies between staining and Flow experiments regarding the proportion of cells
signalling through microglial activin receptors during remyelination. While Flow
results suggest that only a small percentage (7.125% ±2.572) of total mCherry+
cells are CD11b+ at 7dpl, images from immunohistochemistry experiments appear
to have abundant mCherry+ CD68+ cells. There may be a number of reasons for this
observed inconsistency. First, the sensitivity of Flow has been reported to be much
higher than that of immunohistochemistry [361, 362]; suggesting that Flow data may
be more reflective of the true amount of microglia-mediated Smad2/3 signalling in
the slices. Conversely, tissue processing for Flow could result in transfer of cell debris
from one cell to another; this transfer could cause the low signal in CD11b+mCherry+
double positive cells. Other differences between experiments, such as the fact that
Flow uses cells from a whole slice, while stained images were taken from a section
of the slice; or that the two microglial markers CD11b and CD68 reflect different
subpopulations of microglia (all microglia vs activated microglia, respectively), may
also account for some of this variance.
Importantly, however, Acvr1b, the functional activin receptor, was detected on
both Olig2+ oligodendrocytes and CD68+ microglia. This confirms that the signal-
transducing receptor is present on both microglia and oligodendrocytes during re-
myelination. While Flow results suggested only a very low number of mCherry+
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cells signal through oligodendrocyte lineage cells, given the presence of Acvr1b on
these cells, it is likely that oligodendrocyte-specific activin receptor signalling is im-
portant for remyelination. In fact, when Acvr1b was deleted from oligodendrocyte
progenitors, mice had myelin abnormalities and died prematurely at 3 weeks, phe-
notypes consistent with other transgenic mice exhibiting developmental myelination
problems [327]. This finding, however, does not preclude receptor activity on other
cell types being important for myelination or remyelination. Indeed, here, there were
some Acvr1b+ cells that were neither CD68+ nor Olig2+, suggesting that there are
other cell types that may signal through activin receptors during remyelination.
To confirm these results and perhaps shed some light on the apparent discrep-
ancies between techniques, several experiments could have been conducted. First,
it would have been interesting to sort cells from slices using FACS and/or MACS,
and subsequently use Western blotting to check for both mCherry and phospho-
rylated Smad2/3 (p-Smad2/3) expression on microglia and oligodendrocytes. P-
Smad2/3 is a marker of activated Smad signalling [306], and may be used to confirm
whether AR8-mCherry expression reflects all Smad2/3 mediated signalling. The
AR8-mCherry reporter mouse was preferable to using p-Smad2/3: once induced,
mCherry expression is stable, and p-Smads may only be detected transiently. Still,
using p-Smad2/3 as a secondary measure of Smad2/3 signalling could be impor-
tant for confirming the AR8-mCherry reporter, and co-staining slices from AR8-
mCherry mice with p-Smad2/3 would have been a good control. Finally, a co-
immunoprecipitation technique may be used to pull down receptors and determine
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which cell types express Acvr2a/2b/1b during remyelination. This technique may
also have been useful in determining which ligands were bound to Acvr2a/2b, further
clarifying the role of activin receptor ligands during remyelination.
Surprisingly, when inhibin treatment was administered to slices, the proportion
of mCherry+ CD11b+ cells remained unchanged (mean rank difference of 0.75, non-
significant). This may reflect the stable expression of mCherry discussed above.
There is a clear decrease in mCherry+CD11b+ cells from 0dpl (pre-demyelination) to
2dpl. This reduction in mCherry expression on microglia could be due to cell death.
Indeed, unpublished work (currently under review) from our lab established that
within the first two days following demyelination, a switch in microglial phenotypes
(from pro-inflammatory to anti-inflammatory) may occur through a controlled necro-
sis (termed necroptosis). Following this, there is an increase in mCherry+CD11b+
expression from 2dpl to 7dpl. As inhibin treatment was administered from 3-4dpl,
it is possible that mCherry expression on microglia has already ramped up by then
and remains constant. If inhibin treatment does not induce microglial cell death,
then mCherry expression can be expected to be detected at a similar level, even if
Smad2/3 signalling is inhibited after inhibin treatment induction. If this hypothesis
is correct, I would expect levels of mCherry+CD11b+ cells to be similar between 4
and 7dpl; therefore, to confirm this, an additional Flow cytometry experiment run at
3-4dpl (pre-inhibin treatment) would have been useful. Additionally, slice cultures
treated with inhibin could be stained for microglial markers to determine whether
there are any effects on the phenotype/survival of these cells with inhibin treatment.
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Activin receptors are expressed on oligodendrocytes and microglia in MS
tissue
Finally, this chapter identified ligand-binding activin receptor (Acvr2a/2b) ex-
pression on both oligodendrocytes and microglia/macrophages in MS tissue. In-
terestingly, the two receptor subtypes showed differential expression by lesion type
on oligodendrocyte lineage cells. Actively remyelinating lesions (active and chronic
active) had relatively higher densities of oligodendrocyte lineage cells expressing
Acvr2a compared to Acvr2b. In lesions that were failing to remyelinate (chronic
inactive), the density of Acvr2b+ oligodendrocytes increased. This data was pub-
lished in our recent paper, alongside additional experiments showing that Acvr2b
overexpression blocks the positive effects of activin-A on oligodendrocyte lineage
cells (specifically differentiation and membrane actin depolymerization required for
compaction, [327]). As Acvr2b has been shown to have a relatively higher affin-
ity for activin-A ligand compared to Acvr2a [304], our working hypothesis is that
Acvr2b downregulation after injury allows Acvr2a to bind ligands more efficiently
and drive oligodendrocyte lineage cell responses required for repair. If this down-
regulation fails, as it may occur in chronic inactive MS lesions, Acvr2b sequesters
ligands and impairs any Acvr2a-mediated effects. An interesting future experiment
could quantify activin receptor density on microglia/macrophages in MS tissue, as
this may reveal whether immune cell receptors share this lesion-specific expression
pattern with oligodendrocyte activin receptors.
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Taken together, this data shows that while alternative activin receptor ligands
are mostly expressed on microglia, activin receptors signal through both microglia
and oligodendrocytes during remyelination. A hypothetical model (summarized in
Figure 30) is that microglia/macrophages secrete TGF-β ligands important for re-
myelination, and these ligands subsequently act in an autocrine or paracrine fashion,
binding to activin receptors on microglia/macrophages and oligodendrocytes, driv-
ing downstream pathways, and activating genes required for efficient remyelination.
Important caveats to this model, such as axon calibre and ligand-binding receptor
subtype, as well as implications for future therapies, will be discussed in the next
chapter.
Figure 30. Hypothetical model of how microglia-derived ligands act on activin
receptors and drive remyelination. Activin receptor ligands may be secreted by mi-
croglia and act in a paracrine or autocrine fashion, binding to receptors on oligodendrocytes
and/or microglia and driving downstream pathways important for remyelination.
158
6 Chapter 6: Discussion
6.1 Overview of thesis
Stimulation of activin receptors using activin-A in an ex vivo model was sufficient
to accelerate remyelination, and blocking activin receptors using inhibin severely im-
paired remyelination. Similar effects were observed in vivo; however, they were less
pronounced and mostly relevant in small diameter axons. Blocking activin-A ligand
ex vivo had no effect, suggesting that alternative ligands may bind activin recep-
tors and drive remyelination. To investigate the feasibility of this hypothesis, it was
first determined whether alternative ligands were present in toxin-induced focal le-
sioning models during remyelination. GDF1, GDF11, and BMP6 were identified as
activin receptor ligands highly expressed during remyelination. Next, I investigated
whether these ligands were required for remyelination by inhibiting the activity of
each ligand using blocking proteins. These experiments yielded interesting effects:
GDF1 appeared to be important during late remyelination, as blocking its activity
had a slight negative effect at 14dpl. GDF11 was found to be important during both
early and late remyelination, as blocking its activity severely impaired this process
at 7 and 14dpl. Blocking BMP6 resulted in impaired remyelination at 14dpl; when
activin-A was also blocked, this impairment was evident earlier at 7dpl (see Figure
31, top and bottom panels). In vivo blocking experiments revealed a potential axon
calibre-dependent effect of activin receptor activity on remyelination (see Figure 31,
middle panel). Interestingly, while activin-A was sufficient to accelerate remyelina-
159
tion in Chapter 3, supplementing alternative ligands had no effect. While activin
receptors are required for remyelination, it is clear that each receptor-binding lig-
and produces distinct effects, both in terms of timing and myelin morphology. This
suggests each factor may be activating distinct downstream pathways. Given the
importance of context in dictating cellular response upon activation of any TGF-β
superfamily receptor, a logical next step was to clarify which cell types were involved
in expressing ligands, receptors, and active signalling markers. GDF1, GDF11, and
BMP6 were found to be expressed on microglia/macrophages in active MS lesions
and in remyelinating focal lesions in mice. Further, active Smad2/3-mediated activin
receptor signalling was observed in microglia and oligodendrocytes during remyeli-
nation. Finally, ligand-binding activin receptors were expressed both on microglia
and oligodendrocytes in MS lesions. An intriguing difference was uncovered in the
expression of activin receptor subtypes on oligodendrocytes, where Acvr2a is high
in actively remyelinating lesions, and Acvr2b is upregulated in lesions which fail to
remyelinate.
Taken together, data from this thesis supports the following working hypothe-
sis (summarised in Figure 31): activin receptor ligands may be secreted from mi-
croglia/macrophages in actively remyelinating lesions. These ligands may act in an
autocrine or paracrine fashion, binding to receptors on microglia/macrophages, or
on oligodendrocyte lineage cells. These ligand-receptor interactions may drive down-
stream signalling important for remyelination at many stages. Ligand availability,
specific ligand-receptor interactions, density of receptor subtypes, and axon calibre
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may dictate ultimate cellular outcomes and determine remyelination efficacy.
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Figure 31. Summary and Working Hypothesis. In the top panel, overall myelin
effects from modulating activity of each ligand are summarized at 7 days post lesion (dpl)
and 14dpl. In the middle panel, axon calibre based effects are summarized for each ligand.
Arrow thickness represents the strength of effect. No arrow indicates no clear effects. In the
bottom panel, contextual determinants of activin receptor signalling during remyelination
are shown. The red box indicates signalling inhibitors (ligand traps, inhibitory ligands).
Arrow thickness represents affinity for activin receptors. Double arrows represent syner-
gistic interactions between ligands.
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6.2 Future Directions
6.2.1 Microglia/macrophage derived factors during remyelination
Here, I determined that activin receptor ligands GDF1, GDF11, and BMP6 are
expressed on microglia/macrophages during remyelination in both human and experi-
mental mouse tissue. Given previous studies have identified several microglia-derived
factors which play a role in remyelination (reviewed in [363]), a likely hypothesis for
this co-expression is that microglia/macrophages are producing these proteins. To
test this, conditioned media from microglial cell cultures could be analysed to de-
termine whether ligand is present in the media at the protein level using ELISA.
Detection of GDF1, GDF11, or BMP6 would point towards microglial production of
these proteins. Additionally, inducing microglia to either a pro-inflammatory or an
anti-inflammatory phenotype first, then running the above experiment, may reveal
whether microglia of a specific phenotype secrete these proteins. To further confirm
ligand production by microglia in a remyelinating context, in situ hybridization may
be used in both in vivo and ex vivo tissue to determine ligand mRNA expression
within these cells.
Importantly, there is evidence suggesting that macrophages and microglia may
have distinct roles during remyelination. Specifically, one study stratified microglia
from macrophage cell populations from EAE mice by FACS and analysed their tran-
scriptomes using RNA sequencing. Throughout the course of EAE, microglia vs
macrophage transcriptomes were distinct, suggesting differential functions between
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these two immune cell types [364]. These findings were confirmed in two other stud-
ies [365, 366], one of which found that expression of the same gene in either microglia
or macrophages can have distinct effects on EAE disease course [366]. Therefore, it
may be important to distinguish between these two cell types in our in vivo models
and in human tissue. As previously mentioned, in the ex vivo model, there is no
input from the periphery, and therefore no infiltrating macrophages. Until recently,
there were no good markers to distinguish microglia from macrophages in immuno-
histochemical studies. A potential new marker that may be specific to a subset of
microglia is TMEM119 [367]. Future studies may use this marker to characterize
microglial-specific expression of activin receptors or their ligands in human tissue.
6.2.2 Cell-specific activin receptor effects
The working hypothesis diagram (Figure 31) stipulates that activin receptors in-
fluencing remyelination could be present on both microglia/macrophages and oligo-
dendrocytes. To tease apart the contributions of each of these cell-specific receptors,
genetic approaches may be used. Specifically, our lab currently has access to a con-
ditional knockout mouse where Acvr1b (the functional signalling receptor) is deleted
from PDGFRα oligodendrocyte progenitor cells. However, as these mice die pre-
maturely at P21, it is not possible to study the effects of activin receptor signalling
knockout during remyelination. To address this, an inducible knockout could be
developed, where an additional breeding step with a Cre-ERT2 mouse results in a
tamoxifen-inducible OPC-specific Acvr1b knockout animal.
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Additionally, we could create a new mouse line where Acvr1b is excised specifi-
cally from microglia/macrophages. It would be interesting to compare myelination in
this conditional knockout mouse to the OPC-specific knockout effects during devel-
opment, such as hypomyelination and enlarged inner tongues [327]. If these mice also
die prematurely, it would be important to create an inducible conditional knockout
as outlined above. Generating mouse lines is expensive and time-consuming; how-
ever, studying differences between microglia/macrophage-specific and OPC-specific
Acvr1b knockouts during remyelination would shed light on the requirement of cell-
specific activin receptors during myelin regeneration, and have important implica-
tions for developing drug therapies.
6.2.3 Ligand contributions during remyelination
In this thesis, I conducted experiments where ligands of interest were inhibited
using blocking proteins, administered directly to ex vivo cultures via media and to
in vivo lesions through osmotic mini-pumps. To further confirm the role of these
proteins during remyelination, it would be important to use a different technique.
An inducible genetic deletion of each ligand in an in vivo focal demyelination model
may be more effective and reliable in eliminating target ligands, and may therefore
reveal more robust effects. Floxed alleles for GDF1, GDF11, and BMP6 exist and
are commercially available. Importantly, mice with mutations in genes for each of
these ligands results in severe developmental defects, and early death (24-48 hours)
in GDF1 and GDF11 null mice [368–370]. Therefore, it would be crucial to create
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inducible knockout animals in order to determine the effects of a lack of each ligand
after adult demyelinating injury. Additionally, these mouse lines could be used to
test effects of an inducible knockout in ex vivo slices. Knockout mice for each ligand
may be interbred to develop double or triple knockouts, perhaps elucidating the
compensatory or synergistic effects of ligand combinations.
Further, it would have been interesting to determine if GDF1, GDF11, and BMP6
directly affect oligodendrocyte lineage cells (as observed with activin-A [142]). Pri-
mary oligodendrocyte progenitor cell cultures may have been used to test whether
each ligand may influence remyelination via direct effects on oligodendrocyte pro-
liferation, differentiation, or survival. Additionally, as we have identified activin
receptor activity to be important for compaction via actin depolymerization [327],
oligodendrocyte cultures treated with ligands or ligand blocking agents could also
be analyzed for Phalloidin signal, a marker of non-polymerized filamentous actin.
6.2.4 Ligand-receptor combinations and their downstream pathways
To understand how blocking each ligand may elicit a distinct effect on remyelina-
tion, it would be important to determine which downstream pathways are activated
by specific ligand-receptor combinations. To do this, a forward phase phospho-
antibody microarray may be used (as previously described [327]). Specifically, a
microarray containing antibodies against both phosphorylated and unphosphory-
lated residues in proteins associated with 5 TGF-β signalling pathways (summarised
in Figure 3) would be useful in determining which canonical or non-canonical down-
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stream events are active in each condition. As we have found activin receptors to be
expressed in both oligodendrocytes and microglia, it would be interesting to treat
either OPC or microglial cell cultures with each ligand and then process these sam-
ples for forward phase phospho-antibody analysis. Additionally, protein lysates from
slice cultures may be used, as these samples would contain both oligodendrocyte and
microglial activin receptors. However, the former cell culture experiment would be
more specific in terms of pathways upregulated within specific cell types.
Further, given that we found ligand-binding activin receptor subtypes may elicit
distinct effects, it would be important to characterize which receptor subtype these
ligands are endogenously binding to. To do this, a proximity ligation assay (PLA)
may be used. PLA is an immunoassay-based technique which identifies interactions
between proteins in close proximity. Using antibodies for Acvr2a or Acvr2b, to-
gether with GDF1, GDF11, or BMP6 antibodies, interactions between each ligand
and receptor subtype may be characterized. Additionally, to test our hypothesis
that Acvr2b-mediated signalling may be detrimental for remyelination by prevent-
ing ligands binding to Acvr2a, Acvr2b could be overexpressed in slice cultures using
a lentivirus (as previously reported in [327]). If remyelination is negatively affected
by this overexpression, it would support the notion that activin receptor subtypes
have distinct roles in remyelination.
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6.2.5 Axon calibre-dependent effects of activin receptor signalling during
remyelination
Given the axon diameter-dependent effects observed during remyelination in vivo
(summarized in Figure 31, middle panel), as well as during myelination [327], it
would be important to follow up on how axon calibre may affect activin receptor-
mediated myelination and remyelination. Since I observed stronger effects ex vivo
compared to in vivo, and in vivo effects were mainly observed on small calibre axons,
an attractive explanation would be that 4-5 week old ex vivo cerebellar fibres are
smaller in diameter than 6-8 week old in vivo corpus callosum axons. However, the
evidence is against this theory: previous work where EM was carried out on cerebellar
slice cultures shows that most axon diameters were between approximately 0.3-1.5µm
[45]. Despite previous reports that axon diameters may vary up to 100 fold across
brain regions [371], our in vivo corpus callosum axon diameters are very similar to
the ex vivo diameters reported in the ex vivo cerebellar slice study, suggesting that
differences in axon calibre between these particular brain regions is not a major
contributor to the remyelination differences across models. It is possible, however,
that other differences between models (discussed throughout this thesis) contribute
to a nuanced calibre-dependent effect only observable in the in vivo context.
To fully establish whether axon calibre influences activin receptor-mediated ef-
fects on myelin, several experiments may be carried out. First, experiments using
microfibre/oligodendrocyte cultures may be used to test whether administering or
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blocking activin receptor activity affects the cell’s ability to myelinate fibres of spe-
cific sizes. There is evidence that certain properties of myelin sheaths, such as
length, are intrinsic properties of oligodendrocytes, and are not regulated by ax-
onal signals [372]. Specifically, one study used microfibres to test whether oligo-
dendrocytes require external signals to myelinate. Remarkably, results showed that
oligodendrocytes generate sheaths of different lengths based on microfibre diameter,
suggesting that there are oligodendrocyte-intrinsic signals regulating myelin sheath
length [372]. Modulating activin receptor signalling in microfibre/oligodendrocyte
cultures as suggested above may reveal a potential signalling pathway regulating
myelin sheath length. Additionally, it would be interesting to coat fibres with ac-
tivin receptor ligands to see whether myelination could be induced in fibre sizes which
are not normally myelinated.
The myelinating cells of the peripheral nervous system (Schwann cells) are trig-
gered to myelinate axons larger than 1 µm, and axonal Neuregulin-1 type III helps
the Schwann cell determine how much myelin to make based on axon diameter [373].
In the CNS, however, it is not known how oligodendrocytes recognize axon calibre in
order to make the appropriate amount of myelin. The experiments described above
may point towards a potential contribution of activin receptors and their ligands in
calibre-dependent myelination.
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6.2.6 Determining the feasibility of activin receptor-driven therapeutics
Overall, results from this thesis suggest that activin receptors may prove an in-
teresting (albeit difficult) therapeutic target. We know that activin receptor activity
is important during remyelination, and different activin receptor ligands may mod-
ulate remyelination in distinct ways. Given the contribution of contextual factors,
such as the cell type expressing receptors, the subtype of these receptors, and the
availability of the many activin receptor ligands and their extracellular inhibitors,
there are a few challenges that must be considered. First, there is a need to under-
stand how we can target a specific activin receptor subtype. If Acvr2a and Acvr2b
truly have opposing effects as we have seen in our experimental models, then this
would be a crucial aspect of drug development. Second, it may be important to
target the correct cell type. Cell-targeted drug delivery may be accomplished using
targeted nanoparticles: a previous study has shown that nanoparticle delivery of
a pro-myelination factor directly to OPCs was effective in promoting myelin repair
[374]. Before we know which cell type to target however, we need to understand
more about the downstream pathways that are activated by specific combinations
of ligand-receptor-cell. Experiments suggested above may help shed light on the
outcomes of these interactions. Finally, it may be important to fully characterize
extracellular factors regulating activin receptor activity in human lesions, as these
may act against any therapeutic strategy targeting these receptors.
Another important consideration is whether targeting specific subsets of oligo-
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dendrocyte lineage cells or microglia/macrophages matters to the ultimate outcome.
Recent advances in single-cell transcriptomics have revealed distinct sub-populations
of microglia and oligodendrocytes, introducing heterogeneity to cell populations pre-
viously thought of as a homogeneous entities [375, 376]. As we learn more about these
subtypes of microglia/oligodendrocytes, and whether their transcriptomic differences
reflect distinct cellular states or separate cell types, we may uncover an important
caveat to developing therapeutic strategies for MS. If, for example, activin receptor
signalling is only relevant for efficient remyelination on a subset of glial cells, it may
be crucial to target this sub-population in order to avoid any confounding effects.
A final point to consider in activin receptor therapeutics is potential axon calibre-
dependent effects. The experiments outlined in the above section would help deter-
mine whether the calibre-dependent effects observed in my in vivo experiments reflect
a robust difference in activin receptor-mediated myelination/remyelination outcomes
based on axon diameter. If calibre becomes an important consideration, it would fur-




Taken together, results from this thesis provide evidence for the role of activin
receptors in driving remyelination. I found that activin receptors are required for
remyelination, and their stimulation results in accelerated remyelination. Further, I
identified 3 additional activin receptor ligands expressed on microglia with distinct
roles in remyelination. Finally, I established active signalling of receptors to occur
through microglia/macrophages and oligodendrocytes during remyelination. These
findings suggest that activin receptors mediate the process of myelin regeneration
via several ligands and two cell types. This work contains important implications for
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Abstract
The most prevalent neurological disorders of myelin include perinatal brain injury leading to cerebral palsy in infants and 
multiple sclerosis in adults. Although these disorders have distinct etiologies, they share a common neuropathological feature 
of failed progenitor differentiation into myelin-producing oligodendrocytes and lack of myelin, for which there is an unmet 
clinical need. Here, we reveal that a molecular pathology common to both disorders is dysregulation of activin receptors 
and that activin receptor signaling is required for the majority of myelin generation in development and following injury. 
Using a constitutive conditional knockout of all activin receptor signaling in oligodendrocyte lineage cells, we discovered 
this signaling to be required for myelination via regulation of oligodendrocyte differentiation and myelin compaction. These 
processes were found to be dependent on the activin receptor subtype Acvr2a, which is expressed during oligodendrocyte 
differentiation and axonal ensheathment in development and following myelin injury. During efficient myelin regeneration, 
Acvr2a upregulation was seen to coincide with downregulation of Acvr2b, a receptor subtype with relatively higher ligand 
affinity; Acvr2b was shown to be dispensable for activin receptor-driven oligodendrocyte differentiation and its overexpres-
sion was sufficient to impair the abovementioned ligand-driven responses. In actively myelinating or remyelinating areas 
of human perinatal brain injury and multiple sclerosis tissue, respectively, oligodendrocyte lineage cells expressing Acvr2a 
outnumbered those expressing Acvr2b, whereas in non-repairing lesions Acvr2b+ cells were increased. Thus, we propose 
that following human white matter injury, this increase in Acvr2b expression would sequester ligand and consequently impair 
Acvr2a-driven oligodendrocyte differentiation and myelin formation. Our results demonstrate dysregulated activin recep-
tor signaling in common myelin disorders and reveal Acvr2a as a novel therapeutic target for myelin generation following 
injury across the lifespan.
Keywords Myelin · Remyelination · Oligodendrocyte · Multiple sclerosis · Perinatal brain injury · Activin receptor
Introduction
Myelin ensures axon health and function in the CNS via 
trophic/metabolic support and insulation for electrical 
impulse conduction [14, 16, 26, 32, 37, 46]. The lack of 
myelin is, therefore, associated with axon dysfunction and/or 
loss, causing deficits in movement, sensation, and cognition, 
as observed in prevalent myelin disorders of development 
(perinatal brain injury leading to cerebral palsy/cognitive 
deficits) and adulthood [multiple sclerosis (MS)]. Although 
these have distinct etiologies, a shared neuropathological 
feature involves failed differentiation of oligodendrocyte 
precursor cells (OPCs) into myelin-producing oligoden-
drocytes following injury, resulting in impaired myelin 
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formation (myelination) [8, 10, 33, 36, 57] or regeneration 
(remyelination) [38], respectively. However, the mechanisms 
underpinning this pathology are not fully understood, as evi-
denced by the lack of approved therapies aimed at promoting 
oligodendrocyte differentiation and myelin generation.
Our previous work identified activin-A, a member of 
the transforming growth factor beta (TGF-β) superfamily, 
as being a promising pro-differentiation therapeutic target 
[45]. We found that at the onset of remyelination of focally 
demyelinated white matter lesions, microglia/macrophages 
express activin-A, and oligodendrocyte lineage cells express 
the ligand-binding activin receptors (Acvr2a, Acvr2b) and 
the signal-transducing co-receptor (Acvr1b) [45]; depletion 
of these microglia/macrophages caused impairment of remy-
elination [45]. In addition, healthy developmental myelina-
tion has recently been shown to be regulated by other TGF-β 
family members, TGF-β1 and activin-B [19, 49], albeit pri-
marily via signaling through distinct receptors (TGFβR1) or 
co-receptors (Acvr1c), respectively. However, how activin 
receptor signaling regulates oligodendroglial lineage cell 
behavior, and whether this is required for myelination and 
remyelination, remains to be fully elucidated.
Here, we reveal the requirement for activin receptor sign-
aling in regulating oligodendrocyte lineage cell responses 
during healthy white matter development and following 
injury. Furthermore, we demonstrate how dysregulation of 
activin receptor expression underpins myelin pathology in 
human perinatal brain injury and multiple sclerosis, reveal-
ing potentially targetable receptors for clinical intervention 
in myelin disorders across the lifespan.
Materials and methods
Animals
All experiments were performed under UK Home Office 
project licenses issued under the Animals (Scientific Pro-
cedures) Act. Animals were housed at 6 animals per cage 
in a 12 h light/dark cycle with unrestricted access to food 
and water. For animal experiments, power was calculated by 
two-sided 95% confidence interval via the normal approxi-
mation method using OpenEpi software, and reached > 80% 
power (84–100%) for all experiments. ARRIVE guidelines 
were followed in providing details of experiments, quantifi-
cations, and reporting.
Organotypic cerebellar slice cultures
Postnatal day 0–2 (P0-P2) CD1 pup cerebellum and attached 
hindbrains were sagittally sectioned at 300 µm on a McIl-
wain tissue chopper and plated onto Millipore-Millicel-CM 
mesh inserts (Fisher Scientific) in 6-well culture plates at 
six slices per insert. Media was composed of 50% minimal 
essential media, 25% heat-inactivated horse serum, 25% Ear-
le’s balanced salt solution (all from GIBCO), 6.5 mg ml−1 
glucose (Sigma), 1% penicillin–streptomycin, and 1% glu-
tamax. At 21 days in vitro when myelination is complete 
and compact, demyelination was induced by incubation in 
0.5 mg ml−1 lysolecithin (Sigma) for 18-20 h. Slices were 
then washed in media for 10 min and treated at 2 days post 
lysolecithin (dpl) until 7, 10, or 14 dpl with activin-A (100 
ng ml−1, R&D Systems), inhibin-A (100 ng  ml−1, R&D Sys-
tems) or vehicle controls. Slices were fixed in 4% paraform-
aldehyde (PFA, wt/vol) for 10 min and blocked in 5% nor-
mal horse serum (GIBCO) and 0.3% Triton-X-100 (Fisher 
Scientific) for 1 h. Primary antibodies rat anti-MBP (1:250, 
AbD Serotec; MCA409S) and chicken anti-neurofilament-
H (1:10,000, EnCor Biotech; CPCA-NF-H) were applied 
for 48 h at 4 °C. Slices were washed twice in 0.1% Triton-
X-100 and fluorescently conjugated antibodies applied for 
2 h at 20–25 °C (Life Technologies-Molecular Probes). Fol-
lowing counterstaining with Hoechst, slices were washed 
thrice and mounted onto glass slides using Fluoromount-
G. Z-stacks were captured using an Olympus 3i Spinning 
Disk microscope (60× silicone objective) and SlideBook 
software. Stacks were cropped to 14 slices (0.59 µm/slice) 
in SlideBook (3i), and images blinded and imported into 
Volocity (Perkin Elmer) as an image sequence. Remyelina-
tion index was calculated by normalizing voxel counts of 
values of co-localization of myelin (MBP) and axon (NF) to 
NF voxel counts, and this value for treated slices was further 
normalized to vehicle controls. Both males and females were 
assessed.
Breeding strategy for conditional knockout 
generation
Sperm from Acvr1b LoxP mice was generously provided by 
Dr. Gloria H. Su (Columbia University) where exons 2–3 are 
flanked with Cre-LoxP sites, which upon Cre recombination 
causes deletion of a 3.3-kb sequence, frameshift mutation, 
and abolishment of Acvr1b protein expression [53]. Sperms 
were injected into pseudopregnant C57Bl/6J females. The 
offspring were intercrossed to generate mice homozygous for 
the LoxP allele and subsequently crossed to PDGFRa-Cre 
mice (Jax laboratories, 013148). Mice identified as being 
positive for PDGFRa-Cre and heterozygous for the LoxP 
allele were then crossed back to homozygous Acvr1b LoxP 
mice to generate homozygous conditional knockout (cKO) 
mice. Mice were confirmed as a cKO by performing PCR 
on the genomic DNA for detection of the Cre recombinase 
gene and homozygosity of the Acvr1b LoxP allele. Further 
analysis of the recombination by PCR and Cre recombinase 
immunohistochemistry in the corpus callosum confirmed 
the conditional status of these mice (Online Resource 
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Supplemental Fig. 1). This was confirmed by DNA extrac-
tion from cortical OPCs of transgenic mice using the Wizard 
SV genomic purification system (Promega) and PCR using 
Q5 High Fidelity DNA Polymerase (New England Biolabs) 
using amplification with primers P4 and P5 (sequence in 
genotyping section below) (Online Resource Supplemental 
Fig. 1). Both males and females were assessed.
Genotyping
Genomic DNA was extracted from ear tissue using the Wiz-
ard SV genomic purification system (Promega) according 
to the manufacturer’s instructions. Acvr1b floxed mice were 
genotyped using PCR strategies as previously described 
[53]. Briefly, Acvr1b floxed mice were genotyped using 
primers P1 (ATG AAA AGT GCT TGC GTG TG) and P2 
(CAG GGA AGG GCA GAT ATC AA). PDGFRa-Cre mice 
were genotyped using primers 1084 (GCG GTC TGG CAG 
TAA AAA CTATC), 1085 (GTG AAA CAG CAT TGC TGT 
CACTT), 7338 (CTA GGC CAC AGA ATT GAA AGA TCT ) 
and 7339 (GTA GGT GGA AAT TCT AGC ATC ATC C). Cre-
mediated recombination was detected using P4 (CCA GCA 
CCT ACA TCA CAT GG) and P5 (CTC TAT GGA GAG CAC 
CCT CTTTG) (Online Resource Supplemental Fig. 1).
Immunohistochemistry of rodent cryosections
Animals were intracardially perfused with 4% PFA (wt/
vol; Sigma), brains post-fixed overnight and cryoprotected 
in sucrose prior to embedding in OCT (Tissue-Tech) and 
storage at − 80 °C. 8–10 μm cryosections were air-dried, 
permeabilized and blocked for 1 h with 5% normal horse 
serum (GIBCO) and 0.3% Triton-X-100 (Fisher Scientific). 
For Caspr staining, blocking solution and antibody diluent 
was composed of 10% normal horse serum and 0.1% Triton-
X-100. For myelin protein staining, sections were permeabi-
lized in methanol at − 20 °C for 10 min. For Olig1 and Olig2 
staining, sections were permeabilized in Vector Unmasking 
Solution (Vector) by microwaving for 5 min followed by a 
30-min incubation at 60 °C. Primary antibodies were applied 
overnight at 4 °C in a humid chamber and include rat anti-
MBP (AbD Serotec, 1:250; MCA409S), mouse anti-MAG 
(Millipore, 1:100; MAB1567), mouse anti-Olig2 (Milli-
pore, 1:100; MABN50), rabbit anti-Olig2 (1:100, Millipore; 
AB960), mouse anti-Olig1 (Millipore, 1:100; MAB5540), 
mouse anti-NG2 (1:200, Millipore; MAB5384), mouse anti-
CC1 (1:100, Abcam; ab16794), rabbit anti-Caspr (1:500, 
Abcam; ab34151), rabbit anti-cleaved caspase-3 (1:500, BD 
Pharmingen; 559565), rabbit anti-Acvr2a (1:100, Abcam; 
ab135634), goat anti-Acvr2a (1:40, RnD Biosystems; 
AF340), rabbit anti-Acvr2b (1:100, Abgent; AP7105a). 
Fluorescently conjugated secondary antibodies were 
applied for 2 h at 20–25 °C in a humid chamber (1:500, Life 
Technologies-Molecular Probes). Following counterstaining 
with Hoechst, slides were coverslipped with Fluoromount-
G (Southern Biotech). Antibody isotype controls added to 
sections at the same final concentration as the respective 
primary antibodies showed little or no nonspecific stain-
ing. Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL; Promega) assay for apoptosis was carried 
out according to the manufacturer’s instructions; DNase I 
(10 units ml−1) was applied as a positive control for double 
stranded breaks. Sections were imaged on a Leica SPE con-
focal microscope (40× objective) or an Olympus 3i Spinning 
Disk microscope (30×, 60×, or 100× oil immersion objec-
tives). Intensity of MAG or MBP staining in selected white 
matter areas was determined using the Histogram function 
in Adobe Photoshop and normalized to background levels 
in a non-white matter area from the respective sample. Per-
centage area of NF co-localizing with Caspr was calculated 
using Volocity software.
Western blotting
CNS samples were lysed with RIPA buffer (Thermo Scien-
tific) supplemented with 1% protease inhibitor cocktail set III 
ethylenediaminetetraaceticacid (EDTA)-free (Calbiochem). 
Protein concentrations were determined using the Pierce 
BCA Protein Assay Kit (according to the manufacturer’s 
instructions). Samples were diluted in Laemmli buffer (Bio-
Rad) and 5% β-mercaptoethanol (Sigma)], heated at 95 °C 
for 2 min, and 10 µg of protein was loaded onto an acryla-
mide gel (4–20%; Thermo Scientific). Gel electrophoresis 
was performed in tris-hydroxyethyl piperazineethanesulfonic 
acid (HEPES)-sodium dodecyl sulfate (SDS) running buffer 
(Thermo Scientific) at 100 V and proteins transferred onto 
polyvinylidene difluoride (PVDF) membranes (Millipore) 
for 2 h at 10 V in 10% transfer buffer [3% Tris–HCl (Sigma-
Aldrich), 15% glycine (Sigma-Aldrich), pH 8.3] and 20% 
methanol (Fisher Chemical) diluted in water. Membranes 
were blocked with 4% bovine serum albumin in Tris-buff-
ered saline (TBST) [4% sodium chloride (NaCl), 0.1% potas-
sium chloride (KCl), 1.5% Tris–HCl, 0.1% Tween-20 (all 
from Sigma-Aldrich), pH 7.4] for 1 h at room temperature on 
an orbital shaker, then incubated overnight at 4 °C with rab-
bit anti-MBP (1:1000, AB980; Merck Millipore) or mouse 
anti-CNPase (1:1000, AMAb91068; Atlas Antibodies). 
Membranes were washed thrice in TBST for 5 min and incu-
bated with horseradish peroxidase (HRP)-IgG secondary 
antibody conjugates (1:2000; Calbiochem) for 1 h at room 
temperature. Chemiluminescent substrate detection reagent 
RapidStep ECL Reagent (Calbiochem) was used to visualize 
bands. For loading control purposes, all membranes were 
re-blotted with anti-mouse or anti-rabbit beta-Actin.
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Resin embedding, semi‑thin sections, and electron 
microscopy
Mice were intracardially perfused with 4% PFA (wt/vol) and 
2% glutaraldehyde (vol/vol; TAAB Laboratories) in 0.1 M 
phosphate buffer. Tissue was post-fixed overnight at 4 °C 
and transferred to 1% glutaraldehyde (vol/vol) until embed-
ding. 1 mm tissue sections were processed into araldite resin 
blocks. 1 μm microtome-cut sections were stained with a 1% 
toluidine blue/2% sodium borate solution prior to bright field 
imaging at 100× magnification using a Zeiss Axio micro-
scope. Number of myelinated axons was blindly quantified 
in 50 μm × 50 μm images of corpus callosum, with 2–4 sec-
tions counted per mouse and then values averaged. Ultrathin 
sections (60 nm) were cut from corpus callosum, stained in 
uranyl acetate and lead citrate, and grids imaged on a JEOL 
Transmission Electron Microscope. Axon diameter, myelin 
thickness, and inner tongue thickness were calculated from 
measured area based on assumption of circularity using Fiji/
ImageJ (Fiji.sc) (diameter = 2 × √[area/π]), with a mini-
mum of 100 axons per animal analyzed. Enlarged inner 
tongues in conditional knockout mice precluded standard 
g-ratio analysis of myelin thickness, which was instead cal-
culated by subtracting the diameter to the innermost compact 
myelin layer from the diameter to the outermost compact 
myelin layer (see Online Resource Supplemental Fig. 5 for 
outline of quantification methods). Inner tongue thickness 
was calculated by subtracting the axonal diameter from the 
diameter to the innermost compact layer (Online Resource 
Supplemental Fig. 5). ‘Proportion of myelinated axons’ per 
axon diameter was determined by plotting the proportion 
of total myelinated axons (across all axons diameters) from 
each animal that were of a specific diameter, which was fit-
ted with a best-fit polynomial regression.
Oligodendrocyte lineage cell cultures
Cortical mixed glial cultures generated from both male and 
female Sprague–Dawley rat P0–P2 pups were expanded for 
10–14 days in vitro, and microglia depleted by de-adhesion 
following 1 h on a rotary shaker at 37 °C at 250 rpm. OPCs 
were subsequently isolated from collection of the floating 
fraction following 16 h on the rotary shaker, followed by 
depletion of contaminating astrocytes by differential adhe-
sion. OPCs were plated in DMEM containing 4.5 g l−1 glu-
cose, l-glutamine, pyruvate, SATO [16 µg ml−1 putrescine, 
400 ng ml−1 l-thyroxine, 400 ng ml−1 tri-iodothyroxine, 
60 ng ml−1 progesterone, 5 ng ml−1 sodium selenite, 100 
µg ml−1 bovine serum albumin fraction V, 10 µg ml−1 insu-
lin, 5.5 µg ml−1 halo-transferrin (all from Sigma-Aldrich)], 
0.5% fetal calf serum (GIBCO), 1% penicillin/streptomycin, 
10 ng ml−1 platelet-derived growth factor, and 10 ng ml−1 
fibroblast growth factor-2, at 2 × 104 cells per well in 8-well 
PDL-coated permanox chamberslides (Lab-TEK). OPCs 
were treated with activin-A (10 ng ml−1, R&D Systems) 
or vehicle control (0.0002% BSA) for 3 days. In a subset of 
experiments, OPCs were co-treated with activin-A and neu-
tralizing antibodies against Acvr2a or Acvr2b (30 μg ml−1, 
R&D Systems; AF340, AF339) or goat IgG isotype con-
trol (30 μg ml−1, Santa Cruz Biotechnology). Cells were 
matured to oligodendrocytes by withdrawal of growth fac-
tors from the media and treated with activin-A or vehicle 
control, with or without neutralizing antibodies for 5 days 
as above. An average of 120 cells were counted per image, 
with 2 images assessed per condition per biological replicate 
(a total of > 700 cells quantified per condition); values were 
averaged per biological sample. For quantification of mature 
oligodendrocyte membrane area, images were imported 
into Columbus software (Perkin Elmer), individual cells 
identified (by the software) by Hoechst, oligodendrocytes 
identified by MBP staining, and size of cytoplasm meas-
ured in square pixels  (px2) with a threshold of 2000  px2 
set to exclude background/false positives. For Phalloidin 
intensity measurements, Columbus was used to first iden-
tify cells (Hoechst+ nuclei) then mature oligodendrocytes 
(MBP+), and Phalloidin signal intensity was measured in 
each MBP+ cell.
Immunocytochemistry
Cells were fixed with 4% PFA (wt/vol) for 10–15 min and 
blocked for 30 min in 10% goat serum (Sigma), 2% horse 
serum (GIBCO), and 0.3% Triton-X-100 at 20–25  °C. 
Primary antibodies were diluted in blocking solution and 
applied for 1 h at 20–25 °C, and included mouse anti-MAG 
(1:100, Millipore; MAB1567), rat anti-MBP (1:250; AbD 
Serotec; MCA409S), and chicken anti-GFP (1:100; Abcam; 
ab13970). Cells were incubated with fluorescently conju-
gated secondary antibodies diluted in blocking solution 
(1:1000, Life Technologies-Molecular Probes), and in a 
subset of experiments with Phalloidin-Alexa-568 (1:40; 
ThermoFisher), for 1 h at 20–25 °C. Slides were counter-
stained with Hoechst (5 µg ml−1) and coverslipped with 
Fluoromount-G. Cells were imaged on a Leica SPE confo-
cal microscope (40× objective) or an Olympus 3i Spinning 
Disk microscope (30× or 60× objectives).
Lentiviral‑based overexpression
Lentivirus particles generated using 3rd generation lenti-
virus packaging were purchased from Insight Bio/Origene 
(stock  107 TU ml−1), inducing expression of GFP only for 
control transfection (PS100071V), or inducing overexpres-
sion of mouse Acvr2b and GFP (MR212153L2V). Particles 
were added to cultures of OPCs or differentiating oligoden-
drocytes at a multiplicity of infection (MOI) of 2.5 for 3 
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or 5 days, respectively. Cells were then fixed and immu-
nostained or lysed for protein as above.
Microfiber myelination assays
OPCs were plated onto PDL-coated parallel-aligned 2 μm 
electrospun poly-l-lactide acid (PLLA) fibers in 12-well 
plate inserts (The Electrospinning Company) at 35,000 cells 
per insert, as done previously [7]. Media was composed of 
50:50 Neurobasal media and DMEM with high glucose sup-
plemented with SATO [16 µg ml−1 putrescine, 400 ng ml−1 
l-thyroxine, 400 ng ml−1 tri-iodothyroxine, 60 ng ml−1 pro-
gesterone, 5 ng ml−1 sodium selenite, 100 µg ml−1 bovine 
serum albumin fraction V, 10 µg ml−1 insulin, 5.5 µg ml−1 
halo-transferrin), 5 µg ml−1 N-acetyl cysteine, 10 ng ml−1 
d-Biotin (all from Sigma-Aldrich)], ITS supplement 
(Sigma), B27 (Invitrogen), and 1% penicillin/streptomy-
cin. Cultures were treated with activin-A (1–100 ng ml−1, 
R&D Systems) or vehicle control for 14 days, fixed with 4% 
paraformaldehyde (wt/vol, Sigma), permeabilized with 0.1% 
Triton-X-100 (Fisher Scientific) and incubated overnight 
at 4 °C with rat anti-MBP antibody (1:250, AbD Serotec; 
MCA409S). Following three washes in PBS, inserts were 
incubated with secondary antibody (1:1000, Life Technolo-
gies-Molecular Probes) for 1 h at 20–25 °C, counterstained 
with Hoechst and mounted onto glass coverslips with Fluo-
romount G. Inserts were imaged as Z-stacks on an Olympus 
3i Spinning Disk microscope (60×). Myelin sheath number 
per oligodendrocyte and lengths from 20 oligodendrocytes 
per biological preparation were analyzed in a blinded man-
ner using the segmented line tool in Fiji/ImageJ (Fiji.sc) on 
maximum intensity images, using Z stacks to confirm com-
plete wrapping around fibers.
Forward phase phospho‑antibody microarray
OPCs were plated at 1 × 106 cells per well in a 6-well PDL-
coated plate and treated with activin-A (10 ng ml−1) or vehi-
cle control (0.0002% BSA). Cultures were washed with cold 
phosphate buffered saline on ice, scraped, and centrifuged 
thrice at 10,000 rpm at 4 °C and supernatant discarded. Pro-
tein extraction, lysate purification, and protein biotinylation 
were performed using the Antibody Array Assay Kit (Full 
Moon Biosystems) according to the manufacturer’s instruc-
tions. Samples were applied to TGF-β phospho-antibody 
microarray slides (Full Moon Biosystems) which have 176 
immobilized antibodies against phosphorylated and unphos-
phorylated specific residues in proteins associated with the 
5 TGFβ signaling pathways, with 6 technical replicates per 
antibody. All antibodies are against activating phospho-
rylation states, to the exception of Abl Thr754/735, GEF2 
Ser885, Cofilin Ser3, Myc Ser373/Ser62/Thr358/Thr58. 
Following incubation with streptavidin-Cy3 (1:1000), signal 
was detected on an Axon4200 microarray scanner (Edin-
burgh Genomics, The University of Edinburgh). Subsequent 
to background signal subtraction, values from phosphoryl-
ated signal were normalized to total protein signal for each 
protein site, then normalized to vehicle control. Data were 
then Log2 transformed and plotted as heat maps using 
GraphPad Prism 7 (San Diego, USA).
In vivo focal demyelinated lesions
Demyelinating lesions were induced in the caudal cerebel-
lar peduncles of 12-week-old female Sprague–Dawley rats 
by stereotaxic injection of 4 µl of 0.01% ethidium bromide 
(vol/vol) using a Hamilton syringe. Rats were intracardially 
perfused with 4% PFA, cryoprotected, cryosectioned, and 
stained as above. Non-lesioned CCP served as a control.
Post‑mortem brain tissue
Formalin-fixed paraffin-embedded post-mortem perinatal 
brain injury tissue was obtained with full ethical approval 
from the Medical Research Council Edinburgh Brain and 
Tissue Bank (EBTB) (REC/1-/S1402/69). Tissue with 
evidence of white matter injury was selected with neuro-
pathological support from Dr. Julie-Clare Becher (Royal 
Infirmary of Edinburgh) and Dr. Colin Smith (University 
of Edinburgh) (Table S1, Online Resource Supplemental 
Fig. 9a–c). Sections were de-paraffinized twice at 20–25 °C 
in Histoclear for 10 min then rehydrated through an ethanol 
gradient (100% (twice), 95, 70, and 50%, 5 min each). Fol-
lowing washes in 0.1% Tween20 (vol/vol) in Tris-buffered 
Saline (TBS), sections were microwaved in Vector Unmask-
ing Solution for 10 min, washed once, and endogenous phos-
phatase and peroxidase activity blocked for 5 min (Bloxall, 
Vector). Primary antibody was prepared in 2.5% Normal 
Horse Serum (Vector) and applied overnight in a humid 
chamber at 4 °C. Antibodies used included mouse CD68 
(1:100, DAKO; M0814), rat anti-MBP (AbD Serotec, 1:250; 
MCA409S), rabbit anti-INHBA (activin-A subunit; 1:100, 
Sigma-Aldrich; HPA020031), rabbit anti-Acvr2a (1:100, 
Abcam; ab135634), rabbit anti-Acvr2b (1:100, Abgent; 
AP7105a), rabbit anti-PCNA (1:400, Abcam; ab18197), and 
mouse anti-Olig2 (1:100, EMD Millipore; MABN50). Fol-
lowing washes, alkaline phosphatase-conjugated anti-mouse 
or anti-rabbit secondary antibody was applied for 30 min at 
20–25 °C in a humid chamber. Sections were washed in TBS 
and stains visualized by Vector Blue substrate kit according 
to the manufacturer’s instructions (maximum 15 min). For 
co-staining, sections were washed thrice and re-blocked to 
quench any remaining phosphatase activity (Bloxall, Vec-
tor) prior to application of primary antibody, then developed 
using Vector Red substrate kit according to the manufac-
turer’s instructions (maximum 15 min). Following washes 
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in water, the sections were counterstained with Hoechst and 
mounted with Fluoromount-G. Entire tissue sections were 
imaged using a Zeiss AxioScan SlideScanner. Due to non-
neurological age-matched controls not being available, areas 
of injury (high CD68 densities; average 122 ± 30 cells/mm2) 
were compared to areas of non-injury (low CD68 densities; 
average 10 ± 10 cells/mm2) within the same section (pathol-
ogy assessment shown in Online Resource Supplemental 
Fig. 9a–c). Lesion maps were defined for analysis in Zeiss 
Zen2 software; fields of 360 μm × 360 μm were counted per 
sample (injured or non-injured) and counts were multiplied 
to determine density of immunopositive cells per  mm2. Post-
mortem tissue from MS patients and controls who died of 
non-neurological causes were obtained via a UK prospective 
donor scheme with full ethical approval from the UK Multi-
ple Sclerosis Tissue Bank (MREC/02/2/39). MS diagnosis 
was confirmed by neuropathological means by F. Roncaroli 
(Imperial College London) and clinical history was provided 
by R. Nicholas (Imperial College London). Snap frozen 
unfixed tissues blocks (2 × 2 × 1 cm) were cut at 10 µm 
and stored at − 80 °C. MS lesions were classified according 
to the International Classification of Neurological Disease 
using Luxol Fast Blue staining and Oil Red O immunore-
activity using standard methods (pathological assessment 
shown in Online Resource Supplemental Fig. 9d–f). We 
analyzed 4 control blocks and 10 tissue blocks from 8 MS 
patients (Table S2). Sections were fixed in 4% PFA for 1 h 
at 20–25 °C, washed in TBS and permeabilized in methanol 
for 10 min at − 20 °C. Sections were subsequently stained, 
imaged and quantified as above.
Statistics
All manual cell counts were performed in a blinded man-
ner. Data are represented as mean ± s.e.m. Power calcula-
tions for sample size were performed (using OpenEpi), and 
showed power between 84 and 100% for all experiments. 
Statistical tests include one-sample t test for data where val-
ues were normalized to control, two-tailed Student’s t test or 
Mann–Whitney test, and non-parametric one-way ANOVA 
(Kruskal–Wallis) with Dunn’s multiple comparison post hoc 
test when > 3 comparisons were made. A paired Student’s t 
test was used when variation between experiments was high, 
to normalize to baseline levels within each biological prep-
aration. Slopes of myelin thickness versus axon diameter 
were compared using the Extra Sum of Squares F test. Curve 
distributions of proportion of myelinated axons per axon 
diameter were compared using the Kolmogorov–Smirnov 
test. Proportions of CC1+ or CC1− negative cells within the 
Olig2+ population were compared using Multiple t tests and 
two stage step up linear procedure of Benjamini, Krieger, 
and Yekutieli with a false discovery rate of 1%. P < 0.05 
was considered to be statistically significant. Data handling 
and statistical processing were performed using Microsoft 
Excel and GraphPad Prism Software.
Results
Activin receptor signaling is required 
for developmental myelination
To determine whether activin receptor signaling is required 
for developmental myelination, we sought to constitutively 
eliminate all activin receptor signaling in oligodendrocyte 
lineage cells. We achieved this by targeting Acvr1b, the 
activin co-receptor that is required for all intracellular sig-
nal transduction downstream of activin-A binding to either 
activin receptor Acvr2a or Acvr2b [6] (Fig. 1a). We thus 
created a constitutive conditional knockout in which oli-
godendroglial lineage cells cannot respond to any activin 
receptor ligation due to Acvr1b excision in OPCs (PDGFRa-
Cre;  Acvr1bfl/fl) [6, 53] (Fig. 1a; Online Resource Supple-
mental Fig. 1a–c). By immunofluorescence, Cre expression 
was confirmed to be in Olig2+ oligodendrocyte lineage cells 
(Online Resource Supplemental Fig. 1d). At postnatal day 
16 (P16) when myelination is normally underway, PDGFRa-
Cre;  Acvr1bfl/fl mice displayed a tremor, hunched posture, 
and a stiff tail (Online Resource Supplemental Video 1), all 
behaviors associated with myelin abnormalities [17, 44] or 
damage (e.g. in experimental autoimmune encephalomyeli-
tis) [12, 58].
To determine whether this reflected myelin pathol-
ogy, we assessed myelin-associated protein expression 
in the brains of  Acvr1bfl/fl control and PDGFRa-Cre; 
 Acvr1bfl/fl mice by Western blot and observed a decrease 
in 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) and 
myelin basic protein (MBP) in the conditional knockout 
mice (Fig. 1b). We further analyzed expression of myelin 
protein by immunofluorescence in multiple white matter 
tracts (corpus callosum, cerebellum, spinal cord) in PDG-
FRa-Cre;  Acvr1bfl/fl mice and observed a severe reduction 
in myelin-associated glycoprotein (MAG) intensity com-
pared to  Acvr1bfl/fl control and heterozygous (PDGFRa-
Cre;  Acvr1bfl/+) littermates (Fig. 1c, d; Online Resource 
Supplemental Fig. 2a, b). Hypomyelination in PDGFRa-
Cre;  Acvr1bfl/fl mice was further verified by histological 
analysis of semi-thin resin sections, which showed a sig-
nificantly reduced density of myelinated axons by 60% 
(Fig. 1e, f). Peripheral nervous system myelin on dorsal 
root ganglia was unaffected in conditional knockout mice 
(Online Resource Supplemental Fig. 2c, d), as expected 
given the absence of PDGFRα expression in that com-
partment. Ultrastructural assessment of the sparse myelin 
that was produced by P16 in PDGFRa-Cre;  Acvr1bfl/fl 
mice revealed that of all the myelinated axons, the largest 
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Fig. 1  Activin receptor signal-
ing is required for develop-
mental myelination. a Diagram 
of activin receptor signaling: 
Acvr2a and Acvr2b are ligand-
binding receptors that require 
Acvr1b to induce intracellular 
signallng. In PDGFRa-Cre; 
 Acvr1bfl/fl mice, the knock-
out of Acvr1b eliminates all 
activin receptor signaling from 
both ligand binding recep-
tors. b Western blots of brain 
lysates from P16  Acvr1bfl/fl and 
PDGFRa-Cre;  Acvr1bfl/fl mice 
(cerebellum) labeled for CNP 
(46 kDa) or MBP (14–21 kDa) 
with β-Actin as a loading con-
trol. c Images of corpus callo-
sum, cerebellum [counterstained 
with Hoechst (blue)] and dorsal 
spinal cord in P16  Acvr1bfl/
fl and PDGFRa-Cre;  Acvr1bfl/fl 
mice immunostained for myelin 
protein MAG (green). Scale 
bar 25 μm. d Mean MAG 
intensity normalized to back-
ground ± s.e.m. in the corpus 
callosum of P16  Acvr1bfl/
fl (n = 4 mice), PDGFRa-
Cre;  Acvr1bfl/+ (n = 4 mice) 
and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 6 mice). Two-tailed 
Student’s t test, *P = 0.0211, 
**0.0018. e Mean number of 
myelinated fibers ± s.e.m. per 
field of toluidine-blue stained 
semi-thin resin sections of 
corpus callosum at P16 in 
 Acvr1bfl/fl and PDGFRa-Cre; 
 Acvr1bfl/fl mice (n = 3 mice per 
group). Two-tailed Student’s t 
test, **P = 0.0034. f Toluidine-
blue stained semi-thin resin 
sections of corpus callosum in 
 Acvr1bfl/fl (left) and PDGFRa-
Cre;  Acvr1bfl/fl mice (right), 
with expanded field of view 
(f(a) and f(b), respectively). 
Scale bar 20 μm. g Analysis of 
distribution of myelinated axons 
in relation to axon diameter, 
represented as proportion of 
myelinated axons only (from 
all diameters), in  Acvr1bfl/fl 
(magenta) and PDGFRa-Cre; 
 Acvr1bfl/fl mice (green) mice 
(n = 3 mice per genotype) over-
laid with polynomial best-fit 
regression curves (R2 = 0.8897, 
0.8344, respectively). Kolmogo-
rov–Smirnov test, **P = 0.002
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proportion was of a diameter of 0.5–0.6 μm, in comparison 
to that being 0.6–0.7 μm in floxed controls (Fig. 1g). A 
polynomial best-fit regression of the proportion of myeli-
nated axons per axon diameter confirmed a statistically 
significant shift towards myelination of smaller diameter 
axons in activin receptor conditional knockouts (Fig. 1g). 
All PDGFRa-Cre;  Acvr1bfl/fl mice died by P21 preclud-
ing longitudinal analysis of myelination; juvenile death 
is also a feature of some other hypomyelinating mutants 
[9, 15, 18, 34, 54, 64]. Nonetheless, analysis of mice at 
P21 showed some myelination, although hypomyelination 
was still prevalent in the corpus callosum and cerebellum 
(Online Resource Supplemental Fig. 2e). Overall, these 
data show the requirement for activin receptor signaling 
in timely myelination of a significant proportion of CNS 
axons in development.
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Activin receptor signaling drives oligodendrocyte 
differentiation
We next sought to determine the cellular mechanisms 
underpinning the hypomyelination in PDGFRa-Cre; 
 Acvr1bfl/fl mice, by assessing oligodendroglial responses. 
Between genotypes at P16, there were no differences 
in total oligodendroglial lineage cell number (Olig2+) 
(Fig. 2a); we did not observe cell death in the lineage 
at either P16 or earlier (cleaved caspase-3 negative and 
TUNEL negative) in any genotype (Online Resource Sup-
plemental Fig. 3), consistent with oligodendrocyte death 
normally occurring later in development [24]. How-
ever, whereas in floxed control mice, the proportion of 
Olig2+ cells that were mature oligodendrocytes (CC1+) 
was not significantly different from that which were imma-
ture cells (CC1−), PDGFRa-Cre;  Acvr1bfl/fl mice had sig-
nificantly less CC1+ Olig2+ cells versus CC1− Olig2+ 
cells (Fig. 2b), suggesting impaired differentiation into 
mature oligodendrocytes. To specifically address this, we 
quantified differentiating oligodendrocytes (cytoplasmic 
Olig1+ Olig2+ cells) and found that these were signifi-
cantly decreased in PDGFRa-Cre;  Acvr1bfl/fl mice com-
pared to controls (Fig. 2c, d). The oligodendrocyte matura-
tion defect in activin receptor conditional knockout mice 
was observed as early as P1, when few immature oligoden-
drocytes (MAG+ MBP−) cells were observed (Fig. 2e). 
These data support that activin receptor signaling is 
required for differentiation of a significant proportion of 
oligodendrocyte lineage cells.
To assess the sufficiency of activin receptor signaling in 
driving oligodendrocyte differentiation, primary cultures of 
wildtype OPCs were treated with the most potent activat-
ing ligand, activin-A. Even in the presence of proliferation-
inducing growth factors (platelet-derived growth factor and 
fibroblast growth factor) which normally preclude differen-
tiation, activin-A significantly enhanced OPC differentiation 
into mature oligodendrocytes (MAG+) (Fig. 2f, g). Consist-
ent with this finding, data-mining of the human fetal brain 
transcriptome [39] revealed that as development proceeds, 
increased gene expression of activin-A (INHBA) parallels 
that of oligodendrocyte maturation-associated genes MAG 
and MOG (Fig. 2h). The activin-A subunit (Inhba) was also 
found to be expressed in developing mouse brain during 
myelination (Online Resource Supplemental Fig. 4).
Activin receptor signaling drives oligodendrocyte 
membrane compaction
Although we demonstrated impaired oligodendrocyte 
differentiation in the activin receptor conditional mutant 
mouse, there were still some oligodendrocytes that were 
generated resulting in limited myelination taking place. 
We next analyzed whether this myelin was normally 
formed, to determine whether activin receptor signal-
ing is required for proper myelination. In PDGFRa-Cre; 
 Acvr1bfl/fl mice at P16, we observed increased myelin 
inner tongue thickness in PDGFRa-Cre;  Acvr1bfl/fl mice 
compared to floxed controls (Fig.  3a–c), most promi-
nently in association with small-diameter axons (Fig. 3b, 
c; measurement protocol outlined in Online Supplemen-
tal Resource Fig. 5). Enlarged myelin inner tongues are 
normally seen in early myelination during the active 
growth phase, resulting from accumulation of new myelin 
membrane prior to actin disassembly mediated compac-
tion and fusion with myelin sheaths [48, 60, 66]. Persis-
tent enlargement of inner tongues may thus result either 
from (i) increased membrane growth rate, or (ii) impaired 
actin disassembly and myelin membrane compaction [48, 
61, 66]. Given that the former postulate would result in 
a thicker myelin sheath, we measured thickness of com-
pacted layers (as done previously [66]; measurement pro-
tocol outlined in Online Supplemental Resource Fig. 5), 
yet documented significantly thinner myelin at all axon 
diameters in PDGFRa-Cre;  Acvr1bfl/fl mice (Fig.  3d) 
thereby ruling out increased membrane growth. The thin-
ner myelin in conditional knockout mice was confirmed 
to be compact (Fig. 3e). To address the latter postulate, 
we assessed expression of myelin basic protein (MBP), 
which is required for actin disassembly and myelin mem-
brane compaction [60, 66]. PDGFRa-Cre;  Acvr1bfl/fl mice 
Fig. 2  Activin receptor signaling regulates oligodendrocyte differ-
entiation. a Mean number of oligodendrocyte lineage cells (Olig2+) 
per field ± s.e.m. in corpus callosum of P16  Acvr1bfl/fl (n = 3 mice), 
PDGFRa-Cre;  Acvr1bfl/+ (n = 4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n  =  7 mice). b Mean proportion of oligodendrocyte line-
age cells (Olig2+) which are mature oligodendrocytes (CC1+) 
versus immature cells (CC1−), per field  ±  s.e.m. in corpus cal-
losum of P16  Acvr1bfl/fl (n  =  4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 7 mice). Multiple t tests with false discovery rate of 1%, 
***P  =  0.000026. c Images of differentiating oligodendrocytes 
(cytoplasmic Olig1+ and nuclear Olig2+) in corpus callosum of P16 
 Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Scale bar 25  μm. d 
Mean number of cytoplasmic Olig1 and Olig2 double positive cells 
per field ± s.e.m. in corpus callosum of P16  Acvr1bfl/fl (n = 3 mice), 
PDGFRa-Cre;  Acvr1bfl/+ (n = 4 mice) and PDGFRa-Cre;  Acvr1bfl/fl 
mice (n = 7 mice). Two-tailed Student’s t test, **P = 0.0047, 0.0026, 
respectively. e Images of maturing oligodendrocytes (MAG+ MBP−) 
at P1 in corpus callosum of  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/
fl mice. Scale bar 25 μm. f Mean number of MAG+ cultured oligo-
dendrocytes per field in vehicle control-treated or activin-A-treated 
conditions (10  ng  ml−1) in  vitro. n  =  3 biological replicates. Two-
tailed paired Student’s t test, *P = 0.0484. g Images of cultured OPCs 
treated with vehicle or 10 ng ml−1 activin-A and immunostained for 
MAG (green), counterstained with Hoechst (blue). Scale bar 25 μm. 
h Data-mining of microarray of human fetal brain at 9 and 12 ges-
tational weeks (gw) represented as fold change in expression (nor-
malized to 9 gw), showing paralleled expression changes between 
activin-A (INHBA) and oligodendrocyte differentiation-associated 
genes (MAG, MOG) in development
◂
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Fig. 3  Activin receptor signaling regulates myelin membrane com-
paction/maturation. a Electron micrographs of myelinated axons in 
P16  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Scale bars 1 μm. 
b Average inner tongue thickness per axon diameter per animal in 
 Acvr1bfl/fl (magenta) and PDGFRa-Cre;  Acvr1bfl/fl mice (green). 
n  =  3 mice per genotype. c Dot plot of inner tongue thickness per 
axon diameter for all myelinated axons for all animals, in  Acvr1bfl/fl 
(magenta) and PDGFRa-Cre;  Acvr1bfl/fl mice (green). d Myelin thick-
ness versus axon diameter in  Acvr1bfl/fl (magenta) and PDGFRa-Cre; 
 Acvr1bfl/fl mice (green). Extra sum of squares F test between slopes, 
***P = 0.0014. e Electron micrographs of compact myelin layers in 
P16  Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. f Images of myelin 
basic protein (MBP) in corpus callosum of  Acvr1bfl/fl and PDGFRa-
Cre;  Acvr1bfl/fl mice at P16. Scale bar 25  μm. g MBP intensity in 
PDGFRa-Cre;  Acvr1bfl/fl mice normalized to background and to lev-
els in  Acvr1bfl/fl mice. s.e.m. for variance in  Acvr1bfl/fl samples indi-
cated. One sample t test against theoretical mean of 1, **P = 0.0097. 
h Image of PDGFRa-Cre;  Acvr1bfl/fl corpus callosum showing 
MAG+ (green), MBP negative (red) myelin sheaths (arrows). i Per-
centage of total axonal area (neurofilament (NF)+) co-localizing 
with compaction marker Caspr in caudal corpus callosum at P16 in 
 Acvr1bfl/fl and PDGFRa-Cre;  Acvr1bfl/fl mice. Two-tailed Student’s t 
test, **P = 0.0038, n = 2–4 mice per group. Inset example of Caspr 
clusters (green) at paranodes along axon (NF+; purple) (arrow). j 
Images of cultured mature oligodendrocytes treated with vehicle 
control or activin-A (10 ng ml−1) stained with Phalloidin-Alexa-568 
(red) and MBP (green). Scale bar 20  µm. k Phalloidin intensity 
(arbitrary units; A.U.) in MBP+ sheets of mature oligodendrocytes 
plotted against oligodendrocyte size (pixels squared;  px2) in control 
(magenta) or activin-A (10 ng ml−1) treated (green) conditions
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showed significantly decreased MBP intensity relative to 
floxed controls (Fig. 3f, g); MAG+ myelin sheaths devoid 
of MBP were also observed in these mice (Fig. 3h), indica-
tive of non-compact myelin as MAG is normally excluded 
from compact myelin sheaths by MBP [2, 3]. These data 
suggest that activin receptor signaling in oligodendroglial 
lineage cells is required for normal MBP expression and 
myelin membrane compaction.
We next asked whether this impairment in compaction 
would be maintained as myelination proceeds in the condi-
tional knockout mice. Due to these mice dying by P21, we 
addressed this by examining the caudal region of the corpus 
callosum in P16 mice, where myelination is more advanced 
relative to rostral regions. As clustering of the axonal adhe-
sion molecule Caspr along axons only occurs when myelin 
is compacted at the internode [63], we used the percentage 
of axonal area co-localizing with Caspr clusters as a read-
out of compaction. In comparison to  Acvr1bfl/fl mice, the 
percentage of total axonal area (NF+) occupied by Caspr 
clusters was significantly lower in caudal corpus callosum 
of PDGFRa-Cre;  Acvr1bfl/fl mice, indicative of a maintained 
deficiency in myelin compaction (Fig. 3i).
Given that myelin compaction requires actin disassem-
bly [48, 66], the sufficiency of activin receptor signaling 
in accelerating actin depolymerization in oligodendrocyte 
membranes was assessed. Maturing wildtype oligodendro-
cytes were treated with activin-A, and non-depolymerized 
filamentous actin was detected using fluorescently conju-
gated Phalloidin, a method established in recent studies 
of actin dynamic-driven oligodendrocyte membrane com-
paction [48, 66]. Oligodendrocyte membranes in control 
conditions had high Phalloidin signal throughout MBP+ 
membranes at 5 days of in vitro maturation, indicative of 
non-depolymerized actin (average intensity/cell 38.3 ± 0.9 
A.U.; Fig. 3j, k). Conversely, activin-A-treated oligoden-
drocyte membranes showed a reduced Phalloidin intensity, 
demonstrating increased actin depolymerization conse-
quent to activin receptor signaling (average intensity/cell of 
28.0 ± 0.5 A.U.; Fig. 3j, k).
To next test whether activin signaling regulates the total 
amount of myelin membrane made by oligodendrocytes, we 
first measured the average size of oligodendrocyte mem-
branes in activin-A-treated cultures, yet found no difference 
to vehicle-treated cultures (Fig. 3k and Online Resource 
Supplemental Fig. 6a, b). We assessed the number and 
length of myelin sheaths formed by oligodendrocytes on 
poly-L-lactic acid microfibers, and also found no significant 
effect of activin-A treatment (Online Resource Supplemental 
Fig. 6c, d). Overall these results demonstrate that although 
activin receptor signaling does not increase the amount of 
membrane produced once an oligodendrocyte has differen-
tiated, it has an important role in efficient oligodendrocyte 
membrane actin disassembly and myelin compaction.
Activin receptor subtype Acvr2a regulates 
oligodendrocyte differentiation and membrane 
actin disassembly
Having shown that signal transduction via the co-receptor 
Acvr1b is required for oligodendrocyte differentiation and 
membrane compaction, we next asked which ligand-binding 
activin receptor drives this effect. Activin-A can bind to two 
activin receptor subtypes, Acvr2a and Acvr2b; whether these 
have differential function or protein expression patterns in 
the CNS is unknown. We assessed Acvr2a and Acvr2b 
expression in the oligodendrocyte lineage during develop-
mental myelination. Acvr2a expression in the cell bodies of 
Olig2+ cells was found to progressively increase over time 
while oligodendrocyte differentiation is underway (P1–P8), 
and was later also associated with myelin at the peak of 
myelination (P14) (Fig. 4a). We detected Acvr2a expression 
in both NG2+ immature cells and CC1+ mature oligoden-
drocytes (Fig. 4b). Data-mining of oligodendrocyte lineage 
single-cell transcriptomes in later development (P21–30; 
[41]; linnarssonlab.org/oligodendrocytes) confirmed sus-
tained Acvr2a expression throughout the lineage, including 
in subsets of precursors and myelinating oligodendrocytes 
(Fig. 4c). Conversely, Acvr2b protein was not detectable at 
any time point in development (Fig. 4a), in contrast to the 
robust signal observed in positive control placental tissue 
(Online Resource Supplemental Fig. 7a) [56], and consistent 
with undetectable Acvr2b mRNA in the developing brain 
at the onset of myelination (Online Resource Supplemental 
Fig. 7b).
Given that Acvr2a is the receptor subtype expressed at 
the onset of differentiation and myelination, we next tested 
whether this receptor drives these responses by co-treating 
oligodendrocyte lineage cells with activin-A and an Acvr2a-
specific neutralizing antibody, or an isotype IgG control. 
Protein blasting the epitope sequences for the Acvr2a anti-
body showed 100% specificity and selectivity for this recep-
tor subtype. Blocking Acvr2a reversed the effects of activin-
A on differentiation of OPCs into mature oligodendrocytes 
(MBP+) (Fig. 4d, e), and prevented activin-A-driven actin 
disassembly in oligodendrocytes (causing increased Phalloi-
din intensity in MBP+ membranes; Fig. 4f, g). Conversely, 
blocking Acvr2b had no significant effect on oligodendro-
cyte differentiation (Online Resource Supplemental Fig. 8a), 
although it did reduce activin-A-driven actin disassembly 
(Online Resource Supplemental Fig. 8b). Nevertheless, this 
data revealed that Acvr2a is the activin receptor subtype 
expressed by the oligodendrocyte lineage during develop-
mental myelination and can drive activin-A-mediated oligo-
dendrocyte differentiation and membrane actin disassembly.
To next determine which signaling pathways mediate 
Acvr2a-driven oligodendrocyte differentiation and mem-
brane actin depolymerization, we assessed activation of 
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the 5 TGFβ signaling pathways induced downstream of 
activin receptors (Rac1 GTPase, p38 MAPK/JNK, PI3K/
AKT, Smad2/3, ERK1/2,) which are also associated with 
regulation of oligodendroglial lineage responses and mye-
lination [4, 27, 29, 47, 61]. Activation of all pathways in 
activin-A-stimulated oligodendroglial lineage cells was 
simultaneously assessed by measuring phosphorylation 
levels of signaling proteins using a forward-phase anti-
body microarray; phosphorylation signal was normalized 
to respective total protein signal, and values then normal-
ized to vehicle control. We found that activin-A increased 
phosphorylation signal in all pathways, with the highest 
increase in signal observed in the Rac1 GTPase and p38/
MAPK pathways (Fig. 4h). Taken together with our find-
ings, these results are consistent with known roles for 
the Rac1 GTPase and p38 MAPK pathways in regulating 
oligodendrocyte differentiation, myelination, and myelin 
compaction [11, 13, 19, 25, 29, 61].
Fig. 4  Activin receptor Acvr2a regulates oligodendrocyte lineage 
cell behavior. a Acvr2a (top row; green) and Acvr2b (bottom row; 
green) expression by oligodendrocyte lineage (Olig2+; red) through-
out development (P1–P14; double positive cells indicated by arrows), 
counterstained with Hoechst (blue). Inset; isotype control for Acvrs. 
Scale bar 50  μm. b Expression of Acvr2a (red) by NG2+ cells 
(green) (top row), and by CC1+ cells (green) (bottom row). c Data-
mining of oligodendrocyte lineage cell transcriptomes from P21–30 
for Acvr2a expression, represented as t distributed stochastic neighbor 
embedding projection. d OPCs co-treated with activin-A and neutral-
izing antibodies for Acvr2a or isotype IgG. Mean percentage of oli-
godendrocytes (MBP+) normalized to isotype control ± s.e.m. n = 3 
biological replicates, two-tailed Student’s t test, P = 0.0087. e Images 
of MBP+ cells (red) in cultures treated with activin-A (10 ng ml−1) 
and isotype IgG or Acvr2a-neutralizing IgG. Scale bar 75  μm. f 
Phalloidin intensity signal (arbitrary units; AU) per oligodendro-
cyte plotted against oligodendrocyte size  (px2) in cultures co-treated 
with activin-A (10 ng ml−1) and IgG control or neutralizing antibody 
against Acvr2a. n = 3 biological replicates. g Images of MBP+ oligo-
dendrocytes (green) and filamentous actin (Phalloidin+; red) in cul-
tures treated with activin-A and IgG or Acvr2a neutralizing antibody. 
h Log2-transformed phosphorylation signal of TGFβ superfamily 
pathways following treatment with activin-A, normalized to respec-
tive total protein signal then to vehicle control. Heat map: compared 
to vehicle, magenta indicates increased signal, black no change, and 
green reduced signal
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Activin receptor signaling regulates remyelination
Having shown the role of activin receptor signaling in 
developmental myelination, we next asked whether it is 
also relevant to regeneration of myelin following injury. Our 
previous work showed that at the onset of remyelination, 
activin-A levels increase and activin receptors are expressed 
by OPCs [45]. To examine whether this expression has func-
tional significance for remyelination, we used activin-A to 
stimulate activin receptors during remyelination of ex vivo 
organotypic cerebellar brain explants which were demyeli-
nated with lysolecithin. Activin-A significantly increased 
remyelination at 7 days post lysolecithin (dpl) compared to 
vehicle control, as measured by remyelination index (co-
localization of myelin basic protein (MBP) and axonal neu-
rofilament, normalized to area of neurofilament) [63, 65] 
(Fig. 5a, b). Due to remyelination subsequently occurring 
efficiently in controls, no significant differences between 
vehicle and activin-A-treated explants were observed at later 
time points (10, 14 dpl) (Fig. 5b). These data demonstrate 
that activin receptor stimulation is sufficient to accelerate 
remyelination. To determine whether activin receptor sign-
aling is required for remyelination, demyelinated cerebel-
lar explants were treated with an inhibitor of activin recep-
tors, inhibin-A, which competitively binds these receptors 
to prevent endogenous ligand binding [42]. Remyelination 
was significantly repressed by inhibin-A treatment at 7, 10 
and 14 dpl compared to vehicle control (Fig. 5c, d), dem-
onstrating for the first time that activin receptor signaling is 
required for remyelination.
To assess activin receptor subtype expression during effi-
cient remyelination, we took advantage of the temporally 
discrete OPC responses occurring following focal demyeli-
nated lesion induction of the caudal cerebellar peduncles. At 
the time of initiation of oligodendrocyte differentiation and 
remyelination (10 dpl), Acvr2b levels decreased and Acvr2a 
levels concomitantly increased (Fig. 5e, g); these changes in 
expression were confirmed to occur in oligodendroglial line-
age cells (NG2+, Olig2+; Fig. 5f). Non-lesioned CCP had 
no Acvr2b signal, confirming the absence of its expression 
in healthy adult white matter (Fig. 5h). Thus, in contrast to 
the absence of Acvr2b expression during development or 
homeostasis, its transient induction after demyelination is an 
early response to injury, which is followed by a transition to 
Acvr2a expression during efficient remyelination.
Activin receptor expression is dysregulated 
in non‑repairing lesions in human myelin disorders
In light of our results showing that activin receptor signal-
ing regulates developmental myelination and remyelination, 
and that activin receptor subtype expression by oligoden-
droglial lineage cells is strictly controlled following injury, 
we predicted that dysregulation of activin receptor expres-
sion may underpin chronic failure of oligodendrocyte dif-
ferentiation and myelin formation in human disorders [10, 
38]. We first investigated brain tissue from perinatal brain 
injury cases (Online Resource Supplemental Table 1) and 
compared areas of normally developing white matter (low 
microglia density: average 10 ± 10 cells/mm2) to areas of 
injury (high microglia density: average 122 ± 30 cells/mm2) 
(Online Resource Supplemental Fig. 9a–c). We observed 
increased densities of cells positive for the activin-A subunit 
INHBA in the brain parenchyma in injured vs. non-injured 
areas (Fig. 6a, b), consistent with previously reported ele-
vated INHBA in the cerebrospinal fluid following perinatal 
brain injury [23]. However, injured areas had lower densi-
ties of oligodendroglial cells (Olig2+) expressing Acvr2a, 
and higher densities of those expressing Acvr2b (Fig. 6d), 
compared to non-injured areas. This was not associated with 
a normal regenerative response to injury, as proliferating 
oligodendroglial lineage cells (PCNA+ Olig2+) were not 
increased relative to in non-injured regions (Fig. 6e).
We next examined adult progressive MS brain lesions 
with four types of pathology displaying a range of remy-
elination potential: lesions with completed remyelination 
(‘remyelinated’), ongoing damage and active remyelina-
tion (‘acute active’, rim of ‘chronic active’), and little to no 
remyelination (‘chronic inactive’) (Online Resource Supple-
mental Table 2, Online Resource Supplemental Fig. 9d–f). 
Activin-A (INHBA)+ cells were present in lesions regard-
less of pathology, yet densities were significantly increased 
in acute active lesions (Fig. 6f, g) consistent with increased 
INHBA detected in cerebrospinal fluid following recent 
adult brain injury [52]. Within actively remyelinating lesions 
(acute active and chronic active lesions), the proportion of 
Olig2+ cells that were Acvr2a+ was higher than the pro-
portion that were Acvr2b+ (Fig. 6h). However, the propor-
tion of Acvr2b+ Olig2+ cells was significantly increased in 
chronic inactive lesions (Fig. 6h), the lesions with the lowest 
remyelination potential. Thus, a common feature of lesions 
with limited oligodendrocyte differentiation and myelin gen-
eration in both developmental and adult disorders was an 
increase in Acvr2b+ oligodendroglial lineage cells. Both 
the increase in Acvr2b expression and its relatively higher 
affinity for activin-A [5] would be predicted to sequester 
the ligand thereby restricting Acvr2a-mediated signaling in 
oligodendrocyte lineage cells.
To test this hypothesis, Acvr2b was overexpressed in oli-
godendrocyte lineage cells via lentiviral delivery of a con-
struct driving expression of Acvr2b along with a membrane-
tagged green fluorescent protein (GFP) (Acvr2b-LV), and 
using a lentivirus driving GFP expression only as a control 
(control-LV). Successful transfection of OPCs at 3 days of 
exposure was confirmed by detection of GFP expression in 
99% of cells (Fig. 6k). Compared to control-LV conditions, 
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Fig. 5  Activin receptor signaling regulates remyelination. a Rep-
resentative images of organotypic cerebellar slice cultures at 7 days 
post lysolecithin-induced demyelination, treated with vehicle control 
or activin receptor agonist activin-A during remyelination, immu-
nostained against myelin basic protein (MBP; green), and axonal 
neurofilament-H (NF; red). Scale bar 50 μm. b Mean remyelination 
index  ±  s.e.m. in activin-A-treated explants at 7, 10, and 14  days 
post lysolecithin (dpl) normalized to vehicle control from the respec-
tive time point. n = 3 animals, one-sample t test compared to theo-
retical mean of 1 (control), **P  =  0.0057. c Representative images 
of slice cultures at 14 dpl treated with vehicle control or an inhibitor 
of activin receptor signaling inhibin-A during remyelination, immu-
nostained against myelin basic protein (MBP; green) and axonal 
neurofilament-H (NF; red). Scale bar 50  μm. d Mean remyelina-
tion index ± s.e.m. in inhibin-A-treated explants at 7, 10, and 14 dpl 
normalized to vehicle control from the respective time point. n = 3 
animals, one-sample t test compared to theoretical mean of 1 (con-
trol), *P  =  0.0165, *0.0374, **0.0004, respectively. e Acvr2a and 
Acvr2b expression (green) in demyelinated caudal cerebellar pedun-
cles (CCP) at 5  days post-lesion (dpl; prior to remyelination) and 
10 dpl (onset of remyelination), counterstained with Hoechst (blue). 
Scale bar 25 μm. f Colocalization of Acvr2b or Acvr2a (green) with 
NG2 (top 2 rows; red; arrowheads) or Olig2 (bottom 2 rows; red; 
arrowheads) at 5 and 10 dpl in CCP, counterstained with Hoechst 
(blue). g Mean number of cells double positive for Olig2 and Acvr2a 
or Acvr2b per field ± s.e.m. at 5 and 10 dpl. n = 3 = 4 animals per 
group. Two-tailed Student’s t test, P  =  0.0345 (5 dpl), 0.0298 (10 
dpl). h Non-lesioned CCP shows no staining of Acvr2b (green). Scale 
bar 10 μm
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overexpression of Acvr2b significantly impaired both 
activin-A-driven OPC differentiation into mature MBP+ oli-
godendrocytes (Fig. 6j, k) and actin depolymerization in 
maturing oligodendrocyte membranes (causing an increase 
in Phalloidin intensity per cell; Fig. 6l, m). These experi-
ments confirm that increased expression of Acvr2b by oligo-
dendroglial lineage cells impairs ligand-driven oligodendro-
cyte differentiation and actin dynamics involved in myelin 
compaction.
Discussion
In this study, we reveal the role of activin receptor sign-
aling in CNS myelin generation during healthy develop-
ment and following injury. Using a conditional knockout 
approach, in vitro manipulation of oligodendrocyte line-
age cells, ex vivo/in vivo modeling of remyelination, and 
human post-mortem brain tissue analysis, we uncover the 
requirement for activin receptor signaling in driving timely 
oligodendrocyte differentiation and myelin compaction, and 
its dysregulation in disease (summarized in Fig. 6n). These 
findings go beyond previous studies showing that activin 
receptor stimulation is protective for neurons [22, 30, 55], by 
demonstrating a direct and disease-relevant role in oligoden-
drocyte lineage cells. Our results also extend the functions of 
the TGFβ superfamily beyond supporting oligodendrocyte 
differentiation [19, 49] to now include regulation of myelin 
compaction and an appropriate response to white matter 
injury in human disease.
We eliminated all activin receptor responses in the oli-
godendroglial lineage by conditionally knocking out the 
co-receptor Acvr1b at the OPC stage, which would prevent 
all downstream signaling subsequent to ligand binding to 
activin receptors Acvr2a or Acvr2b. By postnatal day 16, 
this caused a 60% reduction in the number of myelinated 
axons, particularly those of intermediate caliber. This find-
ing reveals that there are activin receptor-dependent and 
-independent mechanisms driving axonal ensheathment 
with myelin membrane. This may be regulated by differen-
tial expression of activin receptor ligands across axon calib-
ers, as experimental augmentation of axon caliber to support 
myelination is associated with increased expression of the 
activin-A subunit [28]. Myelination may also be regulated by 
heterogeneity of activin receptor expression in oligodendro-
glial lineage cells, as our data-mining of a single-cell RNA 
sequencing dataset [41] showed that only a subset of cells 
express Acvr2a at each stage of oligodendrocyte maturation.
The hypomyelination in activin receptor conditional 
knockout mice was associated with reduced numbers of 
maturing oligodendrocytes, showing the requirement for 
activin receptor signaling in the differentiation of a signifi-
cant subset of oligodendroglial lineage cells. Importantly, 
activin receptor stimulation of wildtype OPCs (with activin-
A) was sufficient to enhance oligodendrocyte differentia-
tion, even in the presence of proliferation-stimulating growth 
factors. Although in the knockout some myelinating oligo-
dendrocytes were still generated, these cells demonstrated 
impaired myelin membrane compaction, as evidenced by 
a persistent enlargement of the inner tongue, thinner lay-
ers of compact myelin, and myelin sheaths devoid of the 
compaction-inducing protein MBP. In addition, stimulation 
of activin receptors on wildtype maturing oligodendrocytes 
enhanced depolymerization of actin in membranes, a pro-
cess required for myelin membrane compaction [48, 66]. 
Thus, we established that activin receptor signaling regulates 
myelination by driving oligodendrocyte differentiation and 
myelin membrane compaction, which to our knowledge is 
the first time a receptor axis has been directly linked to both 
processes.
These effects were found to be mediated by the ligand-
binding activin receptor subtype Acvr2a, as its neutralization 
in wildtype cells eliminated activin-A-driven oligodendro-
cyte differentiation and membrane actin depolymeriza-
tion. Accordingly, we showed that Acvr2a expression on 
oligodendroglial lineage cells in vivo coincides with oli-
godendrocyte differentiation and myelin generation during 
development and following injury. At the onset of successful 
remyelination, there was a concomitant downregulation of 
Acvr2b. Acvr2b has relatively higher affinity for activin-A 
compared to Acvr2a [5], and importantly its overexpression 
was found to impair activin-A-induced oligodendrocyte dif-
ferentiation and membrane actin depolymerization. Thus, 
the downregulation of Acvr2b after injury may allow Acvr2a 
to bind ligand more readily to drive oligodendroglial lineage 
responses and initiate repair.
Following CNS injury, the rapid increase in expression 
of activin-A [1, 23, 43, 62] likely represents an attempt at 
repair, supported by our previous observation of increased 
activin-A subunit expression in focal demyelinated lesions 
at the onset of remyelination [45]. However, activin-A 
(INHBA)+ cells were found to be present in both repairing 
and non-repairing regions of damaged human white mat-
ter, indicating that following injury oligodendrocyte line-
age cell responses are likely not regulated by activin-A, 
but rather by activin receptors. Indeed, regions that were 
actively myelinating (in perinatal tissue) or remyelinating 
(in multiple sclerosis lesions) demonstrated relatively higher 
densities of oligodendroglial lineage cells expressing Acvr2a 
compared to those expressing Acvr2b. However, an increase 
in Acvr2b+ oligodendroglial lineage cells was observed in 
non-repairing white matter (injured regions following peri-
natal brain injury, and chronic inactive multiple sclerosis 
lesions), which would be predicted to sequester ligand and 
consequently impair Acvr2a-regulated oligodendrocyte 
differentiation and myelin formation. Consistent with this 
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postulate, increased levels of Acvr2b mRNA in umbilical 
cord blood at birth is associated with more severe clinical 
outcome in infants following hypoxic-ischemic perinatal 
brain injury [40].
Oligodendrocyte differentiation, myelination, and remy-
elination have also been associated with activation of other 
receptors, such as endothelin receptor B [63], RXRγ [31], 
and CXCR4 [50]. As we observed both activin receptor-
dependent and -independent oligodendrocyte differentiation 
in vivo, this suggests that complementary pathways likely 
coordinate oligodendroglial lineage responses in parallel. 
This may involve distinct subsets of oligodendroglial line-
age cells preferentially expressing specific receptors; indeed 
data-mining of a single-cell RNAseq database confirms dis-
tinct expression patterns of the abovementioned receptors 
within the oligodendrocyte lineage [41] (data not shown). 
An alternate mechanism may involve context-dependent 
availability of ligand; for example, we have previously dem-
onstrated dynamic changes in activin-A protein levels dur-
ing the course of remyelination [45]. Here, we provide the 
first evidence for a receptor axis that is dysregulated in both 
myelin disorders of development (perinatal brain injury) and 
adulthood (MS), despite having distinct etiologies. These 
disorders also share dysregulation of an intracellular sign-
aling cascade, the Wnt/β-catenin pathway [20, 21], which 
may further antagonize Acvr2a signaling via upregulation 
of an inhibitor of activin-A (follistatin) [35] and a pseudo-
receptor acting as a dominant negative Acvr1b (BAMBI) 
[59]. Whereas other members of the TGFβ superfamily (e.g. 
bone morphogenic proteins) have recently been shown to 
impair remyelination via signaling through distinct receptors 
(BMPR1, Acvr1a) and pathways (Smad1/5/8) [51], our data 
demonstrate the pro-myelination/remyelination properties of 
the TGFβ superfamily via activin receptor signaling. Thus, 
we propose that therapies specifically restoring Acvr2a-
mediated signaling in oligodendroglial lineage cells could 
represent a novel strategy to enhance differentiation and 
myelin generation following CNS injury across the lifespan.
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